Study ID: [REMOVED]
Title: Phase 1 Pharmacokinetics and Safety Study of Oral Soticlestat in Participants with Moderate or Mild 
Hepatic Impairment and Normal Hepatic Function
Study Number: TAK-935-1010
Document Version and Date: Amendment 1; 11 April 2022
Certain information within this document has been redacted (ie, specific content is masked irreversibly from view 
with a black bar) to protect either personally identifiable information or company confidential information. Clinical Study Protocol 
TITLE PAGE
TAKEDA PHARMACEUTICALS
PROTOCOL
Phase 1 Pharmacokinetics and Safety Study of Oral Soticlestat in Participants with 
Moderate or Mild Hepatic Impairment and Normal Hepatic Function 
Study Identifier: TAK-935-1010
Compound: Soticlestat (TAK -935)
Sponsor: [COMPANY_005] Development Center Americas, Inc. 
[ADDRESS_804591]
Lexington, MA 02421Email: [EMAIL_1241]
Date: 11April 2022
Version: Amendment No. 1
Amendment History : 
Date Amendment Number Amendment Type Region
[ADDRESS_804592] of the study.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAmendment Number
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAmendment Number
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInitial Version
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInitial Version
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use01
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use01
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThis document is a confidential communication of [COMPANY_005]. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThis document is a confidential communication of [COMPANY_005]. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe recipi[INVESTIGATOR_607252]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe recipi[INVESTIGATOR_607253]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use[COMPANY_005] except to the extent necessary to obtain informed consent from those person
administered. Furthermore, the information is only meant for review and compliance by [CONTACT_1955][INVESTIGATOR_841], his or her staff, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useadministered. Furthermore, the information is only meant for review and compliance by [CONTACT_1955][INVESTIGATOR_841], his or her staff, 
and applicable institutional review committee and regulatory agencies to enable conduct of the study.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand applicable institutional review committee and regulatory agencies to enable conduct of the study.
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 2of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIALTABLE OF CONTENTS
1.0 STUDY SUMMARY ...................................................................................................... 7
2.0 STUDY SCHEMATIC .................................................................................................. 13
3.0 SCHEDULE OF STUDY PR OCEDURES .................................................................... 14
4.0 INTRODUCTION ......................................................................................................... 17
4.1 Backgrou nd............................................................................................................. 17
4.1.1 Soticlestat (TAK -935) ...................................................................................... 17
4.2 Rationale for the Proposed Study ............................................................................. 19
4.3 Benefit/Risk Profile .................................................................................................[ADDRESS_804593] ive.............................................................................. 20
5.3 Endpoints ................................................................................................................. 21
5.3.1 Primary Endpo ints........................................................................................... 21
5.3.2 Secondary  Endpo ints....................................................................................... 21
6.0 STUDY DESIGN AND DES CRIPTION ....................................................................... 21
6.1 Study  Design ........................................................................................................... 21
6.2 Dose Escal ation....................................................................................................... 23
6.3 Stoppi[INVESTIGATOR_1869] ......................................................................................................... 23
6.4 Rationale for Study  Design, Dose, and Endpoints .................................................... 23
6.4.1 Rationale of Study  Design ............................................................................... 23
6.4.2 Rationale for Dose ........................................................................................... 24
6.4.3 Rationale fo r Endpoints ................................................................................... 25
6.4.4 Future Bio medical Research ............................................................................ 25
6.4.5 Critical Procedures Based on Study  Objectives: Timing of Procedures ............ 25
6.5 Study  Design/Dosing/Procedures Modificat ions Permitted Within Protocol 
Param eters ............................................................................................................... 25
6.6 Study  Beginning and End/Co mpletion..................................................................... 26
6.6.1 Definit ion of Beginning of the Study ............................................................... 26
6.6.2 Definit ion of End of the Study ......................................................................... 26
6.6.3 Definit ion of Study  Com pletion....................................................................... 26Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use7
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use7
..................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.................................. 13
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use13
....................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.................................... 14
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use14
.........................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.........................................
.............................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.............................................
......................................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use......................................................
.............................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.............................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................ ................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................ ..................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use..................................
...............................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use...............................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................ ..................................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use..................................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSTUDY DESIGN AND DES
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSTUDY DESIGN AND DES CRIPTION
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCRIPTION
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
on
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
Stoppi[INVESTIGATOR_607254]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseStoppi[INVESTIGATOR_1869] ................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
onale for Study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useonale for Study
Rati
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRationale of Study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useonale of Study
Rati
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRati
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use6.4.3
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use6.4.3
6.4.4
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use6.4.4
6.4.5
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use6.4.5
6.5
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use6.5
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 3of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIAL6.6.4 Definit ion of Study Discont inuat ion.................................................................26
6.6.5 Criteria for Premature Terminat ion or Suspension of the Study ........................ 26
6.6.6 Criteria for Premature Terminat ion or Suspension of a Site .............................. 27
7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF PARTICIPANTS .....[ADDRESS_804594] ivity.................................................................................................31
7.4.1 Diet and Fluid .................................................................................................. 31
7.4.2 Activity........................................................................................................... 32
7.5 Criteria for Di scontinuati on or Wi thdrawal  of a Parti cipant ...................................... 32
7.6 Procedures for Discont inuat ion or Withdrawal o f a Parti cipant ................................ 33
7.7 Parti cipant Replacem ent.......................................................................................... 33
8.0 CLINICAL STUDY MATER IAL MANAGEMENT ..................................................... 34
8.1 Clinical Study  Drug .................................................................................................34
8.1.1 Clinical Study  Drug Labeling .......................................................................... 34
8.1.2 Clinical Study  Drug Inventory  and Storage ...................................................... 34
8.1.3 Clinical Study  Drug Blinding ........................................................................... 34
8.1.4 Randomization Code Creation and Storage ...................................................... 34
8.1.5 Clinical Study  Blind Maintenance/Unblinding Procedure .................................34
8.1.6 Accountabilit y and Destruction of Sponsor -Supplied Drugs ............................. 34
9.0 STUDY PROCEDURES ............................................................................................... 35
9.1 Administrative Procedures ....................................................................................... 35
9.1.1 Inform ed Consent Procedure ............................................................................ 35
9.1.2 Inclusio n and Exclusio n................................................................................... 35
9.1.3 Medical History /Dem ography .......................................................................... 35
9.1.4 Concomitant Medications ................................................................................ 35
9.2 Clinical Procedures and Assessments ....................................................................... 35
9.2.1 Full Physical Examinat ion............................................................................... 36Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use27
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use27
.....
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.....27
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use27
.....................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.....................................
..........................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use..........................................
....................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use....................................
ent and Healthy Participants
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useent and Healthy Participants
....................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use....................................
.........................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.........................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................ ...................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use...................................
rm
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userme
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useent and Healthy Participants
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usent and Healthy Participants
 Products
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use Products
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
th
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethdrawal
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedrawal
n or Withdrawal o
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen or Withdrawal o
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
CLINICAL STUDY MATER
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCLINICAL STUDY MATER IA
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIAL MANAGEMENT
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseL MANAGEMENT
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
Clinical Study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseClinical Study  Drug 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use Drug Clinical Study  Drug Clinical Study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseClinical Study  Drug Clinical Study
Clinical Study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseClinical Study  Drug Inventory
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use Drug Inventory Clinical Study  Drug Inventory Clinical Study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseClinical Study  Drug Inventory Clinical Study
Clinical Study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseClinical Study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRandomization Code Creation and Storage
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRandomization Code Creation and Storage
Clinical Study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseClinical Study
8.1.6
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use8.1.6 Accountabilit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAccountabilit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSTUDY PROCEDURES
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSTUDY PROCEDURES
9.1
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use9.1
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804595] AEs ......................................................................................... 44
10.2 AE Procedures ......................................................................................................... 44
10.2.1 Assigning Severit y/Intensit y of AEs ................................................................ 44
10.2.2 Assigning Causalit y of AEs ............................................................................. 45
10.2.3 Start Date ......................................................................................................... 45
10.2.4 End Date .......................................................................................................... 45
10.2.5 Pattern of Adverse Event (Frequency) .............................................................. [ADDRESS_804596] ICAL METHODS .......................................................................................... 49
11.1 Statistical and Analyt ical Plans ................................................................................ 49
11.1.1 Analysis Sets ................................................................................................... 49
11.1.2 Analysis of Demography and Other Baseline Cha racteri stics........................... 49
11.1.3 PK Analysis ..................................................................................................... 49
11.1.4 PD Analysis ..................................................................................................... 50
11.1.5 Safety Analysis ................................................................................................ 50
11.2 Interim Analysis and Criteria for Early Terminat ion................................................ 51Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use36
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use36
...................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................... 36
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use36
..............................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use..............................................
...........................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use...........................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
..........................................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use..........................................................
.............................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.............................................
............................................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use............................................................
................................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................................
..........................................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use..........................................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................ ................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
y/Intensit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usey/Intensit y 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usey of
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useof
Assigning Causalit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAssigning Causalit y of AEs
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usey of AEs
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
Pattern of Adverse Event (Frequency)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePattern of Adverse Event (Frequency)
io
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useion Taken Wit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen Taken Wit
Outcom
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseOutcom
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCollect
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCollect
10.2.9
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use10.2.9 Saf
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSaf
STATIST
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSTATIST
11.1
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use11.1
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804597] ions................................ 52
13.0 ETHICAL ASPECTS OF T HE STUDY ........................................................................ 52
13.1 IRB and/or IEC Approval ........................................................................................ [ADDRESS_804598] of Abbreviat ions....................................................................................... 58
15.0 DAT A HANDLING AND RE CORDKEEPI[INVESTIGATOR_1645] ............................................................ 61
15.1 CRFs (El ectronic and Paper) .................................................................................... [ADDRESS_804599] ................................................................ 44Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use51
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use51
..................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.................................. 51
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use51
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
........................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use........................................
........................................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use........................................................
ed Consent, and Participant Authorizat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useed Consent, and Participant Authorizat io
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useion
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen
.......................................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.......................................................
on Policy
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon Policy ...............................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use...............................
...............................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use...............................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................ ..............................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use..............................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
EFERENCE INFORMATION
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEFERENCE INFORMATION
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
INVESTIGATOR AGREEMENT
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseINVESTIGATOR AGREEMENT
Related Responsibilit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRelated Responsibilit ies
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useies
ns
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usens................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
A HANDLING AND RE
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseA HANDLING AND RE CORDKEEPI[INVESTIGATOR_607255]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCORDKEEPI[INVESTIGATOR_607256])
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useectronic and Paper)
Record Retention
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRecord Retention ................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
REFERENCES
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseREFERENCES ................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
APPENDICES
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAPPENDICES ................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
LIST OF IN
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseLIST OF IN -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-TEXT TABLES
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTEXT TABLES
Table 2.a
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTable 2.a
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTable 6.a
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTable 6.a
Table 6.b
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTable 6.b
Table
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTable
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804600] igator Consent to the Use of Personal Information .................................... 68
Appendix D Pregnancy and Contrac eption............................................................................. 69
Appendix ESummary  of Changes fro m Previous Versio n..................................................... 73
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use65
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use65
....................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.................................... 68
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use68
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.............................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.............................................
.....................................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.....................................................
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 7of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIAL1.0 STUDY SUMMARY
Name [CONTACT_790]:
[COMPANY_005] Development Center Americas, Inc. (TDC Americas)
95 Hayden AvenueLexingto n, MA [ZIP_CODE]
Telepho ne: +1 (617) 679-7000Compound:
Soticlestat (TAK -935)
Study Identifier : TAK -935-1010 Phase: 1
Protocol Title: Phase 1 Pharmacokinetics and Safety Study of Oral Soticlestat in Participants with Moderate or Mild 
Hepatic Impairment and Normal Hepatic Function
Study Design:
This is a phase 1, open -label, study of oral soticlestat designed to assess the pharmacokinetics (PK) of single dose 
soticlestat  in participants with moderate or mild hepatic impairment (HI) 
compared to matched healt hy participants with normal hepatic function. At least 12 healthy  participants (up to 24 
participants) with normal hepatic function will be recruited to match the group mean of moderate and mild HI arms by 
[CONTACT_654] (mean ± 10 years), sex (± 2 per sex), and body mass index (BMI, mean ±10%). Eight (8) participants will also be 
enrolled in each HI arm of the study according to the following criteria: 
Arm 1: (N = 8): Moderate HI (Child -Pugh Class B [Score: ≥ 7 and ≤ 9]), 300 mg single dose
Arm 2: (N = 8): Mild HI (Child -Pugh Class A [Score: ≥ 5 and ≤ 6]), 300 mg single dose 
Arm 3: (N = 12 -24): Normal hepatic function, [ADDRESS_804601] of a 28 -day screening period (prior to dosing) and a 7- day confinement period (Day -1 to Day
7).
Two hepatic functio n assessments are required prior to Day [ADDRESS_804602] 48 hours apart. In the case where a participant has an 
available historical Child -Pugh assessment score within 3 months prior to screening, 1 assessment can be conducted 
during the screening period. If the Child -Pugh scores from these 2 assessments indicate the same liver function 
category for the participant (ie, normal hepatic function, m oderate HI, or mild HI), soticlestat can be administered as 
scheduled. If the results of the [ADDRESS_804603] recent assessments (the second and 
third) are in agreement with regard to the participant’s liver function category, the participant may be enrolled and should receive the Day [ADDRESS_804604] measurements differ, the 
participant will not be eligible for the study.
The moderate HI arm (ie, Arm 1) will be conducted first, followed by 12 participants in the matched normal hepatic 
function arm (Arm 3). After all participants in the moderate HI ar m and the matching [ADDRESS_804605] of 
moderate HI on the PK of soticlestat . 
Following completion of enrolment of the mild HI arm, and in the instance any of the previously enrolled healthy
participants cannot be used for matching purposes, up to an additional 12 participants may be enrolled for the matched 
normal hepatic function group (Arm 3) to ensure a minimum of 12 participants with normal hepatic function and matching the mean of the mild HI arm by [CONTACT_654] (mean ± 10 years), sex (± 2 per se x), and body mass index (BMI, 
mean ±10%) are enrolled. 
Participants will receive a single oral dose of 300 mg soticlestat as three 100 mg T4 tablets on Day 1 with approximately 240 mL water under fasting conditions. PK samples will be collected from Days 1 to 7, at 
predetermined time points (Section 3.0), to characterize the PK of soticlestat 
in participants with moderate or mild HI compared to matched healthy participants with normal hepatic 
function (Section 3.0).Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usease 1 Pharmacokinetics and Safety Study of Oral Soticlestat in Participants with Moderate or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usease 1 Pharmacokinetics and Safety Study of Oral Soticlestat in Participants with Moderate or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselabel, study of oral soticlestat designed to assess the pharmacokinetics (PK) of single dose 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselabel, study of oral soticlestat designed to assess the pharmacokinetics (PK) of single dose 
 in participants with moderate or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use in participants with moderate or mild 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemild 
 participants with normal hepatic function. At least 12
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use participants with normal hepatic function. At least 12 healthy
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehealthy
participants) with normal hepatic function will be recruited to match the group mean of moderate and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useparticipants) with normal hepatic function will be recruited to match the group mean of moderate and 
mass index (BMI, mean
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemass index (BMI, mean ±
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use±10%). Eight (8) participants will also be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use10%). Eight (8) participants will also be 
enrolled in each HI arm of the study according to the following criteria: 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useenrolled in each HI arm of the study according to the following criteria: 
Class B [Score: 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseClass B [Score: ≥ 7 and ≤ 9]), 300 mg single dose
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use≥ 7 and ≤ 9]), 300 mg single dose
[Score: 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use[Score: ≥ 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use≥ 5 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use5 and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand 
24): Normal hepatic function, 300 mg single dose 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use24): Normal hepatic function, 300 mg single dose 
day screening period (prior to dosing) and a 7
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useday screening period (prior to dosing) and a 7
n assessments are required prior to Day 1 dosing for participants with HI. These 2
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen assessments are required prior to Day [ADDRESS_804606] 48 hours apart. In the case where a participant has an 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useshould be obtained during the screening period and at least 48 hours apart. In the case where a participant has an 
assessment score within 3 months prior to screening, 1 assessment can be conducted 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useassessment score within 3 months prior to screening, 1 assessment can be conducted 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePugh scores from these 2
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePugh scores from these 2
category for the participant (ie, normal hepatic function, m
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecategory for the participant (ie, normal hepatic function, m
assessments indicate different liver function categories, a third assessment must be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useassessments indicate different liver function categories, a third assessment must be 
conducted at least 24 hours after the second assessment. If the results of t
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useconducted at least [ADDRESS_804607]) are in agreement with regard to the participant’s liver function category, the participant may be enrolled and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethird) are in agreement with regard to the participant’s liver function category, the participant may be enrolled and 
receive the Day 1 dose within 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usereceive the Day 1 dose within 
participant will not be eligible for the study.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useparticipant will not be eligible for the study.
The moderate HI arm (ie, Arm 1) will be conducted first, followed by 12 participants in the matched normal hepatic 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe moderate HI arm (ie, Arm 1) will be conducted first, followed by 12 participants in the matched normal hepatic 
function arm (Arm 3). After all participants in the moderate HI ar
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefunction arm (Arm 3). After all participants in the moderate HI ar
hepatic function arm 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehepatic function arm 
 additionally leverage historical control PK data in healthy participants to gain an i
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use additionally leverage historical control PK data in healthy participants to gain an i
moderate HI on the PK of soticlestat 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemoderate HI on the PK of soticlestat 
Following completion of enrolment of the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFollowing completion of enrolment of the 
participants cannot be used for matching purposes, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useparticipants cannot be used for matching purposes, 
normal hepatic function group (Arm 3) to ensure a minimum of 12 participants with normal hepatic function and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenormal hepatic function group (Arm 3) to ensure a minimum of 12 participants with normal hepatic function and 
matching the mean of the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usematching the mean of the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemean
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemean
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804608] for all participants 
(including those who terminate the study early) will occur 14 ± [ADDRESS_804609] occurred since clinical research unit (CRU) discharge .
Study Primary Objective:
To characterize the plasma PK of soticlestat following a single oral dose in participants with moderate or mild HI
compared to matched healthy participants with normal hepatic function.
Study Secondary Objective:
To evaluate the safety and tolerability of soticlestat following a single oral dose in participants with moderate or 
mild HI as well as matched healthy participants with normal hepatic function.
Study Participant Population: Healthy  male and female participants and participants with moderate and mild HI 
aged ≥ 18 to < 75years and with a BMI ≥18.0 and ≤40.0 kg/m2at screening (at least 50% of the participants will be 
required to be of BMI ≥18.0 and ≤ 35.0 kg/m2).Healthy participants will be matched to hepatic impaired participants 
in this study by [CONTACT_654] (mean ± 10 years), sex (± 2 per sex), and BMI (mean ± 10%). 
Planned Number of Participants:
Up to 40 participants will be enrolled:
8 participant s with moderate HI
8 participants with mild HI
12 to 24 participants with normal hepatic functionPlanned Number of Sites:
Up to 7 clinical sites
Dose Level:
300 mg soticlestat (3 x 100 mg T4 tablets) .Route of Administration:
Oral
Duration of Treatment:
Single -dose on Day 1Planned Study Duration :
Approximately 42 days including screening period and 
follow -up.
Criteria for Inclusion:
Inclusion for Participants with Hepatic Impairment
Participants must fulfill the following inclusion criteria to be eligible for participation in the study (participants who do
not qualify based on a reversible condition or mild intercurrent illness may be re -screened after the condition is 
resolved. Screening tests may be repeated if in the Investigator’s opi[INVESTIGATOR_607257]): 
1.Is an adult male or female participant aged ≥ 18 to < 75 years, at screening.
2.Has a BMI ≥18.0 and ≤40.0 kg/m2, at screening. At least 50% of the participants will be required to be of BMI 
≥18.0 and ≤35.0 kg/m2, at screening. 
3.Aside from HI, be sufficiently healthy for study participation based upon medical history, physical examination, 
vital signs, ECGs, and screening clinical laboratory profiles, as deemed by [CONTACT_18370].
Supi[INVESTIGATOR_9204] (BP) is ≥ 80/40 mmHg (asymptomatic) and ≤ 150/95 mmHg ,at screening;
Supi[INVESTIGATOR_177305] (PR) is ≥ 40 bpm and ≤ 99 bpm ,at screening;
QT interval corrected for PR using Friderica’s formula (QTcF) is ≤ 500 m sec and electrocardiogram (ECG) 
findings considered normal or not clinically significant by [CONTACT_18370] ,at screening.
4.The participant must have had chronic HI for at least [ADDRESS_804610] be stable, ie, no Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useto determine if any AEs 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useto determine if any AEs 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTo characterize the plasma PK of soticlestat following a single oral dose in participants with moderate or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTo characterize the plasma PK of soticlestat following a single oral dose in participants with moderate or mild 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemild 
To evaluate the safety and tolerability of soticlestat following a single oral dose in participants with moderate or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTo evaluate the safety and tolerability of soticlestat following a single oral dose in participants with moderate or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use male and female participants and participants with moderate and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use male and female participants and participants with moderate and 
at screening (at least 50% of the participants
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useat screening (at least 50% of the participants
Healthy participants will be matched to hepatic impaired participants 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHealthy participants will be matched to hepatic impaired participants 
in this study by [CONTACT_654] (mean ± 10 years), sex (± 2 per sex), and BMI (mean ±
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usein this study by [CONTACT_654] (mean ± 10 years), sex (± 2 per sex), and BMI (mean ±
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use12 to 24 participants with normal hepatic function
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use12 to 24 participants with normal hepatic functionPlanned Number of Sites:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePlanned Number of Sites:
Up to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseUp to 7 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use7 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseT4 tablets)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseT4 tablets) .
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInclusion for Participants with Hepatic Impairment
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInclusion for Participants with Hepatic Impairment
must fulfill 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemust fulfill the following inclusion criteria 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe following inclusion criteria 
not qualify based on a reversible condition or mild intercurrent illness may be re
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenot qualify based on a reversible condition or mild intercurrent illness may be re
resolved. Scree
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useresolved. Scree ning tests may be repeated if in the Investigator’s opi[INVESTIGATOR_607257]): 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usening tests may be repeated if in the Investigator’s opi[INVESTIGATOR_607257]): 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIs an adult male or female participant aged 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIs an adult male or female participant aged 
Has a BMI 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHas a BMI 
≥
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use≥18.0
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use18.0
3.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use3.Aside from HI, be sufficiently healthy for study participation based upon medical history, physical examination, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAside from HI, be sufficiently healthy for study participation based upon medical history, physical examination, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 9of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIALsigni ficant changes in hepatic function in the 30 days preceding screening (or since the last visit if within 6 
months before screening) and treatment with stable doses of medication. Has a score on the Child -Pugh Class at 
screening as follows: 
(Arm 1) Moderat e HI, Child -Pugh Class B: ≥ 7 and ≤ 9
(Arm 2) Mild HI, Child -Pugh Class A: ≥ 5and ≤ [ADDRESS_804611] renal dysfunction as demonstrated by a relatively adequate renal function (creatinine 
clearance ≥ 50 mL /min), at screening.
Inclusion for Healthy Participants
Participants must fulfill the following inclusion criteria to be eligible for participation in the study:
1.Is an adult male or female participant aged ≥ 18 to < 75 years, at screening. Healthy participants will be matched 
to hepatic impaired participants in this study by [CONTACT_4321] (± 2 per sex) and by [CONTACT_654] (mean ± 10 years). 
2.Has a BMI ≥18.0 and ≤40.0 kg/m2, at screening. At least 50% of the participants will be requi red to be of BMI 
≥18.0 and ≤35.0 kg/m2, at screening. Healthy participants will be matched to hepatic impaired participants in 
this study by [CONTACT_44207] (mean ± 10%).
3.Medically healthy with no clinically significant medical histor y, physical examination, laborat ory profiles, vital 
signs or ECGs, as deemed by [CONTACT_18370]. 
Supi[INVESTIGATOR_607258] ≥ 90/40 mmHg and ≤ 150/95 mmHg ,at screening;
Supi[INVESTIGATOR_607259] ≥ 40 bpm and ≤ 99 bpm ,at screening;
QTcF is ≤ 450 msec (males) or ≤ 470 msec (females) and ECG findings considered normal or not clinically 
significant by [CONTACT_18370] ,at screening;
Liver function tests including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline 
phosphatase (ALP) and total bilirubin ≤the upper limit of normal (ULN) at screening and check -in.
4.Participants should not have renal dysfunction as demonstrated by a relatively adequate renal function ( creatinine 
clearance ≥60 mL/min ),at screening.
Inclusion for Participants with Hepatic Impairment and Healthy Participants
Participants must fulfill the following inclusion criteria to be eligible for participation in the study:
1.Understands the study procedures in the informed consent form ( ICF), provides a signature/date in the ICF, and is 
willing and able to comply  with the protocol.
2.Continuous non -smoker or moderate smoker ( ≤10 cigarettes/day or the equivalent) before screening. Participant 
must agree to consume no more than 5 cigarettes or equivalent/day from the 7 days prior check -in and until 
discharge f rom the CRU.
3.Female participant s of childbearing potential and male participants agree to comply with any applicable 
contraceptive requirements of the protocol as detailed in Appendix D.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseParticipants should not have renal dysfunction as demonstrated by a relatively adequate renal function (creatinine 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseParticipants should not have renal dysfunction as demonstrated by a relatively adequate renal function (creatinine 
Participants must fulfill the following inclusion criteria to be eligible for participation in the study:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseParticipants must fulfill the following inclusion criteria to be eligible for participation in the study:
75 years, at screening. Healthy participants will be matched 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use75 years, at screening. Healthy participants will be matched 
± 10
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use± 10 years). 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useyears). 
, at screening. At least 50% of the participants will be requi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, at screening. At least 50% of the participants will be requi
, at screening. Healthy participants will be matched to hepatic impaired participants in 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, at screening. Healthy participants will be matched to hepatic impaired participants in 
sical examination, laborat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesical examination, laborat
at screening;
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useat screening;
≤ 450 msec (males) or ≤ 470 msec (females) and ECG findings 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use≤ 450 msec (males) or ≤ 470 msec (females) and ECG findings 
at screening;
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useat screening;
Liver function tests including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseLiver function tests including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline 
the upper limit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe upper limit
Participants should not have renal dysfunction as demonstrated by a relatively adequate renal function (
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseParticipants should not have renal dysfunction as demonstrated by a relatively adequate renal function (
Inclusion for Participants with Hepatic Impairment and Heal
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInclusion for Participants with Hepatic Impairment and Heal
Participants must fulfill the following inclusion criteria to be eligible for participation in the study:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseParticipants must fulfill the following inclusion criteria to be eligible for participation in the study:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usederstands the study procedures in the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usederstands the study procedures in the 
comply
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecomply  with the protocol.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use with the protocol.
smoker or moderate smoker (
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesmoker or moderate smoker (
must agree to consume no more than 5 cigarettes or equivalent/day from the 7 days prior check
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemust agree to consume no more than 5 cigarettes or equivalent/day from the 7 days prior check
m the CRU.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usem the CRU.
participant
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useparticipant s of childbearing potential and male 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uses of childbearing potential and male 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecontraceptive requirements of the protocol as detailed in
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecontraceptive requirements of the protocol as detailed in
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 10of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIALCriteria for Exclusion:
Exclusion for Participants with Hepatic Impairment:
The participant must be excluded from participating in the study if the participant:
1.Has history or presence of clinically significant medical or psychiatric condition or disease (aside from HI) or 
presence of psychotic disorders such as psychosis, delusions, or schizophrenia in the opi[INVESTIGATOR_25285].
2.Has a history of liver or other solid organ transplant.
3.Has history or pre sence of alcoholism and drug abuse within the past 6 months prior to dosing.
4.Positive result at screening for human immunodeficiency virus (HIV). Hepatitis B surface antigen (HBsAg) 
positive participants are allowed to be enrolled if hepatitis B virus (HBV ) deoxyribonucleic acid (DNA) is below 
1000 copi[INVESTIGATOR_014]/mL in the plasma. Participants with moderate or mild HI who are positive for anti -HCV antibody 
(HCVAb) can be enrolled but must not have detectable HCV ribonucleic acid (RNA) in the plasma.
Exclusion for Healthy Participants
The participant must be excluded from participating in the study if the participant:
1.Has history or presence of clinically significant medical or psychiatric condition or disease or presence of 
psychotic disorders such as psychosis, delusions, or schizophrenia in the opi[INVESTIGATOR_25279].
2.Has history or presence of alcoholism and drug abuse within the past 2 years prior to dosing.
3.Positive results at screening for HIV, HBsAg, or hepatitis C virus (HCV).
Exclusion for Participants with Hepatic Impairment and Healthy Participants
The participant must be excluded from participating in the study if the participant:
1.Has history of any illness that, in the opi[INVESTIGATOR_25279], might confound the results o f the 
study or poses an additional risk to the participant by [CONTACT_47361].
2.Has history or presence of clinically significant hypersensitivity or idiosyncratic reaction to the study drug or 
related compounds.
3.Has positive results for the urine or saliva drug screen at screening or check -in, unless the positive drug screen is 
due to prescription drug use that is approved by [CONTACT_737] (cannabinoids can be used for medicinal use at the discretion of the Investigator).
4.Is a female with a positive pregnancy test or who is lactating.
5.Has positive results for urine or breath alcohol screen at screening or check -in.
6.Is unable to refrain from or anticipates the use of any medication or substance (including prescription or over-the-counter, vitamin supplements, natural or herbal supplements) as indicated in Section 7.3(Excluded 
Medications, Supplements, Dietary Products) for the prohibited time period.
7.Has been on a diet incompatible with the on -study diet, in the opi[INVESTIGATOR_25279], w ithin the 
30days prior to dosing.
8.Has made a donation of blood or had significant blood loss within [ADDRESS_804612] dosing in the previous study to Day 1 of the current study.
11.Any positive responses on the Columbia -Suicide Severity Rating Scale (C-SSRS) or has a risk of suicide 
according to the Investigator’s judgment based on the assessment of the C -SSRS at screening or check -in or has 
made a suicide attempt in the previous 12 months prio r to dosing.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use psychiatric condition or disease (aside from HI) or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use psychiatric condition or disease (aside from HI) or 
the opi[INVESTIGATOR_607260]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe opi[INVESTIGATOR_607261] 6 months prior to dosing.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesence of alcoholism and drug abuse within the past 6 months prior to dosing.
Positive result at screening for human immunodeficiency virus (HIV). Hepatitis B surface antigen (HBsAg) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePositive result at screening for human immunodeficiency virus (HIV). Hepatitis B surface antigen (HBsAg) 
) deoxyribonucleic acid (DNA) is below 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use) deoxyribonucleic acid (DNA) is below 
HI who are positive for anti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHI who are positive for anti
(HCVAb) can be enrolled but must not have detectable HCV ribonucleic acid (RNA) in the plasma.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(HCVAb) can be enrolled but must not have detectable HCV ribonucleic acid (RNA) in the plasma.
The participant must be excluded from participating in the study if the participant:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe participant must be excluded from participating in the study if the participant:
Has history or presence of clinically significant medical or psychiatric condition or disease or presence of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHas history or presence of clinically significant medical or psychiatric condition or disease or presence of 
usions, or schizophrenia in the opi[INVESTIGATOR_607262]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useusions, or schizophrenia in the opi[INVESTIGATOR_607263] 2 years prior to dosing.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHas history or presence of alcoholism and drug abuse within the past 2 years prior to dosing.
Positive results at screening for HIV, HBsAg, or hepatitis C virus (HCV).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePositive results at screening for HIV, HBsAg, or hepatitis C virus (HCV).
Participants with Hepatic Impairment and Healthy Participants
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseParticipants with Hepatic Impairment and Healthy Participants
The participant must be excluded from participating in the study if the participant:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe participant must be excluded from participating in the study if the participant:
Has history of any illness that, in the opi[INVESTIGATOR_607262]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHas history of any illness that, in the opi[INVESTIGATOR_2511] I
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInvestigator or designee, might confound the results o
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenvestigator or designee, might confound the results o
study or poses an additional risk to the participant by [CONTACT_47361].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usestudy or poses an additional risk to the participant by [CONTACT_47361].
Has history or presence of clinically significant hypersensitivity or idiosyncratic reaction to the study drug or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHas history or presence of clinically significant hypersensitivity or idiosyncratic reaction to the study drug or 
Has positive results for the urine or saliva drug screen at screening or check
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHas positive results for the urine or saliva drug screen at screening or check
due to prescription drug use that is approved by [CONTACT_737] (cannabinoids can be used for medicinal use at 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedue to prescription drug use that is approved by [CONTACT_737] (cannabinoids can be used for medicinal use at 
the discretion of the Investigator).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe discretion of the Investigator).
Is a female with a positive pregnancy test or who is lactating.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIs a female with a positive pregnancy test or who is lactating.
Has positive results for urine or breath alcohol screen at screening or check
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHas positive results for urine or breath alcohol screen at screening or check
Is unable to refrain from or anticipates the use of any medication or substance (including prescription or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIs unable to refrain from or anticipates the use of any medication or substance (including prescription or 
counter, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecounter, vitamin supplements, natural or herbal supplements) as indicated in Section
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevitamin supplements, natural or herbal supplements) as indicated in Section
Medications, Supplements, Dietary Products) for the prohibited time period.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMedications, Supplements, Dietary Products) for the prohibited time period.
Has been on a diet incompatible with the on
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHas been on a diet incompatible with the on
days prior to dosing.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedays prior to dosing.
Has made a donation of blood or had significant blood loss within 56
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHas made a donation of blood or had significant blood loss within 56
Has made a plasma donation within 7 days prior to dosing.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHas made a plasma donation within 7 days prior to dosing.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use10.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use10.Participated in another clinical study within 30 days prior to dosing. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseParticipated in another clinical study within [ADDRESS_804613] dosing in the previous study to Day
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedate of the last dosing in the previous study to Day
11.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use11.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 11of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIALMain Criteria for Evaluation and Analyses:
Primary  endpoints:
The following PK parameters in plasma will be analyzed for soticlestat:
Maximum observed concentration (C max)
Area under the concentration -time curve from time [ADDRESS_804614] quantifiable concentration (AUC ∞)
Area under the concentration -time curve from time [ADDRESS_804615] quantifiable concentration 
(AUC last)
Secondary endpoints:
Incidence of treatment -emergent adverse events (TEAEs)
Incidence of clinically significant abnormal values for laboratory evaluations, vital signs, ECG parameters, 
and C-SSRS
Statistical Considerations:
Pharmacokinetics:
Descriptive statistics will be used to summarize concentrations of soticlestat and PK parameters according to hepatic 
function group (normal hepatic function and moderate and mild HI). An analysis of variance (ANOVA) will be 
performed on the natural log (ln) -transformed C max, AUC last, and AUC ∞for soticlestat to compare each HI grou p with 
the normal hepatic function group, and 90% confidence intervals (CI) for the ratio of geometric means from each HI group versus normal function group will be provided. The additio n of other factors and covariates such as age, sex, and 
BMI on the relationship between soticlestat PK parameters and level of HI may also be investigated. 
Descriptive statistics will be used to summarize concentrations of  PK 
parameters according to hepatic function group (normal hepatic function and moderate and mild HI).
The fraction of unbound soticlestat will be determined.
Safety:
TEAEs will be tabulated. Summary statistics for vital signs, safety 12 -lead ECGs, C -SSRS, and safety laboratory 
assessments will be computed and provided according to hepatic function group (normal hepatic function and 
moderate and mild HI). Markedly abnormal values (MAV) criteria for vital signs, 12 -lead ECGs, and safety laboratory 
assessments will be defined in the statistical analysis plan (SAP).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetime curve from time 0 to infinity, calculated using the observed value of the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetime curve from time [ADDRESS_804616] quantifiable concentration 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetime curve from time [ADDRESS_804617] quantifiable concentration 
evaluations, vital signs, ECG parameters, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useevaluations, vital signs, ECG parameters, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDescriptive statistics will be used to summarize concentrations of soticlestat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDescriptive statistics will be used to summarize concentrations of soticlestat
function group (normal hepatic function and moderate and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefunction group (normal hepatic function and moderate and 
performed on the natural log (ln)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useperformed on the natural log (ln) -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-transformed C
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetransformed C
the normal hepatic function group, and 90% confidence intervals (CI) for the ratio of geometric means from each HI 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe normal hepatic function group, and 90% confidence intervals (CI) for the ratio of geometric means from each HI 
normal function group will be provided. The 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenormal function group will be provided. The 
ationship between soticlestat PK parameters and level of HI may also be investigated. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useationship between soticlestat PK parameters and level of HI may also be investigated. 
Descriptive statistics will be used to summarize concentrations of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDescriptive statistics will be used to summarize concentrations of 
parameters according to hepatic function group (normal hepatic fu
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useparameters according to hepatic function group (normal hepatic fu
The fraction of unbound soticlestat will be determined.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe fraction of unbound soticlestat will be determined.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTEAEs will be tabulated. Summary statistics for vital signs, safety 12
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTEAEs will be tabulated. Summary statistics for vital signs, safety 12
assessments will be computed and provided according to hepatic function group (normal hepatic function and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useassessments will be computed and provided according to hepatic function group (normal hepatic function and 
moderate and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemoderate and 
assessments will be defined in the statistical analysis plan (SAP).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useassessments will be defined in the statistical analysis plan (SAP).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 12of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIALSample Size Justification:
The planned sample size of [ADDRESS_804618] dose may be 
replaced at the discretion of the Investigators in consultation with the Sponsor to ensure 8 P K-evaluable participants in 
each arm of participants with HI and 12 -24 PK -evaluable participants in matched participants with normal hepatic 
function complete.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use participant who is not PK evaluable including those experiencing emesis within [ADDRESS_804619] dose may be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use participant who is not PK evaluable including those experiencing emesis within [ADDRESS_804620] dose may be 
evaluable participants in 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useevaluable participants in 
evaluable participants in matched participants with normal hepatic 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useevaluable participants in matched participants with normal hepatic 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 13of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIAL2.0 STUDY SCHEMATIC
Table 2.a Study Design for Arms 1, 2, and 3
ScreeningCheck -in and 
Predose 
Assessments aSoticlestat Dosing, 
PK Sampling and 
Study 
AssessmentsPK Sampling 
and Study 
AssessmentsPK Sampling, Study 
Assessments and Study 
DischargebFollow -up
Within 
28days prior 
to soticlestat 
dosingDay -1 Day 1 Days 2 -6 Day 714 ± 2 days following 
the soticlestat dose 
Outpatient 
Visit----------------------------- Confinementa-----------------------------------(Phone Contact)
aParticipants will start the confinement on Day -1 and remain confined in the clinic throughout the study until Day 7. Participants 
may be admitted to the clinic earlier for Coronavirus Disease -19 (COVID -19) procedures not related to the study protocol. 
Participants will be discharged from the clinic on Day [ADDRESS_804621] PK sample collection and study procedures are com pleted.
bStudy Discharge is defined as end of treatment and study procedures.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFollow
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFollow -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-up
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useup
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use14 ± 2 days following 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use14 ± 2 days following 
the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1 and remain confined in the clinic throughout the study until Day 7. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1 and remain confined in the clinic throughout the study until Day 7. 
19) procedures not related to the study protocol. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use19) procedures not related to the study protocol. 
Participants will be discharged from the clinic on Day [ADDRESS_804622] PK sample collection and study procedures are com
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseParticipants will be discharged from the clinic on Day [ADDRESS_804623] PK sample collection and study procedures are com
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 14of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIAL3.0 SCHEDULE OF STUDY PROCEDURES
Study ProceduresaStudy Days in Arms 1, 2, and 3
Days in Period → Sb-1 1 2 34 56 7 (EOS)/ET FUc
Hours → C- Id00.133 0.25 0.5 0.75 11.5 2 4 6 8 10 14 24 36 48 72 96 120 144
Administrative Procedures
Informed Consent X
Inclusion/Exclusion Criteria XX
Medical History X
Safety Evaluations
Full Physical ExaminationeX XfXg
Height X
Weight X
Child -Pugh AssessmenthX
12-Lead Safety ECGjX XiX X Xg
Vital Signs (PR and BP)jX XiX X Xg
Vital Signs (RR and T)jX XiX Xg
Hem, Coag, Serum Chemk, and UA XX X Xg
Serum Pregnancy Test ( ♀only) XX
Serum FSH ( ♀only) X
Urine/Saliva Drug Screen XX
Urine/Breath Alcohol Screen XX
HIV/Hepatitis B and C Screen X
C-SSRSlXX Xg
AE Monitoring X X
ConMeds Monitoring X
Study Drug Administration / PK
Soticlestat Administration Xm
Blood for SoticlestatXnX X XXX XXX X X X X X XXX XX Xg
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2 34 56
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2 34 56
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2 4 6 8 10 14 24 36 48 72 96 120 144
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2 4 6 8 10 14 24 36 48 72 96 120 144
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 15of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIALStudy ProceduresaStudy Days in Arms 1, 2, and 3
Days in Period → Sb-1 1 2 34 56 7 (EOS)/ET FUc
Hours → C- Id00.[ADDRESS_804624] all participants (including participants who terminate the study early) by [CONTACT_648] 14 ± [ADDRESS_804625] occurred since CRU discharge.
dParticipants will be admitted to the CRU on Day -1 at the time indicated by [CONTACT_47365] .Participants may be admitted to the CRU earlier for COVID -19 
procedures not related to the study protocol.
eSymptom -driven phy sical examinations may be performed during the study , at the Investigator’s or designee’s discretion.
fIf the screening assessment was conducted within 4 -7 days prior to dosing (Day 1), assessment will be conducted at check -in only if, in the opi[INVESTIGATOR_47338], there is reason to believe they have substantially changed. 
gTo be performed at Day 7 (EOS) or prior to ET from the study.
hTwo hepatic function assessments are required prior to Day [ADDRESS_804626] 48 
hours apart. In the case where a participant has an available historical Chil d-Pugh assessment score within 3 months prior to screening, 1assessment can be 
conducted during the screening period. If the Child-Pugh scores from these 2 assessments indicate the same liver function category for the participant (ie, 
normal function, moderate impairment, or mild impairment), soticlestat can be administered as scheduled. If the results of the [ADDRESS_804627] recent assessments (the 
second and third) are in agreement with regard to the participant’s liver function category, the participant may be enrolled and should receive the Day [ADDRESS_804628] measurements differ, the participant will not be eligible for the study .
iTo be performed within 24 hours prio r to dosing.
jAll assessments will be performed (supi[INVESTIGATOR_2547]) after participants have rested for at least [ADDRESS_804629] fasted for 8 hours prior to when the serum chemistry sample is taken.
lAt screening, the C -SSRS Baseline/Screening version will be administered; at all other time points, the Since Last Visit version will be administered. When
possible, it is highly recommended that assessments are conducted by [CONTACT_607296].
mAfter an overnight fast of at least [ADDRESS_804630] 4 hours after drug administration, no food is a llowed.
nPrior to soticlestat administration.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2 34 56
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2 34 56
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2 4 6 8 10 14 24 36 48 72 96 120 144
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2 4 6 8 10 14 24 36 48 72 96 120 144
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe clinic will contact [CONTACT_55473] (including participants who terminate the study early) by [CONTACT_648] 14 ± 2 days after th
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe clinic will contact [CONTACT_55473] (including participants who terminate the study early) by [CONTACT_648] 14 ± 2 days after th
1 at the time indicated by [CONTACT_607297]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1 at the time indicated by [CONTACT_47365] .
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.Participants may be admitted to the CRU earlier for COVID
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseParticipants may be admitted to the CRU earlier for COVID
, at the Investigator’s or designee’s discretion.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, at the Investigator’s or designee’s discretion.
7 days prior to dosing (Day 1), assessment will be conducted at check
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use7 days prior to dosing (Day 1), assessment will be conducted at check
nvestigator or designee, there is reason to believe they have substantially changed. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenvestigator or designee, there is reason to believe they have substantially changed. 
Two hepatic function assessments are required prior to Day 1 for participants with HI. These 2 assessments should be obtained
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTwo hepatic function assessments are required prior to Day 1 for participants with HI. These 2 assessments should be obtained
In the case where a participant has an available historical Chil
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIn the case where a participant has an available historical Chil
Pugh scores from these 2 assessments indicate the same liver function category for the participant (ie, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePugh scores from these 2 assessments indicate the same liver function category for the participant (ie, 
impairment), soticlestat can be administered as scheduled. If the results of the 2 assessments indicate different 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useimpairment), soticlestat can be administered as scheduled. If the results of the [ADDRESS_804631] 24 hours after the second assessment. If th
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useliver function categories, a third assessment must be conducted at least [ADDRESS_804632]) are in agreement with regard to the participant’s liver function category, the participant may be enrolled 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesecond and third) are in agreement with regard to the participant’s liver function category, the participant may be enrolled 
hours of the third assessment. If the s
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehours of the third assessment. If the s econd and third measurements differ, the participant will not be eligible for the study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useecond and third measurements differ, the participant will not be eligible for the study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useto dosing.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useto dosing.
All assessments will be performed (supi[INVESTIGATOR_2547]) after participants have rested for at least 5 minutes. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAll assessments will be performed (supi[INVESTIGATOR_2547]) after participants have rested for at least [ADDRESS_804633] 8
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of User serum chemistry will be obtained in the fasted state following a fast of at least 8
hours prior to when the serum chemistry sample is taken.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehours prior to when the serum chemistry sample is taken.
Baseline/Screening version will be administered; at all other time points, the Since Last Visit version will be administered.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseBaseline/Screening version will be administered; at all other time points, the Since Last Visit version will be administered.
possible, it is highly recommended that assessments are conducted by [CONTACT_607296].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepossible, it is highly recommended that assessments are conducted by [CONTACT_607296].
fast of at least [ADDRESS_804634] 4 hours after drug administration, no food is a
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefast of at least [ADDRESS_804635] 4 hours after drug administration, no food is a
r to soticlestat administration.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of User to soticlestat administration.
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804636] PK sample collection and study procedures are completed .
Abbreviations: ♀=Females, AE =Adverse events, BP =Blood pressure, C -I =Check -in, Chem =Chemistry, Coag = Coagulation, ConMeds =Concomitant medication, 
COVID -19 = Coronavirus disease 2019, CRU =Clinical research unit, C -SSRS = Columbia -Suicide Severity Rating Scale, ECG =Electrocardiogram, EOS/ET =End-of-Study  or 
early  termination, FSH =Follicle-stimulating hormone, FU =Follow -up, Hem =Hematology, HIV =Human immunodeficiency virus, PK =Pharmacokinetics, PR = Pulse rate, 
RR=Respi[INVESTIGATOR_697], S =Screening, T =Temperature, UA =Urinalysis.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehroughout the study until Day 7. Participants will be discharged from the
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehroughout the study until Day 7. Participants will be discharged from the
mistry, Coag = Coagulation, ConMeds
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemistry, Coag = Coagulation, ConMeds
ECG
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseECG =
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use=Electrocardiogram, EOS/ET
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseElectrocardiogram, EOS/ET
Human immunodeficiency virus, PK
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHuman immunodeficiency virus, PK
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 17of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIAL4.0 INTRODUCTION
4.1 Background
4.1.1 Soticlestat (TAK-935)
Soticlestat i s a potent and select ive cho lesterol  24Shydroxylase (CH24H) inhibitor currently in 
development as an oral adjunct to standard of care therapy  for the treatm ent of rare pediatric 
epi[INVESTIGATOR_424094] (DEE) which are a cluster 
of pedi atric epi[INVESTIGATOR_30989] y syndromes and includes Dravet Syndro me (DS) and Lennox Gastaut 
Syndrome (LGS). Epi[INVESTIGATOR_607264] a dysregulatio n in glutamatergic signaling brought upon by 
[CONTACT_591637] -activation of CH24H. This enzyme is predominant ly expressed in neurons and invo lved in
the homeostasis of brain cho lesterol  by [CONTACT_607298] 24 S-hydroxycho lesterol  (24HC), a pol ar 
metabo lite capable of passing the brain barrier via lipoproteins. 
Soticlestat i s a fi rst-in-class therapeut ic candidate that has the potential to control seiz ures in 
treatm ent-resistant pati ents wi th epi[INVESTIGATOR_607265] -activated glutamate signaling by 
[CONTACT_607299] -activated glutamate signaling in neurons. This 
mechanism o f action is thought to clinically manage seizures by [CONTACT_607300] y as well as brain damage and cognitive deficits that are pathological sequelae of the 
epi[INVESTIGATOR_607266] .
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehydroxylase (CH24H) inhibitor currently in 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehydroxylase (CH24H) inhibitor currently in 
ent of rare pediatric 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useent of rare pediatric 
epi[INVESTIGATOR_424094] (DEE) which are a cluster 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useepi[INVESTIGATOR_424094] (DEE) which are a cluster 
me (DS) and Lennox Gastaut 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useme (DS) and Lennox Gastaut 
n in glutamatergic signaling brought upon by 
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen in glutamatergic signaling brought upon by 
[CONTACT_607301]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usely expressed in neurons and invo
hydroxycho
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehydroxycho le
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselesterol
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesterol
ic candidate that has the potential to control seiz
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useic candidate that has the potential to control seiz
 reducing over
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use reducing over activated glutamate signaling by 
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useactivated glutamate signaling by 
[CONTACT_607302]. This 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useactivated glutamate signaling in neurons. This 
on is thought to clinically manage seizure
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon is thought to clinically manage seizure
ive deficits that are pathological sequelae of the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useive deficits that are pathological sequelae of the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usens where excessive glutamatergic signaling act
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usens where excessive glutamatergic signaling act
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 18of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIAL4.1.1.2 Clinical Safety and Pharmacokinetics
The PK, safet y,tolerabili ty, and/or efficacy o f soticlestat have been evaluated in 6 phase 1 clinical 
studi es in heal thy participants (com pleted), a phase 1b/2a study in part icipants wi th DEEs 
(com pleted), and 3 phase 2 studies in part icipants wit h DS, LGS, 15q11 -q13 dup lication syndro me
(Dup15q), cy clin-dependent kinase -like 5 (CDKL5) deficiency disorder (CDD), or complex 
regional pain syndrom e (com pleted). One (1) phase [ADDRESS_804637] received active treatment based on actual exposure and enrollment data from co mpleted and 
ongoing clinical trials as of the safet y data cut- off date (19 November 2021).
Soticlestat was rapi[INVESTIGATOR_607267] a median t ime of t maxof 0.25 to 0.52 hours following 
single- dose administration (15 to 1350 mg; Study  TAK -935-101) and a median t maxof 0.33 to 0.5 
hours fo llowing mult iple dose administration (100 t o 600 mg) under fast ing condit ions in healt hy 
participants (Study  TAK -935- 1002). When administered under fed condit ions, soticlestat t maxwas 
delayed by [CONTACT_2902] 1.5 hours andCmaxwas decreased by 60%; however, food had little impact on the 
total exposure of the drug as AUC decreased by  [INVESTIGATOR_13701]  11% using the tabl et formulation (Study
TAK  935 -1005). Soti clestat was shown to cross the blood brain barrier and was able to block Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usef soticlestat have been evaluated in 6 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usef soticlestat have been evaluated in 6 
ic
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useicipants wi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useipants wi
h DS, LGS, 15q11
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useh DS, LGS, 15q11 -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-q13 dup
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useq13 dup
like 5 (CDKL5) deficiency disorder (CDD), or complex 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselike 5 (CDKL5) deficiency disorder (CDD), or complex 
bel, l
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebel, l ong
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useong
ous DEEs, including DS, LGS, Dup15q, or CDD, 2
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useous DEEs, including DS, LGS, Dup15q, or CDD, 2 p
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usephase 1 drug
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehase 1 drug
 m
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use mild
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useildto 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useto 
hase 3 studies in DS and LGS patients are ongoing.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehase 3 studies in DS and LGS patients are ongoing.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselled in the clinical trials wit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselled in the clinical trials wit
ive treatment based on actual exposure and enrollment data from co
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useive treatment based on actual exposure and enrollment data from co
data cut
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedata cut -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-off date (19 November 2021).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useoff date (19 November 2021).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSoti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSoticlestat was rapi[INVESTIGATOR_607268]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useclestat was rapi[INVESTIGATOR_607269]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesingle
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804638] (St udy 
TAK  935 -1003). Mean soticlestat t 1/2zranged from 4.39 to 7.16 hours fro m 200 to 1350 mg 
following a single -dose administration, and 3.49 to 4.83 hours across the 100 to 600 mg dose range 
after administration of multiple doses and similar between Days 1 and 14. 
.
The PK profile fo llowing single -dose and mult iple-dose administration were further characterized 
in healthy Japanese participants (Study  TAK -935-1004). Soticlestat was rapi[INVESTIGATOR_607270], with t maxof 0.5 to 0.75 hours. Soticlestat t 1/2zvalues ranged fro m 5.075 to 8.695 
hours after a single- dose and fro m 2.620 to 3.630 hours after mult iple doses with up ti tration. PK 
exposure to soticlestat increased in a greater than dose- proporti onal manner in the dose ranges 
from [ADDRESS_804639] of HI on the PK of single dose soticlestat 
. After entering the body, drugs are eliminated by [CONTACT_607303]/or 
metabo lism. Although eliminat ion can occur through a variety o f routes, most drugs are cleared by 
[CONTACT_607304]/or small intest ine and/or by  [CONTACT_607305]. Liver disease is associated with several pathophysio logic changes that may alter the PK of 
adrug. These include alterations in hepat ic blo od flow, changes in liver enzyme activit y, decreased 
binding of drug to plasma proteins, and impaired biliary  excret ion [2, 3] . Accordingly, current 
[LOCATION_002] (US) FDA guidance reco mmends a PK study in pat ients with impaired hepatic 
funct ion if hepati c met abolism and/or excretion accounts for a substant ial porti on (≥ 20 % of the 
absorbed drug) of the eliminat ion of a parent drug or active metabo lite[4].
The m agnitude of  the effect of mild, moderate ,or severe HI on the PK of soticlestat was assessed 
based on m odel-based simulat ions of HI effect using in vitro enzyme phenoty pi[INVESTIGATOR_607271]. The simulat ions suggested that in participants with mild, moderate, 
or severe HI, soticlestat AUC ∞ is expected to be 1%, 23%, and 33% higher, respectively, than 
healt hy participants with normal hepat ic function; soti clestat C maxis expected to be 0%, 6%, and 
7% hi gher, respectively, compared with healthy participants with normal hepat ic function.Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use600 mg dose range 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use600 mg dose range 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedose administration were further characterized 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedose administration were further characterized 
1004). Soticlestat was rapi[INVESTIGATOR_607272]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1004). Soticlestat was rapi[INVESTIGATOR_607273]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevalues ranged fro m 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usem 5.075 to 8.695 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use5.075 to 8.695 
iple doses with
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useiple doses with up
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useup
anner in the dose ranges 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useanner in the dose ranges 
g single dose and 100 to 300 mg BID. Accumulat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useg single dose and 100 to 300 mg BID. Accumulat io
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useion of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen of 
n ratios less than 1.06 at steady state.  
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen ratios less than 1.06 at steady state.  
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useonale for the Proposed Study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useonale for the Proposed Study
, the impact of HI on the PK of single dose soticlestat 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, the impact of HI on the PK of single dose soticlestat 
. After entering the body
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. After entering the body
lism. Although eliminat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselism. Although eliminat
in the liver and/or small intest
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usein the liver and/or small intest
dney. Liver disease is associated with several pathophysio
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedney. Liver disease is associated with several pathophysio
drug. These include alterations in hepat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedrug. These include alterations in hepat
binding of drug to plasma proteins, and impaired biliary
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebinding of drug to plasma proteins, and impaired biliary
[LOCATION_002] (US) FDA guidance reco
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use[LOCATION_002] (US) FDA guidance reco
funct
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefunct io
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useion 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen if 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useif 
absorbed drug) of the eliminat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useabsorbed drug) of the eliminat
The m
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe m
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804640] evaluated the PK in part icipants with moderate 
HI (n=8) and healthy matched participants with normal hepatic function (n=12) and an interim PK 
analysis was conducted. The interim analysis indicated higher impact of moderate HI on sot iclestat 
PK than the modelpredicted . For participants with moderate HI, soticlestat PK exposure increased 
to 214.93%, 316.47%, and 299.38% for C max, AUC last, and AUC ∞, respectively, when compared to 
the respective PK exposure in matched participants with norm al hepatic function. As a result, this 
study will  further evaluate the impact of mild HI on the PK of soticlestat. In addit ion, the Sponsor 
decides not to dose participants with severe HI. Soticlestat will not be recommended to use in 
subjects wi th severe HI.
4.3 Benefit/Risk Profile
The single dose of 300 mg soticlestat has been selected for this study  as it is the recommended 
phase 3 dose [1] . In addit ion, doses up to 1350 m g were administered in healt hy participants and 
were found to be safe and well tolerated.
The inclusio n and exclusio n criteria, screening, and safet y monitoring practices emplo yed by [CONTACT_47375]  (ie, 12 -lead ECG, vital signs, clinical laboratory tests, AE questioning, C -SSRS, and 
physical examinat ions) are adequate to protect the participant’s safet y and should detect all 
TEAEs.There will be no direct healt h benefit for study participants from receipt of the study drugs. An 
indirect health benefit  to the healthy participants enrolled in this study  is the free medical tests 
received at screening and during the study.
5.0 STUDY OBJECTIVES AND ENDPOINTS
5.1 Hypothesis
Not applicable.
5.2 Study Objectives
5.2.1 Study Primary Objective
To characterize the plasma PK of soticlestat following a single oral dose in participants with 
moderate or mild HI com pared to m atched healt hy participants with normal hepat ic function.
5.2.2 Study Secondary Objective
To evaluate the safet y and tolerabilit y of soticlestat fo llowing a single ora l dose in participants 
with moderate or mild HI as well as matched healthy part icipants with normal hepat ic function.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselestat 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselestat 
. For participants with moderate HI, soticlestat PK exposure increased 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. For participants with moderate HI, soticlestat PK exposure increased 
, respectively, when compared to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, respectively, when compared to 
n. As a result, this 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen. As a result, this 
n, the Sponsor 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen, the Sponsor 
des not to dose participants with severe HI. Soticlestat will not be recommended to use in 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedes not to dose participants with severe HI. Soticlestat will not be recommended to use in 
 as i
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use as it is the recommended 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uset is the recommended  as it is the recommended  as i
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use as it is the recommended  as i
g were administered in healt
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useg were administered in healt
mo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemonit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenitori
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useori
-lead ECG, vital signs, clinical laboratory
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-lead ECG, vital signs, clinical laboratory tests, AE questioning, C
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetests, AE questioning, C
ns) are adequate to protect the participant’s safet
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usens) are adequate to protect the participant’s safet
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use participants from receipt of the study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use participants from receipt of the study h benefit for study  participants from receipt of the study h benefit for study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useh benefit for study  participants from receipt of the study h benefit for study
 to the healthy participants enrolled in this study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use to the healthy participants enrolled in this study
received at screening and during the study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usereceived at screening and during the study .
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.
STUDY OBJECTIVES AND ENDPOINTS
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSTUDY OBJECTIVES AND ENDPOINTS
Objectives
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseObjectives
Study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseStudy Primary Objective
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePrimary Objective
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTo characterize the plasma PK of soticlestat following a single oral dose in participants with 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTo characterize the plasma PK of soticlestat following a single oral dose in participants with 
derate or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usederate or 
5.2.2
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use5.2.2

Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTo evaluate the safet
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTo evaluate the safet
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 21of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIAL5.3 Endpoints
5.3.1 Primary Endpoints
The fo llowing PK parameters in plasma will be analyze d for soti clestat:
Cmax
AUC ∞
AUC last
5.3.2 Secondary Endpoints 
Incidence of TEAEs
Incidence of clinically significant abnormal values for laboratory  eval uations, vi tal signs, 
ECG parameters, and C-SSRS
6.[ADDRESS_804641] 12 healthy 
participants (up to 24 participants) with normal hepatic funct ion will  be recrui tedto match the 
group m ean of  moderate and mild HI arms by [CONTACT_654] (m ean ± 10 y ears), sex (± 2 per sex), and BMI 
(mean±10%). Eight (8) participants will also be enro lled in each HI arm o f the study according to 
the following cri teria: Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIncidence of clinically significant abnormal values for laboratory
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIncidence of clinically significant abnormal values for laboratory
STUDY DESIGN AND DESCRIPTION
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSTUDY DESIGN AND DESCRIPTION
Study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseStudy
This is a phase 1, open
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThis is a phase 1, open
soti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesoticlestat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useclestat
com
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecom
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 22of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIALArm 1: (N = 8): Moderate HI (Child -Pugh Class B [Score: ≥ 7 and ≤ 9]), 300 mg single 
dose
Arm 2: (N = 8): Mild HI (Child -Pugh Class A [Score: ≥ 5 and ≤ 6]), 300 mg single dose 
Arm 3: (N = 12 -24): Normal hepatic funct ion, [ADDRESS_804642] of a 28 -day s creening peri od (pri or to dosing) and a 7- day confinement 
period (Day  -1 to Day  7).
Two hepatic funct ion assessments are required prior to Day  [ADDRESS_804643] ion category  for the 
participant (i e, norm al hepatic funct ion, moderate HI, or mild HI), soti clestat can be administered 
as scheduled. If the results of the [ADDRESS_804644] recent assessments (the second and third) are in agreement with regard to the participant’s 
liver funct ion category , the parti cipant m ay be enrolled and shou ld receive the Day [ADDRESS_804645] measurements differ, the participant will 
not be eligible for the study .
The m oderate HI arm  (ie, Arm  1) will  be conducted first, foll owed by 12 parti cipants in the 
matched normal hepat ic function arm  (Arm 3). After all participants in moderate HI arm and the 
matching 12participants in the m atched norm al hepati c function arm  have co mpleted the 
treatm ent period, an inform alinterim PK data analysis is planned and may additionally leverage 
histori cal control  PK data in healthy participants to gain an init ial estimate of the effect of 
moderate HI on the PK of soticlestat .
Following com pletion of enrolment of the mild HI arm , and in the instance any  ofthe previously 
enrolled healthy participants cannot be used for matching purposes, up to an addit ional 
12participants may be enrolled for the mat ched normal hepatic funct ion group ( Arm 3) to ensure a 
minimum o f 12 participants with normal hepat ic function and matching the m ean of  the mild HI 
arm by [CONTACT_654] (m ean ± 10 years), sex (± 2 per sex), and body  mass index (BMI, mean ± 10%) are 
enrolled. 
Parti cipants will receive a single oral dose of 300 mg soticlestat as three 100 mg T4 tablets on Day 
1 with approxi mately  240 mL water under fasting condit ions. PK samples will be collected from 
Days 1 to 7, at predetermined t ime po ints (Section 3.0), to characte rize the PK o f soticlestat  
in participants with moderate or mild HI compared to matched 
healt hy participants with normal hepat ic function (Section 3.0).
Parti cipants will remain in the clinic throughout the study. Participants will be discharged from the 
clinic on Day  [ADDRESS_804646] of all participants (including those who terminate the study early) will occur 14 
± [ADDRESS_804647] occurred since the CRU discharge.Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use]), 300 mg single dose 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use]), 300 mg single dose 
 confinement 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use confinement 
 1 dosing for participants with HI. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use 1 dosing for participants with HI. 
These 2 assessments should be obtained during the screening period and at leas
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThese 2 assessments should be obtained during the screening period and at leas t 48 hours apart. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uset 48 hours apart. 
Pugh assessment score within 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePugh assessment score within 
or to screening, 1 assessment can be conducted during the screening period. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useor to screening, [ADDRESS_804648]
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee liver funct io
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useio
HI), soti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHI), soti clestat can be administered 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useclestat can be administered 
assessments indicate different liver funct
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useassessments indicate different liver funct
hours after the second assessment. If the results of the 2 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehours after the second assessment. If the results of the [ADDRESS_804649] recent assessments (the second and third) are in agreement with regard to the participant’s 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usest recent assessments (the second and third) are in agreement with regard to the participant’s 
ay be enrolled and shou
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useay be enrolled and shou
[ADDRESS_804650] measurements differ, the participant will 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use48 hours of the third assessment. If the second and third measurements differ, the participant will 
 be conducted first, foll
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use be conducted first, foll
 (A
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use (Arm
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userm 3). After all participants in moderate HI arm and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use 3). After all participants in moderate HI arm and rm 3). After all participants in moderate HI arm and rm
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userm 3). After all participants in moderate HI arm and rm
atched norm
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useatched norm
erim
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useerim PK
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePK data analysis
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use data analysisPK data analysisPK
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePK data analysisPK
 PK data in healthy participants to gain an init
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use PK data in healthy participants to gain an init
derate HI on the PK of soticlestat 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usederate HI on the PK of soticlestat 
n of enrolment of the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen of enrolment of the 
ic
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useicipants cannot be used for matching purposes, up to an addit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useipants cannot be used for matching purposes, up to an addit
participants may be enro
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useparticipants may be enro
12 participants with normal hepat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use12 participants with normal hepat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use by [CONTACT_654] (m
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use by [CONTACT_654] (m
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useean ± 10 years), sex (± 2 per sex), and body
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useean ± 10 years), sex (± 2 per sex), and body
pants will receive a single oral dose of 300 mg soticlestat as three 100 mg T4 tablets on Day 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepants will receive a single oral dose of 300 mg soticlestat as three 100 mg T4 tablets on Day 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1 wi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1 with
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useth1 with1 wi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1 with1 wi  approxi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use approxith approxith
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useth approxith
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDays 1 to 7, at predetermined t
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDays 1 to 7, at predetermined t
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehealt
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehealt
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 23of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIAL6.2 Dose Escalation
Not applicable.
6.3 Stoppi[INVESTIGATOR_304499].6.4 Rationale for Study Design, Dose, and Endpoints
6.4.1 Rationale of Study Design 
After entering the body, drugs are eliminated by  [CONTACT_337424]/or metabolism. Alt hough 
eliminat ion can occur through a variet y of routes, most drugs are cleared by m etabo lism in the liver 
and/or sm all intestine and/or by  [CONTACT_607306]. Liver disease is 
associ ated wi th several  pathophysi ologic changes that may  alter the PK of a drug. These include 
alterati ons in hepat ic blood flow, change s in liver enzyme act ivity, decreased binding of drug to 
plasma proteins, and impaired biliary excret ion [2, 3]. Accordingly the current [LOCATION_002] (US) 
Food and Drug Administration (FDA) guidance recommends a PK study in patients with impaired 
hepat ic function if hepat ic metabo lism and/or excretion accounts for a substant ial porti on 
(ie,≥ 20 % of the absorbed drug) of the eliminat ion of a parent drug or active metabo lite [4] . 
Urinary  excret ion is the major route for soticlestat eliminat ion with 95% of  the dose excreted in 
urine; however, urinary  excret ion of the parent drug is low (< 1% of the dose) indicat ing that 
metabo lism is the near exclusive clearance pathway  of soticlestat. TAK -935-G excreted in urine 
contributed to 86% of the dose suggesting that soticl estat was predominant ly cleared by [CONTACT_298315], thus the potential implicat ions of HI on soticlestat’s hepatic metabo lism, should 
be evaluated.
This study  will invest igate the impact of impaired hepat ic function on the plasma PK of soticl estat 
and safet y compared to matched healthy part icipants wi th norm al
hepat ic function in order to provide dosing recommendat ions to clinicians for future treatments of 
soticlestat to pati ents wi th varying degrees of HI. An info rmalinterim PK data analysis was
perform ed following soti clestat administration in participants with moderate HI (n
=8)and healt hy 
matched participants with normal hepat ic function , which has dem onstrated hi gher tha nexpected 
soticlestat exposure in parti cipants wi th moderated HI than in healt hy matched parti cipants wi th
norm al hepat ic function . The Sponsor has decide dnot to recommend soticlestat dosing in patients
with severe HI, therefore participants with severe HI will not be enrolled in the current study . 
Instead, t hisstudy will enroll an arm of parti cipants with mild HI in order to further investigate the 
impact of HI on soticlestat PK . Due to the variability  of soticlestat PK and easier accessibilit y of 
healt hy participants in co mparison to parti cipants wi th HI, an increased number of healt hy 
participants will be enrolled.
The Child-Pugh classificat ion will be used to categorize HI due to its widespread use and 
acceptance by  [CONTACT_55746] (including the FDA). It has been shown to correl ate wi th
hepat ic (ie, metabo lic) clearance for several co mpounds [4] . In the current study, participants with 
chronic, stable HI with features of cirrhosis due to a ny et iology will be enrolled using the Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon and/or metabolism. Alt
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon and/or metabolism. Alt
es, most drugs are cleared by m
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usees, most drugs are cleared by m etabo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useetabo
 the ki
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use the ki dneys. Liver disease is 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedneys. Liver disease is 
ter the PK of a drug. These include 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useter the PK of a drug. These include 
ivit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useivity,
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usey, decreased binding of drug to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use decreased binding of drug to 
. Accordingly the current [LOCATION_002] (US) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. Accordingly the current [LOCATION_002] (US) 
Food and Drug Administration (FDA) guidance recommends a PK study in patients with impaired 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFood and Drug Administration (FDA) guidance recommends a PK study in patients with impaired 
lism and/or excretion accounts for a substant
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselism and/or excretion accounts for a substant
n of a parent drug or active metabo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen of a parent drug or active metabo
is the major route for soticlestat eliminat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useis the major route for soticlestat eliminat
n of the parent drug is low (< 1
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen of the parent drug is low (< [ADDRESS_804651]
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useis the near exclusive clearance pathway
contributed to 86% of the dose suggesting that
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecontributed to 86% of the dose suggesting that
n, thus the potential implicat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen, thus the potential implicat
igate the impact of impaired hepat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useigate the impact of impaired hepat
and safet
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand safet
in order to provide dosing recommendat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usein order to provide dosing recommendat
ents wi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useents wi th
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useth ents wi th ents wi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useents wi th ents wi  varying degrees of HI. An info
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use varying degrees of HI. An infoth varying degrees of HI. An infoth
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useth varying degrees of HI. An infoth
wing soti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewing soti
matched participants with normal hepat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usematched participants with normal hepat
clestat exposure in parti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useclestat exposure in parti
 hepat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use hepat ic function
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useic function
 severe 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use severe HI, therefore participants with severe HI will not be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHI, therefore participants with severe HI will not be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInstead, t
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInstead, t h
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useh
impact of HI on soticlestat PK
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useimpact of HI on soticlestat PK
healt
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehealt
parti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useparti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804652] severe derangement. Participants’ scores of 
5 to 6, 7 to 9, and 10 to15 on this scale are classified as having mild, moderate, and severe HI, 
respectively .
Table 6.a Derivation of C hild-Pugh Classification Score 1
Parameter 1 point 2 points 3 points
Serum albumin (g/dL) >3.5 2.8 to 3.5 <2.8
Total serum bilirubin (mg/dL) <2.0 2.0 to 3.0 >3.0
Prothrombin time (PT) (second prolonged) or
International normalized ratio (INR) (ratio)<4
<1.704 to 6
1.70 to 2.30>6
>2.30
Ascites Absent SlightModerate or participants on medication 
to control ascites
Hepatic encephalopathy grade None Grade 1 or 2Grade 3 or 4 or
participant receiving medication(s) to 
prevent encephalopathy
1Adapted from U.S. Department of Health and Human Services. Guidance for Industry. Pharmacokinetics in Patients 
with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling (2003) [4] .
Table 6.b Determination of Encephalopathy Grade 1
Encephalopathy Grade Definition
0 Normal consciousness, personality, neurological exam
1 Restless, sleep disturbed, irritable/agitated, tremor, impaired handwriting
[ADDRESS_804653] -disoriented, hyperactive reflexes, rigidity
4 Unrousable coma, no personality/behavior, decerebrat e
1Adapted from U.S. Department of Health and Human Services. Guidance for Industry. Pharmacokinetics in Patients 
with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling (2003) [4] .
6.4.2 Rationale for Dose 
T4 tablets are immediate release tablets of 100 mg strength that will be utilized for phase 3 clinical 
studies and will be used in this study . The m odel simulat ion (Sim CYP®) predi cted increase in 
soticlestat exposure in participants with moderate or mild HI is within two -fold, therefore the dose 
of soticlestat selected for the HI study is 300 mg, the recommended phase 3 dose. The 300 mg dose 
is approximately 22% of the highest single dose of 1350 mg evaluated in healt hy participants, and 
soticlestat exposure at 1350 mg was > [ADDRESS_804654] of moderate or mild HI on the 
exposure to soticlestat  will be characterized in this study Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use3 points
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use3 points
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use<2.8
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use<2.8
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use>3.0
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use>3.0
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use>6
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use>6
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseModerate or participants on medication 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseModerate or participants on medication 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseGrade 1 or 2
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseGrade 1 or 2
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAdapted from U.S. Department of Health and Human Services. Guidance for Industry. Pharmacokinetics in Patients 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAdapted from U.S. Department of Health and Human Services. Guidance for Industry. Pharmacokinetics in Patients 
with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling (2003) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewith Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling (2003) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDetermination of Encephalopathy Grade 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDetermination of Encephalopathy Grade 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseNormal consciousness, personality, neurological exam
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseNormal consciousness, personality, neurological exam
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRestless, sleep
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRestless, sleep
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseLethargic, time
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseLethargic, time
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSomnolent, stuporous, place
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSomnolent, stuporous, place
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAdapted from U.S. Department of Health and Human Services. Guidance for Industry. Pharmacokinetics in Patients 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAdapted from U.S. Department of Health and Human Services. Guidance for Industry. Pharmacokinetics in Patients 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewith Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling (2003) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewith Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling (2003) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRationale for Dose 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRationale for Dose 
tablets are immediate release tablets of 100 mg strength that will be ut
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetablets are immediate release tablets of 100 mg strength that will be ut
studi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usestudi es and will
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usees and will
soti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesoticlestat exposure in participants with moderate or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useclestat exposure in participants with moderate or 
of
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useof
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804655] ion. 
6.4.3 Rationale for Endpoints
[IP_ADDRESS] Pharmacokinetic Endpoints
The PK endpo ints are standard for this ty pe of  study .
[IP_ADDRESS] Safety Endpoints
The key safet y endpo ints are typi[INVESTIGATOR_607274] 1 studies and will be assessed through monitoring o f 
AEs, vital signs, ECGs, laboratory  assessments, C -SSRS, and physical examinat ions.
6.4.5 Critical Procedures Based on Study Objectives: Timing of Procedures 
For thi s study , the cri tical com ponent is the blood collect ion for plasma concentrati ons of 
soticlestat , and is to be collected within the sampling windows.
6.5 Study Design/Dosing/Procedures Modifications Permitted Within Protocol 
Parameters
The do se and administration of soticlestat for all participants with moderate HI , mild HI, and 
healt hy participants with normal hepat ic function (ie, Arms 1, 2, and 3) may not be modified.Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePugh scores will be compared to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePugh scores will be compared to 
r phase 1 studies and will be assessed through 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of User phase 1 studies and will be assessed through 
SSRS, and physical examinat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSSRS, and physical examinat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use6.4.5
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use6.4.5 Critical Procedures Based on 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCritical Procedures Based on 
For thi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFor thi
soti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesoticlestat 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useclestat 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804656] ion group (A rm 3) to ensure a minimum of 
12participants with normal hepat ic function and matching the mean o f the mild HI arm  by [CONTACT_654] 
(mean ± 10 y ears), sex (± 2 per sex), and body  mass index (BMI, mean ± 10%) are enrolled.
If necessary, a participant may be discontinued for the reasons described in Section 7.5and 
Secti on7.6.
6.6 Study Beginning and End/Completion
6.6.1 Definition of Beginning of the Study
The beginning of the study  will be defined as the beginning of the screening (ie, signing of the 
ICF) of the first participant.
6.6.[ADDRESS_804657] scheduled study  procedure as outlined in the 
Schedule of Study  Procedures (Section 3.0)
6.6.[ADDRESS_804658] to foll ow-up. 
6.6.4 Definition of Study Discontinuation
The clinical site(s) reserve(s) the right to terminate the study  in the interest of pa rticipant welfare.
The Sponsor reserves the right to suspend or terminate the study  at any  time.
6.6.[ADDRESS_804659] anned unless one or more of the fo llowing cri teria are satisfied
that require temporary  suspensi on or early  terminati on of  the study :
New informat ion or other evaluat ion regarding the safet y or efficacy  of the study  medicat ion 
that indicates a change in the known risk/benefit profile for the product, such that the risk is no 
longer acceptable for participants participat ing in the study .Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use enrolled 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use enrolled 
cipants may 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecipants may 
 3) to ensure a minimum of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use 3) to ensure a minimum of 
HI arm
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHI arm  by [CONTACT_607307]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use by [CONTACT_607308]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHI arm  by [CONTACT_607309]
10%) are enrolled.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use10%) are enrolled.
inued for the reasons described in Section
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinued for the reasons described in Section
beginning of the screening (ie, signing of the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebeginning of the screening (ie, signing of the 
s defined as the date of the last scheduled study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uses defined as the date of the last scheduled study
3.0
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use3.0)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use)
Definition of Study Completion
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDefinition of Study Completion
The end of the study is scheduled after complet
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe end of the study is scheduled after complet
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useime period may change in the event that 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useime period may change in the event that 
Definition of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDefinition of 
The clinical site(s) reserve(s) the right to terminate the study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe clinical site(s) reserve(s) the right to terminate the study
The Sponsor reserves the right to suspend or terminate the study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe Sponsor reserves the right to suspend or terminate the study
6.6.5
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use6.6.5
The study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe study
th
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethat require temporary
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useat require temporary
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 27of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIALSignificant vio lation of Good Clinical Practice (GCP) that compromises the ability to achieve 
the primary  study  objectives or compromises participant safet y.
6.6.6 Criteria for Premature Termi nation or Suspension of a Site
[IP_ADDRESS] Criteria for Premature Termination or Suspension
A study  site m ay be terminated prematurely  or suspended if the site (including the Investigator) is 
found in significant vio lation of GCP, the study  protocol , or contractual agreement; if the site 
(including the Investigator) is unable to ensure adequate performance of the study; or as otherwise 
permitted by [CONTACT_55731].
[IP_ADDRESS] Procedures for Premature Termination or Suspension
In the event that the sponsor, an Institutio nal Review Board (IRB)/ Independent Ethics Committee
(IEC) , or a regulatory  authori ty elects to terminate or suspend the participat ion of an 
investigat ional site, a study -specific procedure for early  terminat ion or suspensio n will be 
provi ded by [CONTACT_456] ; the procedure will be fo llowed by [CONTACT_424109](s) 
during the course of terminat ion or study  suspension.
7.0 SELECTION AND DISCON TINUATION/WITHDRAWAL OF PARTICIPANTS
7.[ADDRESS_804660] fulfill the fo llowing inclusio n criteria to be eligible for participation in the study 
(parti cipants who do not qualify based on a reversible condit ion or mild intercurrent illness may be 
re-screened after the condit ion is reso lved. Screening tests may be repeated if in the I nvest igator’s 
opi[INVESTIGATOR_3078] n the test needs to be repeated):
1.Is an adult male or female part icipant aged ≥ 18 to < 75 years, at screening.
2.Has a BMI ≥18.0 and ≤40.0 kg/m2, at screening. At least 50% of the participants will be
requi red to be of BMI ≥ 18.0 and ≤35.0 kg/m2, at screening. 
3.Aside from HI, be sufficient ly healthy for study  parti cipation based upon m edical history , 
physical examinat ion, vital signs, ECGs, and screening clinical laboratory profiles, as deemed 
by [CONTACT_47385].
Supi[INVESTIGATOR_607275] ≥ 80/40 mmHg (asymptomatic) and ≤ 150/95 mmHg, at screening;
Supi[INVESTIGATOR_607276] ≥ 40 bpm and ≤ 99 bpm ,at screening;
QTcF is ≤ [ADDRESS_804661] be stable, ie , no si gnificant changes in hepat ic function in the 30 days preceding Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenvestigator) is 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenvestigator) is 
reement; if the site 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usereement; if the site 
nvestigator) is unable to ensure adequate performance of the study; or as otherwise 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenvestigator) is unable to ensure adequate performance of the study; or as otherwise 
(IRB)/
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(IRB)/ Independent Ethics Co
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIndependent Ethics Co
 elects to terminate or suspend the participat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use elects to terminate or suspend the participat
 terminat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use terminat io
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useion or suspensio
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen or suspensio
llowed by [CONTACT_424109](s) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usellowed by [CONTACT_424109](s) 
TINUATION/WITHDRAWAL
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTINUATION/WITHDRAWAL
Inclusion for Participants with Hepatic Impairment
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInclusion for Participants with Hepatic Impairment
wing inclusio
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewing inclusio
cipants who do not qualify based on a reversible condit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecipants who do not qualify based on a reversible condit
io
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useion is reso
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen is reso
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen the test needs to be repeated):
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen the test needs to be repeated):
Is an adult male or female part
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIs an adult male or female part
18.0
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use18.0 and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand 
red to be of BMI ≥
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usered to be of BMI ≥
de f
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usede from
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useromde fromde f
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usede fromde f  HI, be sufficient
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use HI, be sufficientrom HI, be sufficientrom
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userom HI, be sufficientrom
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usephysical examinat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usephysical examinat
by [CONTACT_177972]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useby [CONTACT_607310]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInvest

Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 28of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIALscreening (or since the last visit if wit hin 6 mont hs before screening) and treatment with stable 
doses of m edicat ion. Has a score on the Child -Pugh Class at screening as fo llows: 
(Arm  1) Moderate HI, Child- Pugh Class B: ≥ 7 and ≤ 9
(Arm  2) Mild HI, Child- Pugh Class A: ≥ 5and ≤ [ADDRESS_804662] ion (creati nine clearance ≥ 50 m L/min), at screening.
7.1.[ADDRESS_804663] fulfill the fo llowing inclusio n criteria to be eligible for participat ion in the study:
1.Is an adult male or female part icipant aged ≥ 18 to < 75 years, at screening. Healthy 
participants will be matched to hepatic impaired participa nts in this study  by [CONTACT_4321] ( ±2per sex) 
and by  [CONTACT_654] (m ean± 10 years). 
2.Has a BMI ≥18.0 and ≤40.0 kg/m2, at screening. At least 50% of the participants will be 
requi red to be of BMI ≥ 18.0 and ≤35.0 kg/m2, at screening. Healthy  parti cipants will be 
matched to hepatic impaired participants in this study  by [CONTACT_44207] (mean ± 10%).
3.Medically  healthy wi th no cl inically  significant m edical history , physical examinat ion, 
laboratory  profiles, vi tal signs or ECGs, as deemed by  [CONTACT_47385]. 
Supi[INVESTIGATOR_607258] ≥ 90/40 mmHg and ≤ 150/95 mmHg, at screening;
Supi[INVESTIGATOR_607259] ≥ 40 bpm and ≤ 99 bpm ,at screening;
QTcF is ≤ 450 msec (males) or ≤ 470 msec (females) and ECG findings considered norma l 
or not clinically  significant by  [CONTACT_47385] , at screening;
Liver function tests including ALT , AST , ALP and total bilirubin ≤the ULN at screening 
and ch eck-in.
4.Parti cipants shoul d not have renal dysfunct ion as dem onstrated by  a rel atively adequate renal 
funct ion (creatinine clearance ≥ 60 m L/min), at screening.
7.1.[ADDRESS_804664] fulfill the fo llowing inclusio n criteria to be eligible for participat ion in t he study:
1.Understands the study  procedures i n the ICF, provides a signature/date in the ICF, and is 
willing and able to comply with the protocol.
2. Continuous non- smoker or m oderate smoker ( ≤ 10 cigarettes/day or the equivalent) before 
screening. Participant must agree to consume no more than 5 cigarettes or equivalent/day fro m 
the 7 days prior check -in and unt il discharge fro m the CRU.
3. Female participants of childbearing potential and male participants agree to comply wit h any 
applicable contraceptive requirements of the protocol as detailed in Appendix D.Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useively adequate renal 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useively adequate renal 
a to be eligible for participat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usea to be eligible for participat
ears, at screening. Healthy 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useears, at screening. Healthy 
s in this study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uses in this study
, at screening. At least 50% of the participants will be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, at screening. At least 50% of the participants will be 
, at screening. Healthy
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, at screening. Healthy
matched to hepatic impaired participants in this study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usematched to hepatic impaired participants in this study  by [CONTACT_44207] (mean ± 10%).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use by [CONTACT_44207] (mean ± 10%). matched to hepatic impaired participants in this study  by [CONTACT_44207] (mean ± 10%). matched to hepatic impaired participants in this study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usematched to hepatic impaired participants in this study  by [CONTACT_44207] (mean ± 10%). matched to hepatic impaired participants in this study
 significant m
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use significant m edi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useedical history
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecal history
 signs or ECGs, as deemed by
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use signs or ECGs, as deemed by
≥ 90/40 mmHg and ≤ 150/95 mmHg
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use≥ 90/40 mmHg and ≤ 150/95 mmHg
≥ 40 bpm and ≤ 99 bpm
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use≥ 40 bpm and ≤ 99 bpm
≤ 450 msec (males) or ≤ 470 msec (females) and ECG findings considered norma
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use≤ 450 msec (males) or ≤ 470 msec (females) and ECG findings considered norma
 significant by
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use significant by
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use the Invest
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use the Invest  significant by  [CONTACT_607311]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use significant by  [CONTACT_607312]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseLiver function tests including 
pants shoul
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepants shoul d not have renal dysfunct
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Used not have renal dysfunct
n (creatinine clearance 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen (creatinine clearance 
Inclusion for Participants with Hepatic Impairment and Healthy Participants
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInclusion for Participants with Hepatic Impairment and Healthy Participants
pants m
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepants m ust f
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useust f pants m ust f pants m
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepants m ust f pants m
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseUnderstands the study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseUnderstands the study
willing and able to comply with the protocol.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewilling and able to comply with the protocol.
2.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2.
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804665] be excluded from  parti cipat ing in the study  if the part icipant:
1.Has history  or presence of clinically significant medical or psy chiatri c condi tion or di sease 
(aside from HI) or presence of psychoti c disorders such as psychosis, delusio ns, or 
schizophrenia in the opi[INVESTIGATOR_3078] n of the Invest igator or designee.
2.Has a history  of liver or other solid organ transplant.
3.Has history or presence of alcoholism and drug abuse within the past 6 months prior t o dosing.
4.Positive result at screening for HIV. HBsAg positive participants are allowed to be enrolled if 
HBV DNA is below 1000 copi[INVESTIGATOR_014]/mL in the plasma. Participants with moderate or mild HI who 
are positive for HCVAb can be enro lled but must not have detectable HCV RNA in the plasma.
7.2.[ADDRESS_804666] be excluded from  parti cipat ing in the study  if the part icipant:
1.Has history  or presence of clinically significant medical or psy chiatri c condi tion or di sease or 
presence of psychotic disorders such as psychosis, delusions, or schizophrenia in the opi[INVESTIGATOR_3078] n 
of the Invest igator or designee.
2.Has history or presence of alcoh olism  and drug abuse wi thin the past [ADDRESS_804667] be excluded from  parti cipat ing in the study if the part icipant:
1.Has history  of any illness that, in the opi [INVESTIGATOR_304495], might confound 
the results of the study or poses an additional risk to the participant by [CONTACT_607313] .
2.Has history or presence of cli nically  significant hypersensit ivity or idiosyncratic reaction to the 
study  drug or rel ated com pounds.
3.Has posi tive resul ts for the urine or saliva drug screen at screening or check- in, unless the 
positive drug screen is due to prescript ion drug use that is approved by [CONTACT_737] 
(cannabino ids can be used for medicinal use at the discretion of the Investigator).
4.Is a female wit h a posit ive pregnancy test or who is lactating.
5.Has posi tive resul ts for urine or breath alcoho l screen at screening or check- in.
6.Is unable to refrain fro m or anti cipates the use of any  medicat ion or substance (including 
prescri ption or over -the-counter, vitamin supplements, natural or herbal supplements) as 
indicated in Section 7.3(Excl uded Medicat ions, Supplements, Dietary  Products) for the 
prohibited time period.Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon or di
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon or di sease 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesease 
ns, or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usens, or 
lism and drug abuse within the past 6 months prior t
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselism and drug abuse within the past 6 months prior t
ve result at screening for HIV. HBsAg positive participants are allowed to be enrolled if 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useve result at screening for HIV. HBsAg positive participants are allowed to be enrolled if 
HBV DNA is below 1000 copi[INVESTIGATOR_014]/mL in the plasma. Participants with moderate 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHBV DNA is below 1000 copi[INVESTIGATOR_014]/mL in the plasma. Participants with moderate 
lled but must not have detectable HCV RNA in the plasma.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselled but must not have detectable HCV RNA in the plasma.
ing in the study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useing in the study
 or presence of clinically significant medical or psy
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use or presence of clinically significant medical or psy
presence of psychotic disorders such as psychosis, delusions, or schizophrenia in the opi[INVESTIGATOR_607277]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepresence of psychotic disorders such as psychosis, delusions, or schizophrenia in the opi[INVESTIGATOR_607278]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useolism  and drug abuse wi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use and drug abuse wi olism  and drug abuse wi olism
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useolism  and drug abuse wi olism
HIV
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHIV, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, HBsAg,
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHBsAg,
Exclusion for Participants with Hepatic Impairment and Healthy Participants
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseExclusion for Participants with Hepatic Impairment and Healthy Participants
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useust be excluded from
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useust be excluded from
 illness that, in the opi
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use illness that, in the opi
e results of the study or poses an additional risk to the participant by [CONTACT_607314]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee results of the study or poses an additional risk to the participant by [CONTACT_607315]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHas history or presence of cli
 drug or rel
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use drug or rel
Has posi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHas posi tive resul
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetive resul Has posi tive resul Has posi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHas posi tive resul Has posi
posi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepositi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetipositiposi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepositiposi ve drug screen is due to prescript
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useve drug screen is due to prescript
(cannabino
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(cannabino
4.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use4.
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804668] dosing in the previous study  to Day 1 of the current study .
11.Any posi tive responses on the C-SSRS or has a risk of suicide according to the Investigator’s 
judgment based on the assessment of the C- SSRS at screening or check -in or has made a 
suicide attem pt in the previous 12 months prior to dosing.
7.3 Excluded Medications ,Supplements, Dietary Products
Healthy partici pants will be restricted of using any prescription medicat ions/products and any
over-the-counter, nonprescript ion preparations (including herbal products, natural or herbal 
supplements) from at least [ADDRESS_804669] igator (or designee) and Sponsor.
Parti cipants wi th HI who are taking medicat ions to treat manifestations of hepat ic disease or 
medicat ions needed to treat for stable diseases (e.g., diuret ics, angiotensin converting enzyme 
inhibitors, angiotensin II receptor antagonists, and beta-blockers) will be allowed to participate in 
the study  at the discret ion of the Invest igator and following consultat ion with the Sponsor. For 
hepat ic disease related medical condit ions, p articipants m ust be on a stable dose (steady  dose, 
drug, and regimen) for at least 30 days and/or for non- hepat ic disease related medical condit ions 
for 14days before dosing and able to withho ld the use for at least 4 hours postdose. Phosphate 
binders con taining al uminum , calcium, or l anthanum salts; iron supplements or other metal 
cations; H2-receptor antagonists (except cimet idine); or multivitamins containing i ron or zinc 
must be withheld at least [ADDRESS_804670]. John’s Wort, will be restricted for [ADDRESS_804671] igator 
or desi gnee. Appropriate sources (e.g., Flockhart TableTM) will be consulted to confirm lack of 
PK/PD interaction with study drug. Cannabino ids can be used for medicinal use at the discretion of 
the Invest igator.
For all participants, fo llowing dosing, acetaminophen (up to 2 g per 24 hours) may be 
administered at the discret ion of the Invest igator or designee. Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use window will 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use window will 
 the current study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use the current study
SSRS or has a risk of suicide according to the Investigator’s 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSSRS or has a risk of suicide according to the Investigator’s 
in or has made a 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usein or has made a 
pants will be restricted of using any prescription medicat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepants will be restricted of using any prescription medicat
n preparations (including herbal products, natural or herbal 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen preparations (including herbal products, natural or herbal 
supplements) from at least 14 days before dosing and throughout the study. However, healt
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesupplements) from at least [ADDRESS_804672] 30 days prior to dosing
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen for at least 30 days prior to dosing
igator (or designee) and Sponsor.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useigator (or designee) and Sponsor.
ns to treat manifestations of hepat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usens to treat manifestations of hepat
ns needed to treat for stable diseases (e.g., diuret
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usens needed to treat for stable diseases (e.g., diuret
inhibitors, angiotensin II receptor antagonists, and beta
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinhibitors, angiotensin II receptor antagonists, and beta
igator and following consultat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useigator and following consultat
ic disease related medical condit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useic disease related medical condit io
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useions, p
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usens, p
days and/or for non
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedays and/or for non
days before dosing and able to withho
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedays before dosing and able to withho
uminum
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useuminum , calcium, or l
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, calcium, or l
receptor antagonists (except cimet
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usereceptor antagonists (except cimet
must be withheld at least [ADDRESS_804673] 4 hours postdose.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemust be withheld at least [ADDRESS_804674] 4 hours postdose.
th
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useth HI is prescribed prohibited medicat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use HI is prescribed prohibited medicatth HI is prescribed prohibited medicatth
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useth HI is prescribed prohibited medicatth
nvestigator, the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenvestigator, the 
allowed one for the purpose of this study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useallowed one for the purpose of this study
For all participants,
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFor all participants,
UGT2B4, including St. John’s Wort, will be restricted for 14 days or 28 days, respectively, before 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseUGT2B4, including St. John’s Wort, will be restricted for 14 days or 28 days, respectively, before 
dosing and throughout the study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedosing and throughout the study
inducers may be deemed acceptable fo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinducers may be deemed acceptable fo
or desi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useor desi
PK/PD interaction with study drug. Cannabino
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePK/PD interaction with study drug. Cannabino
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 31of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIALAny medicat ion (including over -the-coun ter) tha t woul d significantly alter creatinine clearance , 
which, by [CONTACT_607316], might interfere with the study (e.g., cimet idine) 
must be discont inued at least [ADDRESS_804675] igator or designee and sponsor can be consulted. 
If deviat ions occur, the Investigator or desi gnee in consul tation wi th the Sponsor if needed will 
decide on a case by  [CONTACT_607317].
Use of excluded agen ts (prescri ption or non -prescript ion) or dietary  products i s outlined in
Table 7.a.
Table 7.a Excluded Medications, Supplements, and Dietary Products
CategoryBetween Screening and First Dosing 
(Days -28 to Predose [Day 1])After Dosing (Day 1) to 
Discharge (Day 7)
Alcohol Prohibited from 48 hours prior to dosing Prohibited from dosing until 
discharge from CRU completed.
Xanthine and/or caffeine Prohibited from 24 hours prio r to dosing aProhibited from dosing until 
discharge from CRU completed.a
Medications See Section 7.3 See Sections 7.3
Food substance
Grapefruit/Seville orange Prohibited from 14 days prior to dosing Prohibited from dosing until 
discharge from CRU completed.
Nicotine and analogous 
derivatives≤5 cigarettes/day 7 days prior to dosing ≤5 cigarettes/day until discharge 
from CRU completed.
(a) small amounts of caffeine derived from normal foodstuffs e.g., 250 mL/8 oz./1 cup decaffeinated coffee or other 
decaffeinated beverage, per day, with the exception of espresso; 45 g/1.5 oz. chocolate bar, per day, would not be 
considered a deviation to this restriction.
7.4 Diet, Fluid, Activity 
7.4.1 Diet and Fluid
Water (except water provided wit h dosing) will be restricted 1 hour prior to and 1 hour after 
dosin g, but will be allowed ad libitum at all other times, when dosing occurs at the CRU. Other 
fluids m ay be given as part of meals and snacks but will be restricted at all other times throughout 
the confinement period.Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use drug administrati
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use drug administrati on and i
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon and i
igator or designee and sponsor prior to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useigator or designee and sponsor prior to 
d begin before the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Used begin before the 
 the Sponsor if needed will 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use the Sponsor if needed will 
inue participation in the study 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinue participation in the study 
lo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselogy
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usegy.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.
n) or dietary
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen) or dietary  products i
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use products i n) or dietary  products i n) or dietary
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen) or dietary  products i n) or dietary
Excluded Medications, Supplements, and Dietary Products
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseExcluded Medications, Supplements, and Dietary Products
Between Screening and First Dosing 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseBetween Screening and First Dosing 
28 to Predose [Day 1])
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use28 to Predose [Day 1])
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProhibited from 48 hours prior to dosing
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProhibited from 48 hours prior to dosing
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProhibited from 24
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProhibited from 24 hours prio
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehours prio
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSee Section
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSee Section 7.3
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use7.3
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProhibited from 14 days prior to dosing
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProhibited from 14 days prior to dosing
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseNicotine and analogous 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseNicotine and analogous 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use≤
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use≤
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(a) small amounts of caffeine derived from normal foodstuffs e.g., 250
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(a) small amounts of caffeine derived from normal foodstuffs e.g., 250
decaffeinated beverage, per day, with the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedecaffeinated beverage, per day, with the 
considered a deviation to this restriction.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useconsidered a deviation to this restriction.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use7.4
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use7.4 Diet, Fluid, Activity 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDiet, Fluid, Activity 
7.4.1
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use7.4.1
Water (except water provided wit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseWater (except water provided wit
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804676] 4 hours postdose, participants ma y 
be allowed to rise for br ief periods under supervision (e.g., in order to use the toilet facilit ies).
Parti cipants will be instructed to refrain from strenuous phy sical activity which coul d cause 
muscle aches or injury, including contact [CONTACT_607318] t ime from screening unt il complet ion of the 
study . 
Parti cipants m ust not consum e more than 5 ci garettes or equivalent/day  from the 7 day s prior to 
check -in and unt il discharge fro m the CRU. Depending on the CRU rules and regulat ions, 
participants m ay be prohibited from  smoking during their confinement or during portions of their 
confinement. 
7.5 Criteria for Discontinuation or Withdrawal of a Participant
The primary  reason for di scont inuat ion or wi thdrawal  of the parti cipant from  the study  or study
drug should be recorded in the case rep ort form  (CRF) using the fo llowing categori es.
1. Pretreatment event (PTE) or AE: The participant has experienced a PTE or AE that requires 
early  terminat ion because continued participation imposes an unacceptable risk to the 
participant’s healt h or the parti cipant i s unwilling to conti nue because of the PTE or AE.
Liver Funct ion Test (LFT) Abnormalit ies
Appropriate clinical fo llow-up will be conducted (including repeat laboratory tests, until a 
participant’s laboratory profile has returned to normal/baseline status, see Section [IP_ADDRESS] ), 
if the fo llowing ci rcumstances occur at any  time following study  drug treatm ent:
–ALT or AST >8x ULN, or
–ALT or AST >5x U LN wi th appearance of fat igue,  nausea, vomit ing, ri ght upper 
quadrant pain or tenderness, fever, rash and/or eosinophilia (>5%).
QTcF interval: 
Appropriate clinical fo llow-up will be conducted if a QTcF interval >500 msec and/or an 
increase from baseline > 60 msec is detected by  [CONTACT_25310] a repeat ECG at 
any time fo llowing study  drug treatm ent. Appropriate clinical fo llow-up includes a repeat 
ECG.Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewill be required to fast from all 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewill be required to fast from all 
All participants will remain seated for the first 4 hours following dosing, except when they are 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAll participants will remain seated for the first [ADDRESS_804677]
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usell then resume normal act
aced in an appropri
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useaced in an appropri
to lie down on their right side. During the first 4 hours postdose, participants ma
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useto lie down on their right side. During the first 4 hours postdose, participants ma
ods under supervision (e.g., in order to use the toilet facilit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useods under supervision (e.g., in order to use the toilet facilit
sical
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesical act
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use actsical actsical
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesical actsical ivit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useivit
ime from screening unt
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useime from screening unt
garettes or equivalent/day
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usegarettes or equivalent/day
Depending on the CRU rules and regulat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDepending on the CRU rules and regulat
oking during
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useoking during th
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useth
Criteria for Discontinuation or Withdrawal of a Participant
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCriteria for Discontinuation or Withdrawal of a Participant
inuat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinuat io
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useion or wi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen or wi
drug should be recorded in the case rep
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedrug should be recorded in the case rep
Pretreatment event (PTE) or AE: The participant has experienced a PTE or AE that requires 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePretreatment event (PTE) or AE: The participant has experienced a PTE or AE that requires 
n because continued participation imposes an unacceptable risk to the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen because continued participation imposes an unacceptable risk to the 
h or the parti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useh or the parti
Liver Funct
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseLiver Funct io
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useion Test (LFT) Abnormalit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen Test (LFT) Abnormalit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAppropriate clinical fo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAppropriate clinical fo
parti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useparticipant’s laboratory profile has returned to normal/baseline 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecipant’s laboratory profile has returned to normal/baseline 
if the fo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useif the fo
–
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use–
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 33of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIAL2.Significant protocol  deviat ion: The discovery post -enrollment that the participants failed to 
meet protocol  entry  criteria or di d not adhere to protocol requirements, and continued 
participat ion poses an unacceptable risk to the participant’s healt h.
3.Lost to follow- up: Attem pts to contact [CONTACT_424116]. Attempts to contact 
[CONTACT_291596] m ust be docum ented in the parti cipant’s source documents.
4.Voluntary  withdrawal: The participants (or participant’s legally acceptable representative) 
wish to withdraw from the study. The reason for withdrawal, if provided, should be recorded in 
the CRF. 
Note: All attempts should be made to determine the underlying reason for the withdrawal 
and, where possible, the primary underlying reason should be recorded (ie, withdrawal due 
to an AE should not be recorded in the “voluntary  withdrawal” category ). If a parti cipant 
chooses to withdraw fro m study  parti cipat ion due to personal concerns related to the 
COVID -19 pandemic (other than a COVID -19-related AE), this should be specified as the 
reason for participant withdrawal in the CRF.
5.Study  terminat ion: The Sponsor, IRB/ IEC, or regulatory  agency  terminates the study .
6.Pregnancy: as described in Appendix D.
7.Parti cipants may be withdrawn fro m the study by [CONTACT_607319]:
Difficult ies in blood collect ion. 
Positive urine drug or alcoho l test.
Other: The specific reasons for discont inuat ion shoul d be entered into the CRF i ncluding 
unavo idable circumstances such as the COVID -19 pandemic. Participants may be withdrawn fro m 
the study  at any  time at the di screti on of  the Investigator or sponsor for safety  reasons which 
shoul d be entered into the CRF.
7.6 Procedures for Discontinuat ion or Withdrawal of a Participant
The Investigator may  discontinue a participant’s study  parti cipat ion at any  time during the study
when the participant meets the study  terminat ion criteria described in Sect ion7.5. In addit ion, a 
participant m ay discont inue his or her participat ion without giving a reason at any time during the 
study . Shoul d a parti cipant’s parti cipat ion be discont inued, the primar y criterion for terminati on 
must be recorded by [CONTACT_737]. In addit ion, efforts should be made to perform all procedures 
scheduled for the end- of-study  or early  terminat ion as described in Sect ion3.0.
7.[ADDRESS_804678] igators in consultat ion with the sponsor to ensure 8 PK -evaluable participants in each Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepts to contact [CONTACT_424116]. Attempts to contact 
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepts to contact [CONTACT_424116]. Attempts to contact 
 [CONTACT_607320]) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use acceptable representative) 
sh to withdraw from the study. The reason for withdrawal, if provided, should be recorded in 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesh to withdraw from the study. The reason for withdrawal, if provided, should be recorded in 
Note: All attempts should be made to determine the underlying reason for the withdrawal 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseNote: All attempts should be made to determine the underlying reason for the withdrawal 
and, where possible, the primary underlying reason should be recorded (ie, withdrawal due 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand, where possible, the primary underlying reason should be recorded (ie, withdrawal due 
drawal” category
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedrawal” category
n due to personal concerns related to the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen due to personal concerns related to the 
ated AE), this should be specified as the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useated AE), this should be specified as the 
The Sponsor, IRB/ IEC, or regulatory
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe Sponsor, IRB/ IEC, or regulatory  agency
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use agency The Sponsor, IRB/ IEC, or regulatory  agency The Sponsor, IRB/ IEC, or regulatory
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe Sponsor, IRB/ IEC, or regulatory  agency The Sponsor, IRB/ IEC, or regulatory
he study by [CONTACT_177972]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehe study by [CONTACT_607321].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetest.
Other: The specific reasons for discont
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseOther: The specific reasons for discont inuat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinuat
idable circumstances such as the COVID
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useidable circumstances such as the COVID
 time at the di
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use time at the di screti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usescreti
d be entered into the CRF.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Used be entered into the CRF.
Procedures for Discontinuat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProcedures for Discontinuat
nvestigator may
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenvestigator may  discontinue a participant’s study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use discontinue a participant’s study nvestigator may  discontinue a participant’s study nvestigator may
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenvestigator may  discontinue a participant’s study nvestigator may
when the participant meets the study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewhen the participant meets the study
cipant m
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecipant m ay
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useay discont
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use discont
. Shoul
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. Shoul d a parti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Used a parti
must be recorded by [CONTACT_177972]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemust be recorded by [CONTACT_177972]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usescheduled for the end
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usescheduled for the end
7.7
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use7.7
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804679] Name: [CONTACT_424128] (TAK -935)
Strength: 100 m g 
Dose: 300 m g, 3 x 100m g 
Dosage Form/Formulat ion: T4 immediate- release tablet
Dosing regimen: Single dose 
Route of Administration: Oral
8.1.1 Clinical Study Drug Labeling
Study  drug containers will be affixed with a clinical label in accordance wit h local regulatory
requi rements.
8.1.2 Clinical Study Drug Inventory and Storage
The same lot number will be used throughout the study . The l ot numbers and expi[INVESTIGATOR_1659] 
(where available) of the study drug supplied will be recorded in the final report. Study  drugs will 
be stored according to the product labels provided with the product.
Records will be made of the receipt, preparation, dispensing, and final disposit ion of the study
drugs supplied.
8.1.3 Clinical Study Drug Blinding
This is an open- label study .
8.1.4 Randomization Code Creation and Storage 
Not applicable.8.1.5 Clinical Study Blind Maintenance/Unblinding Procedure
Not applicable. 8.1.6 Accountability and Destruction of Sponsor-Supplied Drugs
Records will be made of the receipt and dispensing of the study drugs supplied. At the conclusio n 
of the study , any unused soticlestat will be retained by  [CONTACT_47381]/clinical sites, as applicable, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use drug containers will be affixed with a clinical label in accordance wit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use drug containers will be affixed with a clinical label in accordance wit
Drug Inventory and Storage
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDrug Inventory and Storage
The same lot number will be used throughout the study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe same lot number will be used throughout the study
 drug supplied will be recorded in the final report. Study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use drug supplied will be recorded in the final report. Study
he product labels provided with the product.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehe product labels provided with the product.
Records will be made of the receipt, preparation, dispensing, and final disposit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRecords will be made of the receipt, preparation, dispensing, and final disposit
Study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseStudy Drug Blinding
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDrug Blinding
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThis is an open
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThis is an open label study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselabel study
Randomization Code Creation and Storage 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRandomization Code Creation and Storage 
Not applicable.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseNot applicable.
8.1.5
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use8.1.5
Not applicable. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseNot applicable. 
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804680] accountabilit y records.
9.0 STUDY PROCEDURES
9.1 Administrative Procedures
9.1.1 Informed Consent Procedure
The purpose of the study , the procedures to be carried out and the potential hazards will be 
described to the participants in non -technical terms. Participants will be required t o read, sign, and 
date an ICF summarizing the discussio n prior to screening, and will be assured that they  may 
withdraw from  the study at any  time wi thout jeopardi zing thei r medical  care.
Parti cipants will be given a copy  of their signed ICF.
[IP_ADDRESS] Assignment of Screening and Identification Numbers 
Each participant will be assigned a unique ident ification number upon screening. Participants who 
complete the study  screening assessments and meet all the eligibilit y criteria will be assigned a 
unique identificat ionnumber at the time of dosing, different from the screening number.
If replacement participants are used, the replaceme nt participant number will be 100 more than the 
original  parti cipant’s i dentificat ion number (eg, Participant No. 101 will be assigned to the 
replacement of Participant No. 1).
[IP_ADDRESS] Study Drug Assignment
All participants will receive the treatments as detailed in Sect ion9.2.8 .
9.1.2 Inclusion and Exclusion 
Please refer to Section 7.1and Section 7.2.
9.1.3 Medical History/ Demography
Medical history  and dem ographic data, including name, sex, age, race, ethnicit y, history  of
tobacco use, and Child -Pugh classificat ion will be recorded.
9.1.4 Concomitant Medications
Concomitant medicat ions will be prohibited as listed in Section 7.3. All medications taken by 
[CONTACT_424114].
9.2 Clinical Procedures and Assessments
The Schedule o f Study  Procedures (Section 3.0) summarizes the clinical procedures to be 
perform ed at each visit. Individual clinical procedures are described in detail below. Additional Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, the procedures to be carried out and the potential hazards will be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, the procedures to be carried out and the potential hazards will be 
technical terms. Participants will be required t
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetechnical terms. Participants will be required t o read, sign, and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useo read, sign, and 
or to screening, and will be assured that they
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useor to screening, and will be assured that they
edical
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useedical  care.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use care. edical  care. edical
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useedical  care. edical
Screening and Identification Numbers 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseScreening and Identification Numbers 
on number upon screening. Participants who 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon number upon screening. Participants who 
 screening assessments and meet all the eligibilit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use screening assessments and meet all the eligibilit
number at the time of dosing, different from the screening number.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenumber at the time of dosing, different from the screening number.
If replacement participants are used, the replaceme
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIf replacement participants are used, the replaceme nt
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usent participant number will be 100 more than the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use participant number will be 100 more than the 
n number (eg, Participant No. 101 will be assigned to
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen number (eg, Participant No. 101 will be assigned to
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseStudy Drug Assignment
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseStudy Drug Assignment
All participants will receive the treatments as detailed in Sect
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAll participants will receive the treatments as detailed in Sect
Inclusion and Exclusion 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInclusion and Exclusion 
ase refer to Section
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usease refer to Section 7.1
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use7.1and Section
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand Section
Medical History/
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMedical History/
history
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehistory
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use and dem
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use and dem history  and dem history
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehistory  and dem history
tobacco use, and Child
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetobacco use, and Child
9.1.4
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use9.1.4 Concomitant Medications
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseConcomitant Medications
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseConcomitant medicat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseConcomitant medicat
parti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useparti
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 36of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIALevaluat ions/testing may be deemed necessary  by [CONTACT_47384]/or the Sponsor 
for reasons rel ated to parti cipant safet y.
For thi s study , collect ion of blood for plasma soticlestat  PK is the crit ical 
param eter and n eeds to be collected as close to the exact time point as possible. All other 
procedures should be completed as close to the prescribed/scheduled time as possible, but can be 
perform ed pri or to or after the prescribed/scheduled time.
Any nonscheduled proce dures required for urgent evaluat ion of safet y concerns take precedence 
over all routine scheduled procedures.
9.2.1 Full Physical Examination
A full physical examinat ion will be performed as outlined in the Schedule o f Study  Procedures 
(Secti on3.0). Symptom -driven physical examinat ions may be performed at other times, if deemed 
necessary  by [CONTACT_47385].
9.2.2 Height and Weight
Body  height (cm) and weight (kg) will be reported as outlined in the Schedule of Study Procedures 
(Secti on3.0).
9.2.3 BMI
BMI will be calculated based on the height and weight m easured at screening.
9.2.4 Vital Signs
Single measurements of temperature, respi[INVESTIGATOR_697], BP, and PR will be measured as outlined in 
the Schedule of Study  Procedures (Secti on3.0). Addi tional vital signs may  be taken at any  other 
times, if deemed necessary.
Blood pressure and pulse rate measurements will be performed with participants in a supi[INVESTIGATOR_12251] (after resting in a supi[INVESTIGATOR_72126] 5 minutes), except when they  are 
semi-reclined because of study  procedures and/or AEs (e.g. nausea, dizziness) or if deemed 
necessary  by [CONTACT_47385].
Vital signs will  be measured wit hin 24 hours pri or to dosing for the predose time point. When 
scheduled postdose, vital signs will be performed within approximately 15 minutes of the 
scheduled time po int.
9.2.5 12-Lead ECG
Single 12 -lead ECGs will be performed as outlined in the Schedule of Study Procedures 
(Secti on3.0). Addit ional ECGs may  be taken at any  other times, if deemed necessary  by [CONTACT_47383].
ECGs will be performed with part icipants in a supi[INVESTIGATOR_23571] (after resting in supi[INVESTIGATOR_226354]5 minutes). All ECG tracings will be reviewed by [CONTACT_941] I nvest igator or designee.Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useprocedures should be completed as close to the prescribed/scheduled time as possible, but can be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useprocedures should be completed as close to the prescribed/scheduled time as possible, but can be 
concerns take precedence 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useconcerns take precedence 
n will be performed as outlined in the Schedule o
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen will be performed as outlined in the Schedule o f 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usef 
ions may be performed at 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useions may be performed at 
as outlined in the Schedule of Study Procedures 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useas outlined in the Schedule of Study Procedures 
BMI will be calculated based on the height and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseBMI will be calculated based on the height and weight m
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useweight m
ngle measurements of temperature, respi[INVESTIGATOR_697], BP, and PR will be measured as outlined in 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usengle measurements of temperature, respi[INVESTIGATOR_697], BP, and PR will be measured as outlined in 
 Procedures (Secti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use Procedures (Secti
times, if deemed necessary
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetimes, if deemed necessary .
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.
ood pressure and pulse rate measurements will be performed with participants in a supi[INVESTIGATOR_607279]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useood pressure and pulse rate measurements will be performed with participants in a supi[INVESTIGATOR_503473] (after resting in a supi[INVESTIGATOR_607280]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon (after resting in a supi[INVESTIGATOR_607281]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usereclined because of study
 the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseI
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInvest
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenvest
 signs will
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use signs will  b
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use b  signs will  b  signs will
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use signs will  b  signs will
scheduled postdose, vital signs will be performed within approximately 15
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usescheduled postdose, vital signs will be performed within approximately 15
scheduled time po
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usescheduled time po
9.2.5
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use9.2.5
Si
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSi
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804681] clock time of dosing will be recorded.
Treatment will be administered as fo llows: 
Soticlestat 300 mg (3 x 100 mg T4 tablets) at Hour 0 on Day 1.
9.2.7 C-SSRS
Suicidal  ideati on will  be assessed using the C -SSRS at the times stipulated in the Sch edule of 
Study  Procedures (Secti on3.0). Two versions of the C -SSRS will be used in this study : the 
Screening/Baseline C- SSRS Lifet ime and the Since -Last-Visit C-SSRS. Any suicidal ideat ion or 
suicidal behavi or during the tri al periods detected by  [CONTACT_941] C -SSRS will be recorded as an AE. The 
Invest igator will ensure that any suicidal ideat ion or behavior is medically addressed, including 
assessment and treatment by  [CONTACT_607322] m edical  personnel . When possible, i t is highly 
recommended that assessments will be conducted by [CONTACT_607323].
9.2.8 AE Monitoring
Parti cipants will be monitored throughout the study for adverse reactions to the study drugs and/or 
procedures as described in Section 10.0.
9.2.9 Laboratory Procedures and Assessments
All tests listed below will be performed as outlined in the Schedule of Study  Procedures 
(Secti on3.0). In addit ion, laboratory  safet y tests may  be performed at various unscheduled time 
points, if deemed necessary  by [CONTACT_941] I nvest igator or designee.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe pharmacy at the CRU will provide each dose in individual unit dose containers for each 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe pharmacy at the CRU will provide each dose in individual unit dose containers for each 
mg T4 tablets) at Hour 0 on Day 1.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemg T4 tablets) at Hour 0 on Day 1.
-SSRS at the times stipulated in the Sch
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-SSRS at the times stipulated in the Sch
. Two versions of the C
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. Two versions of the C
ime and the Since
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useime and the Since
ods detected by
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useods detected by
[CONTACT_607324]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewill ensure that any suicidal ideat
ified m
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useified m edical
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useedical
recommended that assessments will be conducted by [CONTACT_607323].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userecommended that assessments will be conducted by [CONTACT_607323].
AE Monitoring
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAE Monitoring
pants will be monitored throughout the study for adverse reactions to the study drugs and/or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepants will be monitored throughout the study for adverse reactions to the study drugs and/or 
procedures as described in Section
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useprocedures as described in Section
Laboratory Procedures and
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseLaboratory Procedures and
All tests listed below will be performed as outlined in the Schedule of Study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAll tests listed below will be performed as outlined in the Schedule of Study
on
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon3.0
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use3.0)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use). In addit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. In addit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usets, if deemed necessary
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usets, if deemed necessary
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804682] of the following tests:
Hemoglobin Red blood cell count
Hematocrit Platelet count
Total and differential leukocyte count
Coagulation
Coagulation test will consist of the fo llowing tests:
Activated partial thromboplastin time PT/ INR
Chemistry 
Serum  chemistry tests will be performed in the fasted state after at least an [ADDRESS_804683]; however, in 
case of dropouts or rechecks, participants may not have fasted for [ADDRESS_804684] chemistry  panel:
Amylase Sodium
Lipase Potassium
Blood Urea Nitrogen Chloride
Bilirubin (total and direct) Glucose
ALP Creatinine *
AST Magnesium
ALT
AGP 
Albumin
* At screening, creatinine clearance will be calculated using the Cockcroft -Gault equation.
Urinalysis
Urinalysis will consist of the following tests:
pH Bilirubin
Specific gravity Blood *
Protein * Nitrite *
Glucose Urobilinogen
Ketones Leukocyte esterase *
* If urinalysis is positive for protein, blood, nitrite and/or leukocyte esterase, a microscopic examination (for red blood 
cells, white blood cells, bacteria, casts, and epi[INVESTIGATOR_1663]) will be performed.Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use chemistry tests will be performed in the fasted state after at least an 8
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use chemistry tests will be performed in the fasted state after at least an [ADDRESS_804685] fasted for 8
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecase of dropouts or rechecks, participants may not have fasted for [ADDRESS_804686] chemistry
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewing standard chemistry
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use* At screening, creatinine clearance will be calculated using the Cockcroft
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use* At screening, creatinine clearance will be calculated using the Cockcroft
Urinalysis
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseUrinalysis
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseUrinalysis will consist of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseUrinalysis will consist of 
pH
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsepH
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSpecific gravity
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSpecific gravity
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProtein *
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProtein *
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 39of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIAL9.[IP_ADDRESS] Other 
HIV test Urine/saliva drug screen
Opi[INVESTIGATOR_858] (includes morphine, heroin (diacetylmorphine), 
codeine, 6-acetylmorphine, dihydrocodeine, hydrocodone, thebaine, and, hydromorphone)
Amphetamines
Barbiturates
Benzodiazepi[INVESTIGATOR_607282] (if antibody positive, confirm DNA is below 
1000 copi[INVESTIGATOR_014]/mL in participants with HI)
HCV (if antibody positive, confirm RNA negative in 
participants with HI )
Urine/breath alcohol screen
Serum pregnancy test (for females only)
FSH (for females only)
9.[ADDRESS_804687] ion, processing, and shippi[INVESTIGATOR_323902]. 
Primary specimen co llection parameters are provided i nTable 9.a.
Table 9.a Primary Specimen Collections
Specimen NamePrimary 
SpecimenPrimary 
Specimen 
Derivative Description of Intended UseSample 
Collection
Plasma sample for PK
(Soticlestat 
)Blood Plasma Plasma sample for PK analysis Mandatory
Blood Plasma Mandatory
9.3.[ADDRESS_804688] ion of unbound soticlestat will be determined.Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useacetylmorphine, dihydrocodeine, hydrocodone, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useacetylmorphine, dihydrocodeine, hydrocodone, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen, processing, and shippi[INVESTIGATOR_607283]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen, processing, and shippi[INVESTIGATOR_607284] 
n parameters are provided i
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen parameters are provided i
Primary Specimen Collections
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePrimary Specimen Collections
Primary 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePrimary 
Specimen
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSpecimen
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseBlood
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseBlood
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePK Measurements 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePK Measurements 
Sam
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSamples fro
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useples froSamples froSam
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSamples froSam
Sam
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSamples f
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useples fSamples fSam
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSamples fSam
analyzed using validate
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useanalyzed using validate
Pharmacokinet
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePharmacokinet
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 40of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIAL9.3.1.1 Plasma for PK Measurements
The fo llowing PK parameters will be calculated from plasma concentrations of sotisclestat 
 unless otherwise specified:
AUC last: The area under the concentration-time curve, from time [ADDRESS_804689] 
quant ifiable concen tration, as calculated by [CONTACT_1690] -log trapezoidal 
method.
AUC : The area under the concentration-time curve, from time 0 extrapol ated to 
infinit y. AUC is calculated as AUC last plus the ratio of the last measurable 
blood concentration to the eliminat ion rate constant.
Cmax: Maximum observed concentration.
No value for AUC ,  will be reported for cases that do not exhibit a terminal 
log-linear phase in the concentration versus t ime profile.
No PK parameters will be calculated for participants with d etectabl e concentrations at 2 or fewer 
consecut ive time po ints. 
Individual and mean plasma concentration-curves (both linear and log- linear) will be included in 
the final report.
Addit ional PK parameters may  be estimated as appropriate.
9.3.2 Biomarker Measurements 
Not applicable.Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useg trapezoidal 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useg trapezoidal 
0 extrapol
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use0 extrapol
plus the ratio of the last measurable 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useplus the ratio of the last measurable 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAUC
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAUC
linear phase in the concentration versus t
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselinear phase in the concentration versus t
No PK parameters will be calculated for participants with d
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseNo PK parameters will be calculated for participants with d
consecut
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useconsecut ive time po
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useive time po
Individual and mean plasma concentration
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIndividual and mean plasma concentration
th
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe final report.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee final report.
Addit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAddit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 41of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIAL9.3.3 PGx Measurements 
Not applicable.
9.3.4 Confinement
Parti cipants will be restricted and confined to the CRU on Day  -1, at the time indicated by  [CONTACT_47391], until after the 144-hour blood draw and/or study  procedures (Day  7) as outlined in the
Schedule of Study  Procedures (Section 3.0). Participants m ay be admi tted to the CRU earlier for 
COVID -[ADDRESS_804690] igation parti cipant who 
has signed informed consent to participate in a study; it does not necessarily have to have a causal 
relationship with the treatment.
An AE can therefore be any unfavorable and unintended sign (eg, a clinically signif icant abnormal 
laboratory  finding), symptom, or disease temporally  associ ated wi th the use of a drug, whether or 
not it is considered related to the drug.
A TEAE is defined as any untoward medical occurrence in a clinical investigation participant that 
occurs fo llowing administration of the invest igational study  drug.
An untoward finding generally may:
Indicate a new diagnosis or unexpected worsening of a preexist ing condit ion. (Intermittent 
events for pre -exist ing condit ions or underlying disease should not be considered AEs.)
Necessitate therapeutic intervent ion.
Requi re an invasive diagnostic procedure.
Requi re discontinuation or a change in dose of study medicat ion or a concomitant medicat ion.
Beconsidered unfavorable by [CONTACT_941] I nvestigator for any reason.
Diagnoses versus signs and symptoms:
Each event should be recorded to represent a single  diagnosis. Acco mpanying signs (including 
abnorm al laboratory  values or ECG findings) or symptoms should NOT be recorded as 
additional AEs. If a di agnosis is unknown, sign(s) or symptom(s) should be recorded 
appropriately  as an AE(s). Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1, at the time indicated by
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1, at the time indicated by  [CONTACT_177972]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use the 1, at the time indicated by  [CONTACT_941] 1, at the time indicated by
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1, at the time indicated by  [CONTACT_941] 1, at the time indicated by
 7) as outlined in the
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use 7) as outlined in the
ed to the CRU earlier for 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useed to the CRU earlier for 
imes, a participant may be required to remain at the CRU for longer for safet
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useimes, a participant may be required to remain at the CRU for longer for safet
s defined as any untoward medical occurrence in a clinical invest
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uses defined as any untoward medical occurrence in a clinical invest
has signed informed consent to participate in a study; it does not necessarily have to have a causal 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehas signed informed consent to participate in a study; it does not necessarily have to have a causal 
An AE can therefore be any unfavorable and unintended sign (eg, a clinically signif
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAn AE can therefore be any unfavorable and unintended sign (eg, a clinically signif
inding), symptom, or disease temporally
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinding), symptom, or disease temporallyinding), symptom, or disease temporally  associ inding), symptom, or disease temporally
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinding), symptom, or disease temporally  associ inding), symptom, or disease temporally
A TEAE is defined as any untoward medical occurrence in a clinical invest
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseA TEAE is defined as any untoward medical occurrence in a clinical invest
wing administration of the invest
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewing administration of the invest
An untoward finding generally may:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAn untoward finding generally may:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIndicate a new diagnosis or unexpected worsening of a preexist
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIndicate a new diagnosis or unexpected worsening of a preexist
ing condit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useing condit
Necessitate therapeutic intervent
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseNecessitate therapeutic intervent
re an invasive diagnostic procedure.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usere an invasive diagnostic procedure.
re discontinuation or a change in dose of study medicat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usere discontinuation or a change in dose of study medicat
considered unfavorable by [CONTACT_941] I
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useconsidered unfavorable by [CONTACT_941] I
agnoses versus signs and symptoms:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useagnoses versus signs and symptoms:

Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEach event should be recorded to represent a single
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEach event should be recorded to represent a single
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 42of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIALLaboratory  values and ECG findings:
Changes in laboratory  values or ECG param eters maybe considered AEs if they are judged to 
be clinically  significant (i e, if som e act ion or intervent ion is required or if the Invest igator
judges the change to be beyo nd the range of normal physio logic fluctuati on). A l aboratory
re-test and/or continued monitoring of an abnormal value are not considered an intervention. In 
addition, repeated or addit ional noninvasive testing for verificat ion, evaluat ion or m onitoring 
of an abnorm ality is not considered an intervention.
If abnormal laboratory values or ECG findings are the result of pathology for which there is an 
overall diagnosis (eg, increased creat inine in renal  failure), the di agnosis only  shoul d be 
reported appropriately  as an AE.
Pre-exist ing condit ions:
A pre -exist ing condit ion (present at the time of signing of informed consent) is considered a 
concurrent medical history  condi tion and shoul d NOT be rec orded as an AE. A baseline 
evaluat ion (eg, laboratory  test, ECG, X- ray, etc) shoul d NOT be recorded as an AE unless 
related to a study  procedure. However, if the participant experiences a worsening or 
complicat ion of such a concurrent medical history  condi tion, the worsening or complication 
shoul d be recorded appropriately as an AE (worsening or complicat ion occurs after informed 
consent is signed). Investigators should ensur e that the event term  recorded captures the 
change in the condit ion (eg, “worsening of…”).
If a participant has a pre- exist ing epi[INVESTIGATOR_45283] (eg, asthma, epi[INVESTIGATOR_002]), any occurrence of 
an epi[INVESTIGATOR_607285] m ore frequent, serious, or 
severe in nature, that is, Investigators should ensure that the AE term recorded captures the 
change from Baseline in the condit ion (eg “worsening of…”).
If a participant has a degenerat ive concurrent condit ion (eg, cataracts, rhe umatoi d arthri tis), 
worsening of the condit ion should only be captured as an AE if occurring to a greater extent to 
that which would be expected. Again, I nvest igators should ensure that the AE term recorded 
captures the change in the condit ion (eg, “worsening of…”).
Worsening of AEs:
If the participant experiences a worsening or complicat ion of an AE after the administration of 
study  medicat ion or after any  change in study  medicat ion, the worsening or complicat ion 
shoul d be recorded as a new AE. Invest igato rs should ensure that the AE term recorded 
captures the change in the condit ion (eg, “worsening of…”).
Changes in severit y of AEs:
If the participant experiences a change in the severit y of an AE that i s not associ ated wi th a 
change in study  medicati on, th e event should be captured once with the maximum severit y 
recorded.Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useaboratory
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useaboratory
test and/or continued monitoring of an abnormal value are not considered an intervention. In 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetest and/or continued monitoring of an abnormal value are not considered an intervention. In 
n or m
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen or m oni
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useonitoring 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetoring onitoring oni
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useonitoring oni
If abnormal laboratory values or ECG findings are the result of pathology for which there is an 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIf abnormal laboratory values or ECG findings are the result of pathology for which there is an 
agnosis only
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useagnosis only  sh
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use sh agnosis only  sh agnosis only
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useagnosis only  sh agnosis only
n (present at the time of signing of informed consent) is considered a 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen (present at the time of signing of informed consent) is considered a 
d NOT be rec
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Used NOT be rec orded as an AE. A baseline 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useorded as an AE. A baseline 
d NOT be recorded as an AE unless 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Used NOT be recorded as an AE unless 
cipant
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecipant experiences a worsening or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useexperiences a worsening or 
n of such a concurrent medical history
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen of such a concurrent medical history  condi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use condi n of such a concurrent medical history  condi n of such a concurrent medical history
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen of such a concurrent medical history  condi n of such a concurrent medical history ti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useti  condi ti  condi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use condi ti  condi
d be recorded appropriately as an AE (worsening or complicat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Used be recorded appropriately as an AE (worsening or complicat
consent is signed). Investigators should ensur
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useconsent is signed). Investigators should ensur e that the event term
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee that the event term
n (eg, “worsening of…”).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen (eg, “worsening of…”).
ing epi[INVESTIGATOR_607286]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useing epi[INVESTIGATOR_607287]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usean epi[INVESTIGATOR_607288]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenvestigators should ensure that the AE term recorded captures the 
change from Baseline in the condit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usechange from Baseline in the condit
If a participant has a degenerat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIf a participant has a degenerat
worsening of the condit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useworsening of the condit io
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useion should only be captured as an AE if occurring to a greater extent to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen should only be captured as an AE if occurring to a greater extent to 
at which would be expected. Again, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useat which would be expected. Again, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecaptures the change in the condit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecaptures the change in the condit
rsening of AEs:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usersening of AEs:
If the participant experiences a worsening or complicat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIf the participant experiences a worsening or complicat
study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usestudy  m
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use m study  m study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usestudy  m study edicat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useedicat
shoul
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useshoul d be recorded as a new AE. Invest
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Used be recorded as a new AE. Invest
captures the change in the condit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecaptures the change in the condit
Changes in severit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseChanges in severit
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804691] anned surgeries or procedures:
Prepl anned procedures (surgeries or therapi[INVESTIGATOR_014]) that were scheduled prior to signing of 
inform ed consent are not considered AEs. However, if a preplanned procedure is performed 
early (eg, as an emergency) due to a worsening of the pre -exist ing condit ion, the worsening o f 
the condi tion shoul d be captured appropriately  as an AE. Com plicati ons resul ting fro m any
planned surgery  shoul d be reported as AEs.
Elect ive surgeries or procedures:
Elect ive procedures performed where there is no change in the participant’s medical condit ion 
shoul d not be recorded as AEs but should be documented in the participant ’s source 
docum ents. Com plicat ions result ing from an el ective surgery should be reported as AEs.
Overdose:
An overdose is defined as a known deliberate or accidental administration of investigational 
drug, to or by  a study participant , at a dose above that which is assigned to that individual 
participant accor ding to the s tudy protocol . It is up to the I nvest igator or the reporting 
physician to decide whether a dose is to be considered an overdose, in consultat ion with the 
Sponsor.
All cases of overdose (with or without associated AEs) will be documented on an Overdose 
page of the (e)CRF, in order to capture this important safet y information consistent ly in the 
database. AEs associated with an overdose will be documented on AE CRF(s) according to Secti on10.0.
Serious adverse events (SAEs) of overdose should be reported according to the procedure 
outlined in Sect ion10.2.8 .
In the e vent of drug overdose, the participant should be treated symptomat ically.
10.1.[ADDRESS_804692] medical occurrence that at any  dose:
1.Results in DEATH.
2.Is LIFE THREATENING.
The term “life threatening” refers to an event in which the partici pant was at risk of death at 
the time o f the event; it does not refer to an event that hypothetically might have caused 
death if it were more severe.
3.Requi res inpat ient HOSPI[INVESTIGATOR_39749].
4. Results in persistent or s ignificant DISABILITY/INCAPACITY.
5. Is a CONGENITAL ANOMALY/BIRTH DEFECT.Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useprocedure is performed 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useprocedure is performed 
n, the worsening o
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen, the worsening o f 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usef 
m 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usem any
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useany
ive procedures performed where there is no change in the participant’s medical condit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useive procedures performed where there is no change in the participant’s medical condit
participant
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useparticipant ’s source 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use’s source 
ive surgery should be reported as AEs.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useive surgery should be reported as AEs.
An overdose is defined as a known deliberate or accidental administration of investigational 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAn overdose is defined as a known deliberate or accidental administration of investigational 
, at a dose above that which is assigned to that individual 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, at a dose above that which is assigned to that individual 
. It is up to the I
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. It is up to the I nvest
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenvest
physician to decide whether a dose is to be considered an overdose, in consultat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usephysician to decide whether a dose is to be considered an overdose, in consultat
cases of overdose (with or without associated AEs) will be documented on an 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecases of overdose (with or without associated AEs) will be documented on an 
page of the (e)CRF, in order to capture this important safet
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepage of the (e)CRF, in order to capture this important safet
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedatabase. AEs associated with an overdose will be documented on AE CRF(s) according to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedatabase. AEs associated with an overdose will be documented on AE CRF(s) according to 
ous adverse events (SAEs) of overdose should be reported according to the procedure 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useous adverse events (SAEs) of overdose should be reported according to the procedure 
vent of drug overdose, the participant should be treated symptomat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevent of drug overdose, the participant should be treated symptomat
An SAE is defined as any untoward medical occurrence that at any
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAn SAE is defined as any untoward medical occurrence that at any
Results in DEATH.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseResults in DEATH.
Is LIFE THREATENING.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIs LIFE THREATENING.
The term “life threatening” refers to an event in which the partici
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe term “life threatening” refers to an event in which the partici
th
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe time o
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee time o
3.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use3.
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 44of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIAL6. Is an IMPORTANT MEDICAL EVENT that satisfies any of the fo llowing:
May require intervent ion to prevent items 1 through 5 above.
May expose the parti cipant to danger, even though the ev ent is not immediately  life 
threatening or fatal or does not result in hospi[INVESTIGATOR_059].
Includes any event or synonym described in the [COMPANY_005] Medically  Significant AE List 
(Table 10.a).
Table 10.a [COMPANY_005] Medically Significant AE List
Term
Acute respi[INVESTIGATOR_1399]/acute respi[INVESTIGATOR_4072] / ventricular fibrillation / 
ventricular tachycardiaAnaphy lactic shock
Acute renal failure
Malignant hypertension Pulmonary hypertension
Convulsive seizures Pulmonary fibrosis
Agranulocytosis Confirmed or suspected endotoxin shock
Aplastic anemia Confirmed or suspected transmission of infectious agent by 
a medicinal product
Neuroleptic malignant syndrome / malignant hyperthermia
Spontaneous abortion / stillbirth and fetal deathToxic epi[INVESTIGATOR_194]/
Stevens -Johnson syndrome
COVID -19-related disease
COVID -19 pneumonia
Abbreviations: COVID -19 = Coronavirus disease 2019
AEs that fulfill 1 or more of the serious criteria above are to be considered SAEs and should be 
reported and fo llowed up in the same manner (see Sections 10.1 and10.1.1 ).
10.1.[ADDRESS_804693] for this study.
10.2 AE Procedures
10.2.1 Assigning Severity/Intensity of AEs
The different categories o f severit y/intensity are:
Mild: An adverse event that is usually transient and may require only  minimal 
treatm ent or therapeuti c intervent ion. The event does not generally interfere 
with usual  activi ties of  daily living.Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use Significant AE List 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use Significant AE List 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselactic shock
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselactic shock
Acute renal failure
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAcute renal failure
Pulmonary hypertension
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePulmonary hypertension
Pulmonary fibrosis
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePulmonary fibrosis
Confirmed or suspected endotoxin shock
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseConfirmed or suspected endotoxin shock
Confirmed or suspected transmission of infectious agent by 
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseConfirmed or suspected transmission of infectious agent by 
a medicinal product
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usea medicinal product
Neuroleptic malignant syndrome / malignant hyperthermia
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseNeuroleptic malignant syndrome / malignant hyperthermia
19 = Coronavirus disease 2019
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use19 = Coronavirus disease 2019
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAEs that fulfill 1 or more of the serious criteria above are to be considered SAEs and should be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAEs that fulfill 1 or more of the serious criteria above are to be considered SAEs and should be 
wed up in the same manner (see Sections
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewed up in the same manner (see Sections
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSpecial Interest AEs
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSpecial Interest AEs
There are no AEs of Special Interest for this study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThere are no AEs of Special Interest for this study
AE Procedures
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAE Procedures
10.2.1
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use10.2.1
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAssigning Severity/Intensity of AEs
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAssigning Severity/Intensity of AEs
The different categories o
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe different categories o
Mild:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMild:
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 45of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIALModerate: An adverse event that is usually alleviated with addit ional specific therapeut ic 
intervent ion. The event interferes wit h usual activit ies of daily living, causing 
discomfort but poses no significant or permanent risk of harm to the research 
participant.
Severe: An adverse event that interrupts usual activities of daily living, or significant ly 
affects clinical status, or may require intensive therapeuti c interventi on.
10.2.2 Assigning Causality of AEs
The rel ationship of each AE to study  medicati on(s) will be assessed using the fo llowing 
categori es:
Related: An AE that fo llows a reasonable temporal sequence fro m administration of a 
drug (including th e course after withdrawal o f the drug), or for whi ch a causal
relationship is at least a reasonable possibilit y, ie, the relati onship cannot be 
ruled out , although factors other than the drug, such as underlying diseases, 
complicat ions, conco mitant drugs a nd concurrent treatments, may also be 
responsible.
Not Rel ated: An AE that does not follow a reasonable temporal sequence fro m ad ministration 
of a drug and/or that can reasonably be explained by  [CONTACT_1604], such as 
underlying diseases, complicat ions, conco mitant medi cations and concurrent 
treatm ents.
10.2.[ADDRESS_804694] signs/symptoms were n oted by  [CONTACT_324012]/or I nvest igator.
10.2.4 End Date 
The end date of the AE is the date at which the participant recovered, the event resolved but with 
sequelae or the participant died.
10.2.5 Pattern of Adverse Event (Frequency) 
Epi[INVESTIGATOR_39751] c AEs (eg, headache) or those which occur repeatedly over a period of consecutive days are 
intermittent. All other events are continuous o r single epi[INVESTIGATOR_1841].
10.2.6 Action Taken With Study Treatment
Drug withdrawn –a study  medicat ion is stopped due to the particular AE.
Dose not changed –the particular AE did not require stoppi[INVESTIGATOR_007] a study  medicat ion.
Unknown –only to be used if it has not been pos sible to determine what action has been taken.Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useies of daily living, or significant
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useies of daily living, or significant ly 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usely 
on.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon.
on(s) will be assessed using the fo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon(s) will be assessed using the fo llo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usello
ws a reasonable temporal sequence fro
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usews a reasonable temporal sequence fro m 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usem 
th
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe drug), or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee drug), or 
y, i
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usey, ie, the relati
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee, the relati
, although factors other than the drug, such as underlying diseases, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, although factors other than the drug, such as underlying diseases, 
nd concurrent treatments, may also be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usend concurrent treatments, may also be 
An AE that does not follow a reasonable temporal sequence fro
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAn AE that does not follow a reasonable temporal sequence fro
 a drug and/or that can reasonably be explained by
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use a drug and/or that can reasonably be explained by
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useunderlying diseases, complicat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useunderlying diseases, complicat io
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useions, c
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usens, c
The start date of the AE is the date that the first signs/symptoms were n
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe start date of the AE is the date that the first signs/symptoms were n
The end date of the AE is the date at which the participant 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe end date of the AE is the date at which the participant 
sequelae or the participant died.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesequelae or the participant died.
Pattern of Adverse Event (Frequency) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePattern of Adverse Event (Frequency) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEpi[INVESTIGATOR_607289]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEpi[INVESTIGATOR_607289]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usec AEs (eg, headache) or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usec AEs (eg, headache) or 
ermittent. All other events are continuous o
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useermittent. All other events are continuous o
10.2.6
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use10.2.6
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 46of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIALNot applicable –a study  medicat ion was stopped for a reason other than the particular AE 
eg,the study  has been terminated, the participant died, dosing wit h study  medicat ion had not 
yet started or dosing wit h study  medicat ion was already  stopped before the onset of the AE.
Dose reduced –the dose was reduced due to the particular AE.
Dose increased –the dose was increased due to the particular AE.
Drug interrupted – the dose was interrupted due to the partic ular AE.
10.2.7 Outcome 
Recovered/reso lved –participant returned to first assessment status with respect to the AE.
Recovering/resolving –the intensit y is lowered by  [CONTACT_45332] m ore stages: the diagnosis has or 
signs/symptom s have alm ost disappeared; the abnormal laboratory  value improved, but has 
not returned to the normal range or to the baseline value; the participant died from a cause 
other than the particular AE with the condit ion remaining “recovering/reso lving.”
Not recovered/not resolved –there is no change in the diagnosis, signs or symptoms; the 
intensity of the di agnosis, signs/symptoms or laboratory  value on the l ast day  of the observed 
study peri od has beco me worse than when it started; is an irreversible congenital ano maly; the 
participant di ed fro m another cause with the part icular AE state remaining “Not recovered/not 
resolved.”
Recovered/ Reso lved wit h sequelae –the participant recovered from an acute AE but was left 
with perm anent/si gnificant impairment (eg, recovered fro m a cardiovascular acciden t but with 
some persisting paresis).
Fatal  –an AE that is considered as the cause of death.
Unknown –the course of the AE cannot be fo llowed up due to hospi [INVESTIGATOR_323969]’s part icipation in the study.
10.2.[ADDRESS_804695] ion and Reporting of AEs, SAEs, and Abnormal LFTs
[IP_ADDRESS] Collection Period
Collect ion of AEs (ie, AEs, SAEs, and Abnormal LFTs) will commence at the time the participant
signs the informed consent. Routine co llection of AEs will cont inue unt il the fo llow-up phone call 
on Day  14 ± 2 days after the soticlestat dose. For participants who discont inue prior to the 
administration of study  medicati on, AEs will  be followed until the parti cipant discont inues study 
participat ion. 
[IP_ADDRESS] Reporting AEs
At each study  visit, the Invest igator will assess whether any subjective AEs have occurred. A 
neutral  quest ion, such as “How have you been feeling since your last visit ?” may be asked. 
Parti cipants may  report AEs occurring at any other time during the study . Parti cipants Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecipant returned to first assessment status with respect to the AE.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecipant returned to first assessment status with respect to the AE.
ore stages: the diagnosis has or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useore stages: the diagnosis has or 
laboratory
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselaboratory  value improved, but has 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use value improved, but has laboratory  value improved, but has laboratory
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselaboratory  value improved, but has laboratory
not returned to the normal range or to the baseline value; the participant died from a cause 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenot returned to the normal range or to the baseline value; the participant died from a cause 
n remaining “recovering/reso
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen remaining “recovering/reso
e in the diagnosis, signs or symptoms; the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee in the diagnosis, signs or symptoms; the 
agnosis, signs/symptoms or laboratory
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useagnosis, signs/symptoms or laboratory  value on the l
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use value on the l agnosis, signs/symptoms or laboratory  value on the l agnosis, signs/symptoms or laboratory
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useagnosis, signs/symptoms or laboratory  value on the l agnosis, signs/symptoms or laboratory
me worse than when it started; is an irreversible congenital ano
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useme worse than when it started; is an irreversible congenital ano
nother cause with the part
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenother cause with the part ic
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useicul
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useul
th
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe participant recovered from an acute AE but was left 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee participant recovered from an acute AE but was left 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usegnificant impairment (eg, recovered fro
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usegnificant impairment (eg, recovered fro
AE that is considered as the cause of death.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAE that is considered as the cause of death.
e course of the AE cannot be fo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee course of the AE cannot be fo
change at the end of the participant’s part
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usechange at the end of the participant’s part
ion and Reporting of AEs, SAEs, and Abnormal LFTs
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useion and Reporting of AEs, SAEs, and Abnormal LFTs
Collection Period
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCollection Period
io
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useion of AEs (ie, AEs, SAEs, and Abnormal LFTs) will co
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen of AEs (ie, AEs, SAEs, and Abnormal LFTs) will co
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usegns the informed consent. Routine co
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usegns the informed consent. Routine co
on Day
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon Day  14 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use 14 on Day  14 on Day
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon Day  14 on Day
administration of study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useadministration of study
parti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useparti
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804696] igator concludes that the event is related to the drug treatment. The fo llowing 
inform ation will be documented for each event:
Event term .
Start and end date and time.
Pattern of AE (frequency).
Severit y/Intensi ty.
Causalit y (Invest igator’s opi[INVESTIGATOR_3078] n of the causal relationship between the event and 
administration of study  drug[s]).
Action taken with study  drug.
Outcom e of event.
Seriousness.
[IP_ADDRESS] Reporting SAEs
When an SAE occurs through the AE collection period it should b e reported according to the 
procedure outlined below:
A [COMPANY_005] SAE form must be completed, in English and signed by [CONTACT_941] I nvest igator immediately or 
within [ADDRESS_804697] onset or notification of the event. The informat ion should be co mpleted as 
fully as possible but contain, at a minimum:
A short descript ion of the event and the reason why  the event i s categori zed as serious.
Parti cipant i dentificat ion number.
Invest igator’s name.
Nam e of the study  medicat ion(s).
Causalit y assessment.
The SAE form should be transmitted within [ADDRESS_804698] listed in 
Appendix 14.1.1 .Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useat begin prior to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useat begin prior to 
 procedure, need not be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use procedure, need not be 
All participants experiencing AEs, whether considered associated with the use of the study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAll participants experiencing AEs, whether considered associated with the use of the study
inically relevant 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinically relevant 
til there is a satisfactory
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetil there is a satisfactory  explanat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use explanat til there is a satisfactory  explanat til there is a satisfactory
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetil there is a satisfactory  explanat til there is a satisfactory
 the CRF, whether or not 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use the CRF, whether or not 
igator concludes that the event is related to the drug treatment. The fo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useigator concludes that the event is related to the drug treatment. The fo llo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usello
n of the causal relationship between the event and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen of the causal relationship between the event and 
When an SAE occurs through the AE collection period it should b
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseWhen an SAE occurs through the AE collection period it should b
procedure outlined below:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useprocedure outlined below:
A [COMPANY_005] SAE form must be completed, in English and signed by [CONTACT_177972]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseA [COMPANY_005] SAE form must be completed, in English and signed by [CONTACT_177972]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethin [ADDRESS_804699] onset or notification of the event. The informat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethin [ADDRESS_804700] onset or notification of the event. The informat
fully as possible but contain, at a minimum:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefully as possible but contain, at a minimum:
A short descript
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseA short descript
Parti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseParti ci
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecipant i
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepant icipant ici
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecipant ici

Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInvest
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInvest

Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804701] will fo llow the same 
procedure for SAEs occurring on treatment.
[IP_ADDRESS].[ADDRESS_804702] igator shoul d com plete a follow-up SAE form or provide other written documentation and 
fax it immediately wit hin 24 hours of receipt. Copi[INVESTIGATOR_607290] 
(eg, ECGs, laboratory  tests, di scharge summary, postmortem results) should be sent to the 
addressee, if requested.
All SAEs should be fo llowed up unt il reso lution or perm anent outcome of the event. The timelines 
and procedu re for follow- up reports are the same as those for the init ial report.
[IP_ADDRESS] Reporting Special Interest AEs 
Not Applicable. 
[IP_ADDRESS] Reporting of Abnormal LFTs
Healthy Parti cipants Only
If a participant is noted to have ALT or AST elevated >3 ×ULN on [ADDRESS_804703] >3 ×ULN and total bilirubin >2 ×ULN for which an 
alternat ive etio logy has not been i dentified, the event should be recorded as an SAE and reported 
as per Secti on10.2.8.[ADDRESS_804704] be completed and transmitted with the [COMPANY_005] 
SAE form (as per Section 10.2.9 ). 
10.2.[ADDRESS_804705] ions 
(S[LOCATION_003]Rs) and any other applicable SAEs to regulatory  authori ties, Investi gator s and IRBs or 
IECs, as applicable, in accordance with nat ional regulat ions in the countries where the study  is 
conducted. Relat ive to the first awareness of the event by/or further provisio n to the Sponsor or 
Sponsor’s designee, S[LOCATION_003]Rs will be submitted within [ADDRESS_804706] or that would be Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usew the same 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usew the same 
e first report becomes available at a later date, the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee first report becomes available at a later date, the 
up SAE form or provide other written documentation and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useup SAE form or provide other written documentation and 
ant data from the hospi[INVESTIGATOR_607291]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useant data from the hospi[INVESTIGATOR_607292], postmortem results) should be sent to the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usescharge summary, postmortem results) should be sent to the 
anent outcome of the event. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useanent outcome of the event. 
up reports are the same as those for the init
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useup reports are the same as those for the init ial report.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useial report.
If a participant is noted to have ALT or AST elevated >3 ×ULN on 2 consecutive occa
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIf a participant is noted to have ALT or AST elevated >3 ×ULN on [ADDRESS_804707] be completed 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Used be recorded as an AE. In addition, an LFT Increases CRF must be completed 
information on relevant recent history
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinformation on relevant recent history
symptoms and results of any addit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesymptoms and results of any addit io
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useional
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenal diagnosti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use diagnostinal diagnostinal
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenal diagnostinal
If a participant is noted to have ALT or AST >3 ×ULN and total bilirubin >2 ×ULN for which an 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIf a participant is noted to have ALT or AST >3 ×ULN and total bilirubin >2 ×ULN for which an 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useas not been i
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useas not been i
.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. The 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use The Invest
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInvest
cipant details and possible alternat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecipant details and possible alternat
other acute liver disease. Follow
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useother acute liver disease. Follow
ed. In addit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useed. In addit io
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useio
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSAE form (as per Section
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSAE form (as per Section
10.2.9
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use10.2.9 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSafety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities 
The Sponsor will be responsible for reporting all suspected unexpected serious adverse react
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe Sponsor will be responsible for reporting all suspected unexpected serious adverse react
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(S[LOCATION_003]Rs) and any other applicable SAEs to regulatory
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(S[LOCATION_003]Rs) and any other applicable SAEs to regulatory
IECs, as applicable, in accordance with nat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIECs, as applicable, in accordance with nat
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804708] a copy  of all expedited 
reports to his or her IRB or IEC in accordance wit h natio nal regulat ions.
11.0 STATISTICAL METHODS
11.1 Statistical and Analytical Plans
Detailed methodology  for summary  and stati stical analyses o f the data collected in this study  will
be docum ented in a SAP. The SAP will be prepared by  [CONTACT_607325]. This document may modify the plans outlined in the protocol; however, any major 
modificati ons of  the primary  endpoints definit ion and/or i ts analysis will also be reflected in a 
protocol  amendment. Addit ional statist ical analyses other than those d escribed in this sect ion ma y 
be perform ed if deemed appropriate.
11.1.1 Analysis Sets
[IP_ADDRESS] PK Set
All part icipants who comply sufficient ly with the protocol and display an evaluable PK profile (eg, 
exposure to treatm ent, availabilit y of measurements and absence o f maj or protocol  violations) will 
be included in the statist ical analyses.
[IP_ADDRESS] Safety Set
All participants who received the dose of soticlestat will be included in the safet y evaluat ions.
[IP_ADDRESS] PD Set
Not applicable.
11.1.2 Analysis of Demography and Other Baseline Characteristics
Continuous demographic data (ie, age, weight, height, and BMI) will be listed and summarized 
using appropriate summary statist ics. Categori cal dem ographic data (i e, sex, race, and ethnicit y)
will also be listed and tabulated.
11.1.[ADDRESS_804709] ion group (normal hepatic funct ion,moderate and mild HI). An ANOV A 
will be performed on the ln -transform ed C max, AUC last, and AUC ∞for soticlestat to compare each 
HI group with the normal hepat ic function group, and 90% CIs for the ratio of geometric means 
from each HI group versus normal funct ion group will be provided. The addi tion of  other factors 
and covariates such as age, sex, and BMI on the relat ionship between soticlestat PK parameters 
and level o f HI m ay also be investi gated. Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee data collected in this study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee data collected in this study
on and agreed upon with the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon and agreed upon with the 
ponsor. This document may modify the plans outlined in the protocol; however, any major 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useponsor. This document may modify the plans outlined in the protocol; however, any major 
ts analysis will also be reflected in a 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usets analysis will also be reflected in a 
ical analyses other than those d
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useical analyses other than those d escribed in this sect
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useescribed in this sect
he protocol and display an evaluable PK profile (eg, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehe protocol and display an evaluable PK profile (eg, 
f measurements and absence o
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usef measurements and absence o
All participants who received the dose of soticlestat will be included in the safet
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAll participants who received the dose of soticlestat will be included in the safet
Demography
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDemography
Continuous demographic data (ie, age, weight, height, and BMI) will be listed and summarized 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseContinuous demographic data (ie, age, weight, height, and BMI) will be listed and summarized 
using appropriate summary statist
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useusing appropriate summary statist
will also be listed and tabulated.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewill also be listed and tabulated.
PK Analysis
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePK Analysis
Stati
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseStatist
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usest
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useical an
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useical an
Descript
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDescript
according to hepatic funct
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useaccording to hepatic funct
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804710] ion group (normal hepat ic funct ion and 
moderate and mild HI).
The fract ion of unbound soticlestat will be determined.
11.1.4 PD Analysis 
Not applicable.
11.1.5 Safety Analysis
All safet y data will be populated in the individ ual CRFs.
Dosing dates and t imes will be listed by [CONTACT_3445].
TEAEs will be tabulated. The remaining quant itative safet y data as well as the difference to 
baseline, when appropriate, will be summarized using the appropriate descript ive statistics.
[IP_ADDRESS] AEs
AEs will be coded using the most current version of Medical Dict ionary for Regulatory  Activit ies 
(MedDRA®) available at Celerio n and summarized by [CONTACT_607326]. A by -participant AE data list ing including 
verbat im term, coded term, treatment, severit y, and relat ionship to treatm ent will be provided. AEs 
that occur before administration of study  drug will be included in list ings but will not be 
summarized.
[IP_ADDRESS] Clinical Laboratory
Clinical laboratory  resul ts will be summarized by [CONTACT_607327] a shift
table describing out of normal range shifts will be provided. 
MAV cri teria for safet y laboratory  assessments will be defined in the SAP.
[IP_ADDRESS] Vital Signs
Vital signs assessments will be summarized by [CONTACT_607327] a shift 
table describing out of normal range shifts will be provided . 
MAV criteria for vi tal signs will be defined in the SAP.
[IP_ADDRESS] Other Safety Parameters
Physical examinat ion findings will be presented in the data list ings.
ECGs and C- SSRS results will be summarized by [CONTACT_607328] o f collect ion and a shift
table describing out of normal range shifts will be provided . 
MAV cri teria for ECGs will be defined in the SAP.Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedata as well as the difference to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedata as well as the difference to 
baseline, when appropriate, will be summarized using the appropriate descript
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebaseline, when appropriate, will be summarized using the appropriate descript
AEs will be coded using the most current version of Medical Dict
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAEs will be coded using the most current version of Medical Dict
n and summarized by [CONTACT_607329]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen and summarized by [CONTACT_607330] 
e number of TEAEs reported. A by
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee number of TEAEs reported. A by
, treatment, severit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, treatment, severit y,
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usey, and relat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use and relat
 drug will be included in list
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use drug will be included in list at occur before administration of study  drug will be included in list at occur before administration of study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useat occur before administration of study  drug will be included in list at occur before administration of study
ts will be summarized by 
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usets will be summarized by 
e describing out of normal range shifts will be provided. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee describing out of normal range shifts will be provided. 
teria for safet
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useteria for safet y 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usey 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselaboratory
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselaboratory
Vital Signs
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseVital Signs
 signs as
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use signs as sessments will be summarized by
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesessments will be summarized by
e describing out of normal range shifts will be provided
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee describing out of normal range shifts will be provided
MAV cri
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMAV cri teria for vi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useteria for vi MAV cri teria for vi MAV cri
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMAV cri teria for vi MAV cri
[IP_ADDRESS]
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use11.1.5.4
Physical examinat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePhysical examinat
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 51of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIALMedical history  and concurrent condi tions will be coded using the MedDRA®and conco mitant 
medicat ions will be coded using the World Healt h Organizat ion (WHO) drug dict ionary and will 
be listed by [CONTACT_323999].
11.[ADDRESS_804711] to review by [CONTACT_47399]’s designee, including but not limited to the Invest igator’s Binder, study drug, participant 
medical records, informed consent documentation, and review of CRFs and associated source 
docum ents. It i s important that the Investigator and other study personnel are available during the 
monitoring visits and that sufficient time is devoted to the process.
12.[ADDRESS_804712] igator should consul t with the 
sponsor or designee (and IRB or IEC, as required) to determine the appropriate course of act ion. Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useparticipants in the matched normal hepat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useparticipants in the matched normal hepat ic 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useic 
 addi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use addi ti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useti  addi ti  addi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use addi ti  addi on
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon
imate of the effect 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useimate of the effect 
The planned sample size of 8 participants in each HI arm is not based on power calculat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe planned sample size of 8 participants in each HI arm is not based on power calculat
n of the PK of soticlestat  
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen of the PK of soticlestat  
pared to healthy participants with norma
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepared to healthy participants with norma
Any participant who is not PK evaluable including those experiencing emesis 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAny participant who is not PK evaluable including those experiencing emesis 
aced at the discretion of the Investigators in consultat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useaced at the discretion of the Investigators in consultat
ipants in each arm of participants with HI and 12
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useipants in each arm of participants with HI and 12
al
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useal hepati
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use hepatial hepatial
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useal hepatial
QUALITY ASSURANCE
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseQUALITY ASSURANCE
Site Monitoring Visits
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSite Monitoring Visits
tes will be made peri
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetes will be made peri
aspects of the protocol are followed. Detailed informat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useaspects of the protocol are followed. Detailed informat
ented in a Clinical Research Associate Monitoring Plan and fo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useented in a Clinical Research Associate Monitoring Plan and fo
. Source documents will be reviewed for verificat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. Source documents will be reviewed for verificat
CRFs. Source documents are defi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCRFs. Source documents are defi
te guarantee access to source documents by
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usete guarantee access to source documents by
[CONTACT_607331]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useresearch organizat io
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useion and by [CONTACT_4186].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen and by [CONTACT_4186].
aspects of the study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useaspects of the study
Sponsor’s designee, including but not limited to the Invest
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSponsor’s designee, including but not limited to the Invest
medical records, informed consent documentation, and review of CRFs and associated source 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemedical records, informed consent documentation, and review of CRFs and associated source 
docum
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedocum ents. It i
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useents. It i
mo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemonit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenitoring visits and that sufficient time is devoted to the process.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useoring visits and that sufficient time is devoted to the process.
12.2
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use12.2
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 52of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIALThere will be no exempt ions (a prospectively approved deviat ion) from the inclusion or exclusio n 
criteria.
For COVID -19-related protocol deviat ions,the specific protocol deviation, the reason for the 
deviat ion, and the relat ionship to COVID -[ADDRESS_804713] ed by [CONTACT_17513], including 
those of foreign governments (eg, the FDA, the United Kingdo m Medicines and Healthcare 
products Regulatory  Agency , the Pharmaceut icals and Medical Devices Agency o f Japan). If the 
study  site is contact[CONTACT_4190] a regul atory  body , the Sponsor should be notified 
immediately . The Invest igator guarantees access for qualit y assurance auditors to all study
docum ents as described in Sect ion12.1.
13.[ADDRESS_804714] for the individual participants (ie, 
participants) accordi ng to the protocol, the ethical principles that have their origin in the 
Declaration of Helsinki, and the Internat ional Council on Harmo nisat ion (ICH) Harmonised 
Tripartite Guideline for GCP. Each Investi gator will conduct the study according to applicable 
local or regi onal regulatory  requi rements and align his or her conduct in accordance with the 
“Responsibilit ies of the Investigator” that are listed in Appendix A. The principles of Helsinki are 
addressed through the protocol and through appendices contain ing requirements for informed 
consent and I nvest igator responsibilities.
13.1 IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable state and federal/local requirements 
of each participat ing region. The Sponsor or designee will r equire documentation noting all names 
and tit les of members who make up the respective IRB or IEC. If any member of the IRB or IEC 
has di rect parti cipat ion in this study , written notification regarding his or her abstinence fro m 
voting must also be obtained. Those Americas sites unwilling to provide names and tit les of all 
members due to privacy and conflict of interest concerns should instead provide a Federal Wide 
Assurance Number or comparable number assigned by [CONTACT_607332] s.Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefraud or misconduct, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefraud or misconduct, 
health risk to the participant, or confound interpretation of primary study assessment. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehealth risk to the participant, or confound interpretation of primary study assessment. 
oring to be conducted in this study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useoring to be conducted in this study  will
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use will oring to be conducted in this study  will oring to be conducted in this study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useoring to be conducted in this study  will oring to be conducted in this study
ality Assurance Audits and Regulatory Agency Inspections
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useality Assurance Audits and Regulatory Agency Inspections
ts by [CONTACT_607333]. In 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usets by [CONTACT_607333]. In 
designated auditor will contact [CONTACT_178057]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedesignated auditor will contact [CONTACT_607334]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useies where laboratory
where the medication is stored and prepared, and any other facilit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewhere the medication is stored and prepared, and any other facilit
y that this study may be inspect
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usey that this study may be inspect
ose of foreign governments (eg, the FDA, the United Kingdo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useose of foreign governments (eg, the FDA, the United Kingdo
als and Medical Devices Agency o
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useals and Medical Devices Agency o
on by a regul
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon by a regul atory
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useatory
igator guarantees access for qualit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useigator guarantees access for qualit
ETHICAL ASPECTS OF T
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseETHICAL ASPECTS OF T HE STUDY
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHE STUDY
 be conducted wi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use be conducted wi th
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useth  be conducted wi th  be conducted wi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use be conducted wi th  be conducted wi  the highest respect for the individual participants (ie, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use the highest respect for the individual participants (ie, th the highest respect for the individual participants (ie, th
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useth the highest respect for the individual participants (ie, th
ng to the protocol, the ethical principles that have their origin in the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useng to the protocol, the ethical principles that have their origin in the 
sinki, and the Internat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesinki, and the Internat
e Guideline for GCP. Each 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee Guideline for GCP. Each 
 regulatory
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use regulatory
ies of the Investigator” that are listed in
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useies of the Investigator” that are listed in
addressed through the protocol and through appendices contain
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useaddressed through the protocol and through appendices contain
consent and I
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useconsent and I nvest
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenvest
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIRB and/or IEC Approval
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIRB and/or IEC Approval
IRBs and IECs must be constituted according to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIRBs and IECs must be constituted according to 
of
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useof each participat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use each participatof each participatof
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useof each participatof
and tit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand tit
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 53of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIALThe Sponsor or designee will supply  relevant documents for submission to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the IB, a copy  of the ICF, and, if 
applicable, participant recruit ment materi als and/or advertiseme nts and other documents required 
by [CONTACT_1763], must be submitted to a central or local IRB or IEC for 
approval . The IRB’s or IEC’s written approval of the protocol and participant informed consent 
must be obtained and submitted to the Sponsor or designee before commencement of the study (ie, 
before shipment of the Sponsor-supplied drug or study specific screening act ivity). The IRB or 
IEC approval must refer to the study  by [CONTACT_39819], number, and versio n date; ident ify 
versions of other documents (eg, ICF) reviewed; and state the approval date. The Sponsor will ship 
drug/notify site once the Sponsor has confirmed the adequacy  of site regul atory  docum entati on 
and, when applicable, the Sponsor has received permissio n from c ompetent authori ty to begin the 
study . Unt il the site receives drug/notification no protocol activit ies, including screening, may
occur.
Sites m ust adhere to all requirements stipulated by  [CONTACT_4195]. This may include 
notification to the IRB or IEC regarding protocol amendments, updates to the ICF, recruit ment
materi als intended for viewing by  [CONTACT_183568], l ocal safet y reporting requirements, reports and 
updates regarding the ongoing review of the study  at intervals specified by [CONTACT_607335], and submissio n of the Investigator’s final status report to IRB or IEC. All IRB and IEC 
approval s and rel evant docum entati on for these items must be provi ded to the Sponsor or its 
designee.
Parti cipant incent ives should not exert undue inf luence for participat ion. Payments to participant 
must be approved by [CONTACT_47400].
13.2 Participant Information, Informed Consent, and Participant Authorization
Written consent documents will embody  the elements of informed consent as described i n the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. The ICF, participant authorizat ion form (if applicable), and 
participant informat ion sheet (if applicable) describe the planned and permitted uses, transfers, and 
disclosures of the parti cipant’s personal and personal healt h informat ion for purposes of 
conducting the study. The ICF and the participant informat ion sheet (if applicable) further explain 
the nature of the study, its o bject ives, and potential risks and benefits, as well as the date informed 
consent is given. The ICF will detail the requirements of the participant and the fact that he or she is free to withdraw at any  time without giving a reason and without prejudice to his or her further 
medical care.
The Investigator is responsible for the preparation, content, and IRB or IEC approval of the ICF 
and, if applicable, the participant authorizat ion form. The ICF, parti cipant authori zation form (if 
applicable), and particip ant inform ation sheet (if applicable) must be approved by [CONTACT_304535].The ICF, participant authorizat ion form (if applicable), and participant informat ion sheet (if 
applicable) must be written in a language fully compr ehensible to the prospective participant. It is 
the responsibilit y of the Invest igator to explain the detailed elements of the ICF, participant Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uses and other documents required 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uses and other documents required 
. The IRB’s or IEC’s written approval of the protocol and participant informed consent 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. The IRB’s or IEC’s written approval of the protocol and participant informed consent 
or designee before commencement of the study (ie, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useor designee before commencement of the study (ie, 
. The IRB or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. The IRB or 
n date; ident
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen date; ident
The Sponsor will ship 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe Sponsor will ship 
atory
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useatory  docum
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use docum atory  docum atory
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useatory  docum atory
petent authori
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepetent authori
ies, including screening, may
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useies, including screening, may
r respect
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of User respect ive IRB or IEC. This may include 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useive IRB or IEC. This may include 
RB or IEC regarding protocol amendments, updates to the ICF, recruit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRB or IEC regarding protocol amendments, updates to the ICF, recruit
y 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usey reporting requirements, reports and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usereporting requirements, reports and 
nt
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usentervals specified by [CONTACT_607336]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useervals specified by [CONTACT_607337]’s final status report to IRB or IEC. All IRB and IEC 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenvestigator’s final status report to IRB or IEC. All IRB and IEC 
tems must be provi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetems must be provi
ives should not exert undue inf
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useives should not exert undue inf luence for participat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useluence for participat ives should not exert undue inf luence for participat ives should not exert undue inf
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useives should not exert undue inf luence for participat ives should not exert undue inf
must be approved by [CONTACT_47400].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemust be approved by [CONTACT_47400].
Participant Information, Informed Consent, and Participant Authorization
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseParticipant Information, Informed Consent, and Participant Authorization
ten consent documents will embody
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useten consent documents will embody
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDeclaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. The ICF, participant authorizat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useapplicable laws and regulations. The ICF, participant authorizat
io
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useion sheet (if applicable) describe 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen sheet (if applicable) describe 
osures of the parti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useosures of the parti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecipant’s personal and personal healt
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecipant’s personal and personal healt
conducting the study. The ICF and the participant informat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useconducting the study. The ICF and the participant informat
e nature of the study, its o
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee nature of the study, its o
consent is given. The ICF will detail the requirements of the participant and the fact that he or she 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useconsent is given. The ICF will detail the requirements of the participant and the fact that he or she 
free to withdraw at any
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefree to withdraw at any
medical care.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemedical care.
The 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe I
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInvestigator is responsible for the preparation, content, and IRB or IEC approval of the ICF 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenvestigator is responsible for the preparation, content, and IRB or IEC approval of the ICF 
and, if applicable, the participant authorizat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand, if applicable, the participant authorizat
applicable), and particip
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useapplicable), and particip
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 54of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIALauthori zation form (if applicable), and participant informat ion sheet (if applicable) to the 
participant. Inform ation should be given in both oral and written form whenever possible and in 
the manner deemed appropriate by [CONTACT_4186]. In the event the participant is not capable of 
rendering adequate written informed consent, then the participant’s legally accepta ble 
representative may provide such consent for the participant in accordance with applicable laws and 
regul ations.
The parti cipant, or the participant’s legally acceptable representative, must be given ample 
opportunit y to: (1) inquire about details o f the study, and (2) decide whether or not to participate in 
the study. If the participant, or the participant’s legally acceptable representative, determines he or 
she will participate in the study , then the ICF and participant authorizat ion form (if applicab le) 
must be signed and dated by  [CONTACT_17071], or the participant’s legally acceptable representative, 
at the time of consent and prior to the participant entering into the study . The parti cipant or the 
participant’s legally acceptable representative sho uld be instructed to sign using their legal names, 
not ni cknames, using blue or black ballpo int ink. The Invest igator must also sign and date the ICF 
and part icipant authorizat ion (if applicable) at the time of consent and prior to participant entering 
into the study ; however, the Sponsor may allow a designee of the Invest igator to sign to the extent
permitted by  [CONTACT_1289].
Once signed, the original ICF, participant authorization form (if applicable), and participant 
inform ation sheet (if applicable) w ill be stored in the Investigator ’s site file. The Invest igator must 
docum ent the date the participant signs the informed consent in the participant’s medical record. 
Copi [INVESTIGATOR_113903], the signed participant authorizat ion form (if applicable), and partici pant 
inform ation sheet (if applicable) shall be given to the participant.
All revised ICFs must be reviewed and signed by [CONTACT_607338]’s 
legally acceptable representative in the same manner as the original  inform ed consent. The date the 
revised consent was obtained should be recorded in the participant’s medical record, and the participant shoul d receive a copy  of the revised ICF.
13.[ADDRESS_804715] e of the parti cipant’s ri ght to protection 
against invasio n of privacy. Throughout this study , a parti cipant’s source data will only be linked 
to the Sponsor’s clinical study  database or docum entati on via a unique ident ificat ion number. As 
permitted by [CONTACT_39823], limited participant attributes, such as sex, age, or 
date of birth, and participant initials may be used to verify the part icipant and accuracy  of the 
participant’s unique ident ification number.
To comply wit h ICH Guidelin es for GCP and to verify co mpliance with this protocol, the Sponsor 
requi res the Invest igator to permi t its monitor or designee’s m onitor, representatives from  any
regulatory  authori ty (eg, FDA, Medi cines and Heal thcare products Regul atory  Agency, 
Pharmace uticals and Medical Devices Agency), the Sponsor’s designated auditors, and the 
appropriate IRBs and IECs to review the participant’s original medical records (source data or 
docum ents), including, but not limited to, laboratory  test resul t reports, ECG re ports, admissio n 
and discharge summaries for hospi[INVESTIGATOR_45291] a participant’s studyProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee participant in accordance with applicable laws and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee participant in accordance with applicable laws and 
cipant, or the participant’s legally acceptable representative, must be given ample 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecipant, or the participant’s legally acceptable representative, must be given ample 
e study, and (2) decide whether or not 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee study, and (2) decide whether or not to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useto participate in 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useparticipate in 
e study. If the participant, or the participant’s legally acceptable representative, determines he or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee study. If the participant, or the participant’s legally acceptable representative, determines he or 
fo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useform
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userm (if applicab
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use (if applicabrm (if applicabrm
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userm (if applicabrm
cipant, or the participant’s legally acceptable representative, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecipant, or the participant’s legally acceptable representative, 
at the time of consent and prior to the participant entering into the study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useat the time of consent and prior to the participant entering into the study . The parti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. The parti
uld be instructed to sign using their legal names, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useuld be instructed to sign using their legal names, 
igator
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useigator must also sign and date the ICF 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemust also sign and date the ICF 
if applicable) at the time of consent and prior to participant entering 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useif applicable) at the time of consent and prior to participant entering 
; however, the Sponsor may allow a designee of the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use; however, the Sponsor may allow a designee of the 
Once signed, the original ICF, participant authorization form (if applicable), and participant 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseOnce signed, the original ICF, participant authorization form (if applicable), and participant 
ill be stored in the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useill be stored in the Investigator
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInvestigator
ent the date the participant signs the informed consent in the participant’s medical record. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useent the date the participant signs the informed consent in the participant’s medical record. 
es of the signed ICF, the signed participant authorizat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usees of the signed ICF, the signed participant authorizat
n sheet (if applicable) shall be given to the participant.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen sheet (if applicable) shall be given to the participant.
All revised ICFs must be reviewed and signed by [CONTACT_607338]’s 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAll revised ICFs must be reviewed and signed by [CONTACT_607338]’s 
legally acceptable representative in the same manner as 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselegally acceptable representative in the same manner as 
revised consent was obtained should be recorded in the participant’s medical record, and the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userevised consent was obtained should be recorded in the participant’s medical record, and the 
d receive a copy
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Used receive a copy  of
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use of d receive a copy  of d receive a copy
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Used receive a copy  of d receive a copy
Participant Confidentiality
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseParticipant Confidentiality
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe Sponsor and designees affirm 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe Sponsor and designees affirm 
against invasio
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useagainst invasio n of privacy. Throughout this study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen of privacy. Throughout this study
to the Sponsor’s clinical study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useto the Sponsor’s clinical study
permitted by [CONTACT_607339]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepermitted by [CONTACT_607340], and participant init
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedate of birth, and participant init
parti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useparticipant’s unique ident
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecipant’s unique ident
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTo comply wit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTo comply wit
requi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userequi
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 55of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIALparticipat ion, and autopsy  reports. Access to a participant’s original medical records requires the 
specific authorization of the participant as part of the informed consent process (see Section 13.2).
Copi [INVESTIGATOR_607293] (ie, parti cipant nam e, address, and other ident ifier 
fields not collected on the participant’s CRF).
13.[ADDRESS_804716] igator s or to regulatory agencies, except as required by 
[CONTACT_4201]. Except as otherwise allowable in the clinical study  site agreement, any  public 
disclosure (including publicly accessible websites) related to the protocol or study  resul ts, other 
than study  recrui tment m aterials an d/or adverti sements, is the sole responsibilit y of the Sponsor.
The Sponsor may publish any data and information fro m the study (including data and informat ion 
generated by  [CONTACT_24342] ) without the consent of the Investigato r. Manuscript authorship for 
any peer -reviewed publicat ion will appropriately reflect contribut ions to the production and 
review of the document. All publicat ions and presentations must be prepared in accordance with 
this secti on and the Clinical Study  Site Agreement. In the event of any discrepancy  between the 
protocol  and the Clinical Study  Site Agreement, the Clinical Study  Site Agreement will prevail.
13.4.2 Clinical Study Registration 
In order to ensure that informat ion on clinical trials reaches the public in a timely manner and to
comply with applicable laws, regulat ions and guidance, [COMPANY_005] will, at a minimum register all 
intervent ional clinical tri als it Sponsors anywhere in the world on ClinicalTrials.gov and/or other 
publicly  accessible websites before start of study , as defined in [COMPANY_005] Policy/Standard. [COMPANY_005] 
contact [CONTACT_4203], along with Investi gator ’s cit y, state (for Americas invest igators), country, and 
recrui ting status will be registered and available for public viewing. 
For some registries, [COMPANY_005] will assist caller s in l ocating study  sites cl osest to thei r homes by 
[CONTACT_337442], address, and phone number to the callers request ing trial 
inform ation. Once part icipants receive investigator contact [CONTACT_3031], they may call the site 
requesting enroll ment into the trial. The invest igative sites are encouraged to handle the trial 
inquiries according to their established participant screening process. If the caller asks addit ional 
questions bey ond the topic of trial enrollment, they should be referred to the Sponsor.
Any Invest igator who objects to the Sponsor providing this informat ion to callers must provide the 
Sponsor with a written notice requesting that their informat ion not be listed on the registry  site.
13.4.[ADDRESS_804717] the results of clinical studies on ClinicalTrials.gov or other publicly accessible 
websites, as required by [CONTACT_39825]/Standard, applicable laws and/or regulat ions.Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useifier 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useifier 
is obliged to provide the Sponsor with complete test results and all data derived 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useis obliged to provide the Sponsor with complete test results and all data derived 
 the Sponsor m
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use the Sponsor m
s or to regulatory agencies,
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uses or to regulatory agencies,
n. Except as otherwise allowable in the clinical study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen. Except as otherwise allowable in the clinical study  si
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use si n. Except as otherwise allowable in the clinical study  si n. Except as otherwise allowable in the clinical study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen. Except as otherwise allowable in the clinical study  si n. Except as otherwise allowable in the clinical study te agreement, any
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usete agreement, any site agreement, any si
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use site agreement, any si
osure (including publicly accessible websites) related to the protocol or study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useosure (including publicly accessible websites) related to the protocol or study
sements, is the sole responsibilit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesements, is the sole responsibilit
m t
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usem the study (including data and informat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehe study (including data and informat
out the consent of the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useout the consent of the Invest
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInvest
n will appropriately reflect contribut
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen will appropriately reflect contribut
ns and presentations must be prepared in accordance with 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usens and presentations must be prepared in accordance with 
te Agreement. In the event
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usete Agreement. In the event
te Agreement, the Clinical Study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usete Agreement, the Clinical Study
Registration 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRegistration 
io
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useion on clinical trials reaches the public in a timely manner and to
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen on clinical trials reaches the public in a timely manner and to
 applicable laws, regulat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use applicable laws, regulat
als i
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useals it Sponsors anywhere in the world on ClinicalTrials.gov and/or other 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uset Sponsors anywhere in the world on ClinicalTrials.gov and/or other als it Sponsors anywhere in the world on ClinicalTrials.gov and/or other als i
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useals it Sponsors anywhere in the world on ClinicalTrials.gov and/or other als i
 accessible websites before 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use accessible websites before 
n, along with 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen, along with 
ting status will be registered and available for public viewing. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useting status will be registered and available for public viewing. 
For some registries, [COMPANY_005] will assist caller
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFor some registries, [COMPANY_005] will assist caller
ding the Invest
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useding the Invest
at
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useatio
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useion. Once part
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen. Once part
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userequesting enroll
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userequesting enroll
inquiries according to their established participant screening process. If the caller asks addit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinquiries according to their established participant screening process. If the caller asks addit
questions bey
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usequestions bey
Any 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAny 
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804718] be ins ured in accordance with the regulat ions applicable to the 
site where the participant is parti cipat ing. If a local underwriter is required, then the Sponsor or 
Sponsor’s designee will obtain clinical study  insurance against the risk of injury to study
participants. Refer to the study  site agreement regarding the Sponsor’s policy on participant 
compensat ion and treatment for injury. If the Investigator has questions regarding this policy, he or 
she should contact [CONTACT_13679]’s designee.
14.[ADDRESS_804719] Type / Role Contact
[CONTACT_424125], Inc.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useing. If a local underwriter is required, then the Sponsor or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useing. If a local underwriter is required, then the Sponsor or 
te agreement regarding the Sponsor’s policy on participant 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usete agreement regarding the Sponsor’s policy on participant 
nvestigator has questions regarding this policy, he or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenvestigator has questions regarding this policy, he or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePharmacovigilance
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePharmacovigilance
[COMPANY_005] Development Center Americas, Inc.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use[COMPANY_005] Development Center Americas, Inc.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat
Study
 ID
 Page
 [ADDRESS_804720]
 read
 and
that
 I
understand
 this
protocol,
 the
Investigator’s
 Brochure,
 package
insert
 and
any
other
 product
 information
 provided
 by
[CONTACT_75376].
 agree
 to
conduct
 this
study
 in
accordance
 with
 the
requirements
 of
this
protocol
 and
also
 to
protect
 the
rights,
 safety,
 privacy,
and
well-being
 of
study
 participants
 in
accordance
 with
 the
following:
The
ethical
 principles
 that
have
 their
 origin
 in
the
Declaration
 of
Helsinki.
International
 on
Harmonisation,
 E6
Good
 Clinical
 Practice:
 Consolidated
 Guideline.
All
applicable
 laws
 and
regulations,
 without
 limitation,
 data
 privacy
 laws
 and
regulations.
Regulatory
 requirements
 for
reporting
 serious
 adverse
 events
 defined
 in
 10.2.9
 of
this
protocol.
Terms
 outlined
 in
the
study
 site
agreement.
Responsibilities
 of
the
of
the
of
 Investigator
 (Appendix
 B).
that
my
 information
 may
 be
processed
 and
transferred
 in
accordance
CONFIDENTIAL
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
package
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
package
study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
study
 in
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
in
privacy,
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
privacy,
Consolidated
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Consolidated
data
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
data
 privacy
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
privacy
events
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
events
 defined
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
defined
B).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
B).
may
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
may
 be
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
be
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat
 (TAK-935)
Study
 ID
TAK-935-[ADDRESS_804721]
 read
 and
that
I
understand
 this
protocol,
 the
Investigator’s
 Brochure,
 package
insert
 and
any
other
 product
 information
 provided
 by
[CONTACT_75376].
 J
agree
 to
conduct
 this
study
 in
accordance
 with
 the
requirements
 of
this
protocol
 and
also
to
protect
 the
rights,
 safety,
 privacy,
and
well-being
 of
study
 participants
 in
accordance
 with
 the
following:
e
The
ethical
 principles
 that
have
 their
 origin
 in
the
Declaration
 of
Helsinki.
e
 Council
 on
Harmonisation,
 Good
 Clinical
 Practice:
 Consolidated
 Guideline.
e
All
applicable
 laws
 and
regulations,
 including,
 without
 limitation,
 data
privacy
 laws
 and
regulations.
Regulatory
 requirements
 for
reporting
 serious
 adverse
 events
 defined
 in
Section
 10.2.9
 of
this:
protocol.
e
Terms
 outlined
 in
the
study
 site
agreement.
e
Responsibilities
 of
the
Investigator
 (Appendix
 B).
I
further
 authorize
 tha
 pergonal
 information
 may
 be
processed
 and
transferred
 in
accordance
with
 the
uses
 D
of
this
protocol.
CONFIDENTIAL
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
package
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
package
study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
study
 in
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
in
safety,
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
safety,
 privacy,
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
privacy,
Consolidated
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Consolidated
data
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
data
privacy
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
privacy
events
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
events
 defined
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
defined
B).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
B).
information
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
information
 may
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
may
 be
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
be
of
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
of
this
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
this
protocol.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
protocol.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
The
ethical
 principles
 that
have
 their
 origin
 in
the
Declaration
 of
Helsinki.
International
 Council
 on
Harmonisation,
 E6
Good
 Clinical
 Practice:
 Consolidated
 Guideline.
All
applicable
 laws
 and
regulations,
 including,
 without
 limitation,
 data
privacy
 laws
 and
regulations.
Regulatory
 requirements
 for
reporting
 serious
 adverse
 events
 defined
 in
Section
 10.2.9
 of
this
protocol.
Terms
 outlined
 in
the
study
 site
agreement.
Responsibilities
 of
the
of
the
of
 Investigator
 (Appendix
 B).
CONFIDENTIAL
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Consolidated
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Consolidated
data
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
data
privacy
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
privacy
defined
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
defined
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
The
ethical
 principles
 that
have
 their
 origin
 in
the
Declaration
 of
Helsinki.
International
 Council
 on
Harmonisation,
 E6
Good
 Clinical
 Practice:
 Consolidated
 Guideline.
All
applicable
 laws
 and
regulations,
 including,
 without
 limitation,
 data
 privacy
 laws
 and
regulations.
Regulatory
 requirements
 for
reporting
 serious
 adverse
 events
 defined
 in
Section
 10.2.9
 of
this
of
this
of
protocol.
Terms
 outlined
 in
the
study
 site
agreement.
Responsibilities
 of
the
Investigator
 (Appendix
 B).
CONFIDENTIAL
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Consolidated
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Consolidated
 Guideline.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Guideline.
privacy
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
privacy
defined
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
defined
 in
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
in
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804722] Aspartate aminotransferase
AUC Area under the concentration -time curv e
AUC  The area under the concentration -time curve, from time [ADDRESS_804723] quantifiable 
concentration, as calculated by [CONTACT_1690] -log trapezoidal method.
BID Twice daily
BMI Body mass index
BP Blood pressure
bpm Beats per minute
CDD CDKL5 deficiency disorder
C-SSRS Columbia -Suicide Severity Rating Scale
CFR Code of Federal Regulations
CH24H cholesterol 24 Shydroxy lase
CI Confidence interval
Cm Centimeter
Cmax Maximum observed concentration 
COVID -19 Coronavirus Disease -2019
CRF Case report form
CRU Clinical Research Unit
CSR Clinical study report
CYP Cytochrome P450
DEE Developmental and Epi[INVESTIGATOR_607294]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetime curv
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetime curv e
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee
The area under the concentration
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe area under the concentration -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-time curve, from time
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetime curve, from time
The area under the concentration
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe area under the concentration -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-time curve, from time
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetime curve, from time
concentration, as calculated by [CONTACT_607341]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useconcentration, as calculated by [CONTACT_607342]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseBody mass index
Blood pressure
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseBlood pressure
Beats per minute
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseBeats per minute
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCDKL5 deficiency disorder
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCDKL5 deficiency disorder
Columbia
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseColumbia
Code of Federal Regulations
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCode of Federal Regulations
cholesterol 24
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecholesterol 24
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCOVID
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCOVID -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-19
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use19
CRF
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCRF
CRU
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCRU
CSR
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCSR
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 59of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIALDS Dravet Syndrome 
Dup15q 15q11 -q13 duplication syndrome
ECG Electrocardiogram
FDA Food and Drug Administration
FSH Follicle stimulating hormone
g Gram
GCP Good Clinical Practice
h Hour(s)
HBsAg Hepatitis B surface antigen
HBV Hepatitis B virus
hCG Human chorionic gonadotropin
HCV Hepatitis C virus 
HCVAb Hepatitis C virus antibodies
HI hepatic impairment
HIV Human immunodeficiency virus
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Council for Harmonisation
IEC Independent Ethics Committee
INR International normalized ratio
IRB Institutio nal Review Board
IUD Intrauterine device
kg Kilogram
L Liter
LFT Liver function test
LGS Lennox Gastaut Syndrome
ln Natural log
m2Meters squared
MAV Markedly abnormal values
μg Microgram
μmol Micromole
MedDRA®Medical Dictionary for Regulatory Activities®
mg Milligram
min Minute
mL Milliliter
mmHg Millimeter of mercury
msec Millisecond
N Number
OATP organic -anion-transporting polypeptide
PD Pharmacodynamic(s)Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInternational Council for Harmonisation
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInternational Council for Harmonisation
Independent Ethics Committee
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIndependent Ethics Committee
International normalized ratio
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInternational normalized ratio
nal Review Board
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenal Review Board
Liver function test
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseLiver function test
Lennox Gastaut 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseLennox Gastaut 
Natural log
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseNatural log
Meters squared
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMeters squared
Markedly abnormal values
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMarkedly abnormal values
min
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemin
mL
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsemL
mmHg
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsemmHg
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 60of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIALPK Pharmacokinetic(s)
PR Pulse rate
PT Prothrombin time
PTE Pretreatment event
QD Daily
QTcF QT interval corrected for heart rate using Fridericia’s formula
RNA Ribonucleic acid
SAE Serious adverse event
SAP Statistical analysis plan
S[LOCATION_003]R Suspected unexpected serious adverse reaction
t½z Terminal disposition phase half -life
TEAE Treatment -emergent adverse event
tmax Time of first occurrence of Cmax
UGT Uridine 5' diphospho -glucuronosyltransferase
ULN Upper limit of normal
US [LOCATION_002]
[LOCATION_003] [LOCATION_002] of America
WHO World Health Organization
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHealth Organization
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHealth Organization
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 61of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIAL15.0 DATA HANDLING AND RE CORDKEEPI[INVESTIGATOR_85958]. 
AEs, medical history, and concurrent condit ions will be coded using the MedDRA®. Drugs will be 
coded usin g the WHO Drug Dictionary .
15.1 CRFs (Electronic and Paper)
Com pleted CRFs are requi red for each participant who signs an informed consent.
The Sponsor or its designee will supply investigative sites with access to CRFs. The Sponsor will 
make arrangements to train appropriate site staff in the use of the CRF. These forms are used to 
transmit the informat ion collected in the performance o f this study  to the Sponsor and regulatory
authori ties. CRFs must be completed in English. Data are transcribed direct ly onto CRFs.
After complet ion of the entry process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by [CONTACT_1748] (or designees) and will be answered by [CONTACT_941] s ite. 
Corrections are recorded i n an audit trail that captures the old informat ion, the new informat ion, 
ident ificat ion of the person making the correction, the date the correction was made, and the reason 
for change. Reasons for significant corrections sh ould addi tionally be included. 
The principal Invest igator must review the CRFs for completeness and accuracy and must sign and 
date the appropriate CRFs as indicated. Furthermore, the I nvestigator must retain full 
responsibilit y for the accuracy  and authe nticity of all data entered on the CRFs .
After the lock of the clinical study database, any change of, modificat ion of, or addit ion to the data 
on the CRFs should be made by  [CONTACT_607343] h use of change and modificat ion records of 
the CRFs. The prin cipal  Invest igator must review the data change for completeness and accuracy, 
and must sign and date . 
CRFs will be reviewed for completeness and acceptabilit y at the study  site during peri odic visi ts 
by [CONTACT_39810]. The Sponsor or i ts desi gnee will  be permitted to review the participant’s 
medical and hospi[INVESTIGATOR_1680]. The completed CRFs are the sole property  of the Sponsor and should not be made available in any  form to thi rd 
parties, except for auth orized representatives of appropriate governmental health or regulatory
authorities, wi thout wri tten permissio n of the Sponsor.
15.[ADDRESS_804724] Retention
The Investi gator agrees to keep the records stipulated in Section 15.1 and those documents that 
include (but are not limited to) the study -specific documents, the ident ificat ion log of all
participat ing participants, medical records, temporary media such as the rmal sensi tive paper, 
source worksheets, all original signed and dated ICFs, participant authorizat ion forms regarding 
the use of personal healt h information (if separate fro m the ICFs), el ectroni c copy  of CRFs, 
including the audit trail, and detailed reco rds of drug disposit ion to enable evaluat ions or audits 
from regulatory  authori ties, the Sponsor or i ts designees. Any  source documentati on printed on Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe full details of procedures for data handling will be documented in the Data Management Plan. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe full details of procedures for data handling will be documented in the Data Management Plan. 
. Drugs will be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. Drugs will be 
or each participant who signs an informed consent.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useor each participant who signs an informed consent.
ive sites with access to CRFs. The Sponsor will 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useive sites with access to CRFs. The Sponsor will 
to train appropriate site staff in the use of the CRF. These forms are used to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useto train appropriate site staff in the use of the CRF. These forms are used to 
 to the Sponsor and regulatory
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use to the Sponsor and regulatory
ties. CRFs must be completed in English. Data are transcribed direct
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useties. CRFs must be completed in English. Data are transcribed direct
n of the entry process, computer logic checks will be run to identify items, such as 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen of the entry process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by [CONTACT_607344]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinconsistent dates, missing data, and questionable values. Queries may be issued by [CONTACT_11750] 
n an audit trail that captures the old informat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen an audit trail that captures the old informat
the date 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe date 
gnificant corrections sh
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usegnificant corrections sh oul
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useould addi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Used addi
review the CRFs for completeness and accuracy and must sign and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usereview the CRFs for completeness and accuracy and must sign and 
date the appropriate CRFs as indicated. Furthermore, the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedate the appropriate CRFs as indicated. Furthermore, the 
 and authe
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use and authe nt
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenticit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useicit
tudy
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetudy d
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use database, any change of, modificat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useatabase, any change of, modificat
on the CRFs should be made by
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon the CRFs should be made by  [CONTACT_177972]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use the on the CRFs should be made by  [CONTACT_607345]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon the CRFs should be made by  [CONTACT_607346] I
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInvest
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenvest
nvest
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenvest igator must review the data change for completeness and accuracy, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useigator must review the data change for completeness and accuracy, 
CRFs will be reviewed for completeness and acceptabilit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCRFs will be reviewed for completeness and acceptabilit
tors. The Sponsor or i
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetors. The Sponsor or i
medical and hospi[INVESTIGATOR_1680]. The completed 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemedical and hospi[INVESTIGATOR_1680]. The completed 
CRFs are the sole property
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCRFs are the sole property
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usees, except for auth
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usees, except for auth
authorities, wi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useauthorities, wi
15.2
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use15.2
The 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe 
include (but are not limited to) the study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinclude (but are not limited to) the study
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 62of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIALdegradable thermal sensitive paper should be photocopi[INVESTIGATOR_607295]’s chart to ensure long -term legibili ty. Furtherm ore, ICH E6 Secti on 4.9.[ADDRESS_804725] igator to retain essent ial documents specified in ICH E6 (Section 8) unt il at least [ADDRESS_804726] igator and Sponsor.
Refer to the Clinical Study  Site Agreement for the Sponsor’s requirements on record retention. 
The Investi gator and the head of the institution should contact [CONTACT_47405].
16.[ADDRESS_804727] igator’s Brochur e. Edit ion7, 
31 January 2022; plus Addendum 1, 03 February  2022, f or Edi tion 7, 31 January  2022 .
2.Rodi ghiero V. Effects of liver disease on pharmacokinet ics. An update. Clin Pharmacokinet 
1999;37(5):399-431.
3.Verbeeck RK. Pharmacokinet ics and dosage adjustm ent in pat ients with hepatic dy sfunct ion. 
European Journal of Clinical Pharmacology  2008;64(12):1147 -61.
4. U.S. Department of Health and Human Services, Food and Drug Administration, Center for 
Drug Eval uation and Research (CDER), Center for Bio logics Evalua tion and Research 
(CBER). Guidance for Industry. Pharmacokinet ics in Pat ients with Impaired Hepatic Funct ion 
—Study  Design, Data Analysis, and Impact on Dosing and Labeling. May  2003.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useil at least 2 years 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useil at least 2 years 
n being investigated 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen being investigated 
inued and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinued and 
4.9.5 states that the study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use4.9.5 states that the study  records 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use records 4.9.5 states that the study  records 4.9.5 states that the study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use4.9.5 states that the study  records 4.9.5 states that the study
il an amount of time specified by [CONTACT_63227] a 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useil an amount of time specified by [CONTACT_63227] a 
and Sponsor.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand Sponsor.
on record retention. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon record retention. 
r and the head of the institution should contact [CONTACT_607347]: For Non-Commercial Use Only and Subject to the Applicable Terms of User and the head of the institution should contact [CONTACT_607348]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useobal Invest igator’s Brochur
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useigator’s Brochur
 2022, f
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use 2022, f or Edi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useor Edi  2022, f or Edi  2022, f
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use 2022, f or Edi  2022, f
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useghiero V. Effects of liver disease on pharmacokinet
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useghiero V. Effects of liver disease on pharmacokinet ics. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useics. 
s and dosage adjustm
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uses and dosage adjustm
European Journal of Clinical Pharmacology
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEuropean Journal of Clinical Pharmacology  2008;64(12):1147
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use 2008;64(12):1147 European Journal of Clinical Pharmacology  2008;64(12):1147 European Journal of Clinical Pharmacology
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEuropean Journal of Clinical Pharmacology  2008;64(12):1147 European Journal of Clinical Pharmacology
4. U.S. Department of Health and Human Services, Food and Drug Administration, Center for 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use4. U.S. Department of Health and Human Services, Food and Drug Administration, Center for 
n and Research (CDER), Center for Bio
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen and Research (CDER), Center for Bio
(CBER). Guidance for Industry. Pharmacokinet
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(CBER). Guidance for Industry. Pharmacokinet
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use Design, Data Analysis, and Impact on Dosing and Labeling. May
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use Design, Data Analysis, and Impact on Dosing and Labeling. May
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804728] igators by [CONTACT_45348] “Statement of Invest igator” (Form FDA 1572), which must be completed and 
signed before the investigator may participate in this study.
The invest igator agrees to assume the fo llowing responsibilit ies by [CONTACT_2960] a Form FDA 1572:
1.Conduct the study  in accordance wit h the protocol.
2. Personally conduct or supervise the staff that will assist in the protocol.
3.If the invest igator/institution retains the services of any individual or party to perform 
trial-related duti es and funct ions, the invest igator/inst itution shoul d ensure that this individual
or party  is qualified to perform those trial- related duti es and funct ions and should implement 
procedures to ensure the integrit y of the tri al-related duti es and funct ions performed and any 
data generated.
4.Ensure that study  related procedures, including s tudy specific (nonrouti ne/nonstandard panel) 
screening assessments are NOT performed on potent ial participants, pri or to the recei pt of
written approval  from relevant governing bodies/authorities.
5.Ensure that all co lleagues and emplo yees assist ing in the c onduct of the study  are informed of 
these obligat ions.
6.Secure prior approval o f the study and any changes by [CONTACT_4215]/IEC that conform to 
21 CFR Part 56, ICH, and local regulatory  requi rements.
7.Ensure that the IRB/IEC will be responsible for initial review, continuing review, and approva l 
of the protocol. Promptly report to the IRB/IEC all changes in research act ivity and all 
anticipated risks to participants. Make at least yearly reports on the progress of the study to the 
IRB/IEC, and issue a final report wi thin 3 months of study  com pletion.
8. Ensure that requirements for informed consent, as outlined in 21 CFR Part 50, ICH and local 
regul ations, are m et.
9. Obtain valid informed consent from each particiant who participates in the study , and 
docu ment the date of consent in the participant’s medical chart. Valid informed consent is the 
most current versi on approved by [CONTACT_1201]/IEC. Each ICF should contain a participant 
authori zation sect ion that describes the uses and disclosures of a participant’s personal 
inform ation (including personal health informat ion) that will take place in connect ion wit h the 
study . If an ICF does not i nclude such a participant authorizat ion, then the invest igator must 
obtain a separate participant authorization form from ea ch parti cipant or the participant’s 
legally acceptable representative.Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use the Sponsor are subject to ICH GCP and all the applicable 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use the Sponsor are subject to ICH GCP and all the applicable 
FDA 1572), which must be completed and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFDA 1572), which must be completed and 
ies by [CONTACT_2960] a Form FDA 1572:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useies by [CONTACT_2960] a Form FDA 1572:
conduct or supervise the staff that will assist in the protocol.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useconduct or supervise the staff that will assist in the protocol.
igator/institution retains the services of any individual or party to perform 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useigator/institution retains the services of any individual or party to perform 
on shoul
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon shoul d ensure that this individual
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Used ensure that this individual
es and funct
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usees and funct
related duti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userelated duti es and funct
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usees and funct
 related procedures, including s
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use related procedures, including s tudy
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetudy specific (nonrouti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use specific (nonroutitudy specific (nonroutitudy
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetudy specific (nonroutitudy
screening assessments are NOT performed on potent
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usescreening assessments are NOT performed on potent
evant governing bodies/authorities.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useevant governing bodies/authorities.
yees assist
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useyees assist
he study and any changes by [CONTACT_4215]/IEC 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehe study and any changes by [CONTACT_4215]/IEC 
21 CFR Part 56, ICH, and local regulatory
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use21 CFR Part 56, ICH, and local regulatory
e IRB/IEC will be responsible for 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee IRB/IEC will be responsible for 
 the protocol. Promptly report to the IRB/IEC all changes in research act
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use the protocol. Promptly report to the IRB/IEC all changes in research act
ipated risks to participants. Make at least yearly reports on the progress of the study to the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useipated risks to participants. Make at least yearly reports on the progress of the study to the 
IRB/IEC, and issue 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIRB/IEC, and issue a final report wi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usea final report wi
Ensure that requirements for informed consent, as outlined in 21 CFR Part 50, ICH and local 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEnsure that requirements for informed consent, as outlined in 21 CFR Part 50, ICH and local 
io
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useions, are m
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usens, are m
Obtain valid informed consent from each particiant who participates in the study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseObtain valid informed consent from each particiant who participates in the study
docu
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedocu me
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usement
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usent
mo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemost current versi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usest current versi
authori
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useauthori
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804729] and receive written approval fro m the Sponsor before dispos ing o f any such 
docum ents.
11. Allow possible inspection and copying by [CONTACT_4216]- specified essent ial 
docum ents.
12.Maintain current records of the receipt, administratio n, and disposit ion of Sponsor- supplied 
drugs, and return all unused Spo nsor-supplied drugs to the Sponsor. 
13. Report adverse reactions to the Sponsor promptly. In the event of an SAE, notify the Sponsor 
within 24 hours.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinued or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinued or 
igator should 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useigator should 
specified essent
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usespecified essent
n of Sponsor
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen of Sponsor
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use13. Report adverse reactions to the Sponsor promptly. In the event of an SAE, notify the Sponsor 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use13. Report adverse reactions to the Sponsor promptly. In the event of an SAE, notify the Sponsor 
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 65of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIALAppendix B Elements of the Participant Informed Consent
In seeking informed c onsent, the fo llowing information shall be provided to each participant:
1.A statement that the study  involves research.
2.An explanat ion of the purposes of the research.
3. The expected duration of the participant’s participation.
4.A descript ion of the procedures to be fo llowed, including invasive procedures.
5.The i dentificat ion of any  procedures that are experimental.
6.The est imated number of participants invo lved in the study .
7.A descript ion of the participant’s responsibilit ies.
8.A descript ion of the conduct of the study .
9.A statement describing the treatment(s) and the probabilit y for random  assignment to each 
treatm ent.
10.A descript ion of the possible side effects of the treatment that the participant may receive.
11.A descript ion of any  reasonably  foreseeable ri sks or disco mforts to the participant and, when 
applicable, to an embry o, fetus, or nursing infant.
12.A descript ion of any  benefi ts to the partici pant or to others that reasonably may  be expected 
from the research. When there is no intended clinical benefit to the participant, the participant 
shoul d be made aware of this.
13.Disclosures o f appropriate alternative procedures or courses of treatment, if any, that might be 
advantageous to the participant and their important potential risks and benefit s.
14.A statement descri bing the extent to which confident iality of records i dentifying the 
participant will be maintained, and a note of the possibilit y that regulatory agencies, auditor(s), 
IRB/IEC, and the monitor may inspect the records. By [CONTACT_2960] a written ICF, the particip ant or 
the participant’s legally acceptable representative is authorizing such access.
15.For research involving more than minimal risk, an explanat ion as to whether any co mpensatio n 
and an explanat ion as to whether any  medical treatments are available if inj ury occurs and, if 
so, what they  consist of or where further informat ion may be obtained.
16.The ant icipated prorated payment(s), if any, to the participant for participat ing in the study.
17.The ant icipated expenses, if any , to the participant for parti cipating in the study .
18.An explanat ion of whom to contact [CONTACT_39831] 
(invest igator), participant’s rights, and IRB/IEC and whom to contact [CONTACT_44751] a 
research -related inj ury to the parti cipant.Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewed, including invasive procedures.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewed, including invasive procedures.
A statement describing the treatment(s) and the probabilit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseA statement describing the treatment(s) and the probabilit y 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usey fo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefor random
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of User random
n of the possible side effects of the treatment that the participant may receive.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen of the possible side effects of the treatment that the participant may receive.
oreseeable ri
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useoreseeable ri sks or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesks or 
etus, or nursing infant.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useetus, or nursing infant.
ts to the partici
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usets to the partici pant or to others that reasonably may
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepant or to others that reasonably may ts to the partici pant or to others that reasonably may ts to the partici
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usets to the partici pant or to others that reasonably may ts to the partici
e research. When there is no intended clinical benefit to the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee research. When there is no intended clinical benefit to the 
f appropriate alternat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usef appropriate alternat ive procedures or courses of treatment, if any, that might be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useive procedures or courses of treatment, if any, that might be 
advantageous to the participant and their important potential risks and benefit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useadvantageous to the participant and their important potential risks and benefit
bing the extent to which confident
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebing the extent to which confident
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecipant will be maintained, and a note 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecipant will be maintained, and a note 
IRB/IEC, and the monitor may inspect the records. By [CONTACT_2960] a written ICF, the particip
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIRB/IEC, and the monitor may inspect the records. By [CONTACT_2960] a written ICF, the particip
e participant’s legally acceptable representative is authorizing such access.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee participant’s legally acceptable representative is authorizing such access.
research invo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useresearch invo
and an explanat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand an explanat
so, what they
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useso, what they
16.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use16.The ant
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe ant
17.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use17.The ant
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe ant
18.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use18.
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 66of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIAL19.A statement that part icipation is vo luntary, that refusal to participate will invo lve no penalt y or 
loss of benefit s to whi ch the parti cipant otherwi se is ent itled, and that the participant or the 
participant’s l egally acceptable representative may discont inue participat ion atany t ime 
without penal ty or loss of benefit s to whi ch the parti cipant is otherwise ent itled.
20.The consequences o f a participant’s decisio n to withdraw fro m the research and procedures for 
orderly terminat ion of part icipation by [CONTACT_2299].
21.A statement that the participant or the participant’s legally  acceptable representative will be 
inform ed in a t imely manner if informat ion beco mes available that may be relevant to the 
participant’s willingness to continue participation in the study.
22.The foreseeable circumstances or reasons under which the participant’s participat ion in the 
study  may be terminated.
23.A written partici pant authori zation (either contained within the ICF or provided as a separate 
docum ent) describing to the participant the contemplated and permissible uses and disclosures 
of the participant’s personal informat ion (including personal health informat ion) for purposes 
of conducting the study . The parti cipant authori zation must contain the following statements 
regarding the uses and disclo sures of the parti cipant’s personal information:
a)that personal information (including personal healt h informat ion) may be processed by  [CONTACT_45351] y reporti ng 
purposes, including, without lim itation, to the fo llowing: (1) [COMPANY_005], its affiliates, and 
licensing partners; (2) business partners assist ing [COMPANY_005], its affiliates, and licensing 
partners; (3) regulatory  agencies and other health authorities; and (4) IRBs/IECs;
b)it is possible that pers onal informat ion (including personal healt h informat ion) may be 
processed and transferred to countries that do not have data protection laws that offer 
participants the sam e level  of protecti on as the data protection laws within this country; 
however, [COMPANY_005] will make every  effort to keep y our personal  information confident ial, 
and y our name [CONTACT_39846] [CONTACT_2371];
c)that personal information (including personal healt h informat ion) may be added to 
[COMPANY_005]’s research dat abases for purposes of developi[INVESTIGATOR_007] a better understanding of the 
safet y and effect iveness o f the study  medicat ion(s), studying other therapi[INVESTIGATOR_39759], 
developi[INVESTIGATOR_007] a better understanding of disease, and improving the efficiency of future 
clinical studie s;
d)that participants agree not to restrict the use and disclosure of their personal information 
(including personal healt h informat ion) upon withdrawal fro m the study  to the extent that 
the restricted use or disclosure of such informat ion may impact the sc ientific integrity of
the research; and
e)that the participant’s ident ity will remain confidential in the event that study  resul ts are 
published.
24. Female participants of childbearing potential (eg, nonsterilized, premenopausal female 
participants) who are sex ually act ive must use hi ghly effect ive/effect ive contraception (as Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehe research and procedures for 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehe research and procedures for 
 acceptable representative will be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use acceptable representative will be 
mes available that may be relevant to the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemes available that may be relevant to the 
rcumstances or reasons under which the participant’s participat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usercumstances or reasons under which the participant’s participat
er contained within the ICF or provided as a separate 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useer contained within the ICF or provided as a separate 
ent) describing to the participant the contemplated and
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useent) describing to the participant the contemplated and permissible uses and disclosures 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepermissible uses and disclosures 
n (including personal health informat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen (including personal health informat
on
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon m
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use mon mon
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon mon ust contain the following statements 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useust contain the following statements  must contain the following statements  m
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use must contain the following statements  m
cipant’s personal information:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecipant’s personal information:
at personal information (including personal healt
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useat personal information (including personal healt
transferred to other parties in other countries for clinical research and safet
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetransferred to other parties in other countries for clinical research and safet
io
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useion, to the fo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen, to the fo
licensing partners; (2) business partners assist
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselicensing partners; (2) business partners assist
 agencies and other healt
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use agencies and other healt
 i
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use informat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenformat
processed and transferred to countries that do not have data protection laws that offer 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useprocessed and transferred to countries that do not have data protection laws that offer 
e level
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee level  of
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use of e level  of e level
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee level  of e level
da will make every
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useda will make every
our name [CONTACT_607356]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useour name [CONTACT_607357] (including personal healt
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useat personal information (including personal healt
[COMPANY_005]’s research dat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use[COMPANY_005]’s research dat
y 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usey and effect
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand effect
developi[INVESTIGATOR_007] a better understanding of disease, and improving the efficiency of future 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedevelopi[INVESTIGATOR_007] a better understanding of disease, and improving the efficiency of future 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useclinical studie
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useclinical studie
d)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Used)th
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethat participants agree not to restrict the use and disclosure of their personal information 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useat participants agree not to restrict the use and disclosure of their personal information 
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 67of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIALdefined in the informed consent) from signing the informed consent, throughout the duration 
of the study, and [ADDRESS_804730] use effective contraception (as defined in the informed consent) from 
signing the informed consent, throughout the duration of the study and for 90 days after dosing 
of study  drug. 
26. A statem ent that clinical trial informat ion fro m this trial will be publicly disclo sed in a publicly 
accessible website, such as ClinicalTrials.gov.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useust use effective contraception (as defined in the informed consent) from 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useust use effective contraception (as defined in the informed consent) from 
e duration of the study and for 90 days after dosing 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee duration of the study and for 90 days after dosing 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesed in a publicly 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesed in a publicly 
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804731] igator’s personal 
inform ation may be transferred to other parties located in countries through out the worl d (eg, the 
[LOCATION_008], [LOCATION_002], and Japan), including the following:
[COMPANY_005], its affiliates, and licensing partners.
Business partners assisting [COMPANY_005], its affiliates, and licensing partners.
Regulatory  agencies and other health auth orities.
IRBs and IECs.
Invest igator’s personal informat ion may be retained, processed, and transferred by  [CONTACT_39833]:
Assessment of the suitability of invest igator for the study  and/or othe r clinical studies.
Management, monitoring, inspect ion, and audit of the study .
Analysis, review, and verificat ion of the study  results.
Safety reporti ng and pharmacovigilance relat ing to the study.
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regulatory  agencies rel ating to the study.
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regulatory  agencies relat ing to other medications used in other clinical studies that m ay contain 
the sam e chemical com pound present in the study  medicat ion.
Inspect ions and invest igations by [CONTACT_4218].
Self-inspect ion and internal audit within [COMPANY_005], its affiliates, and licensing partners.
Archiving and a udit of study  records.
Posting investigator site contact [CONTACT_4203], study details and results on publicly accessible 
clinical trial registries, databases, and websites.
Invest igator’s personal informat ion may be transferred to other countries that do not have data 
protecti on laws that offer the same level of protection as data protection laws in invest igator’s own 
country .
Invest igator acknowledges and consents to the use of his or her personal information by [CONTACT_607349].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Used (eg, the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Used (eg, the 
be retained, processed, and transferred by
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebe retained, processed, and transferred by
[CONTACT_607350]:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewing:
igator for the study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useigator for the study  and/or othe
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use and/or othe igator for the study  and/or othe igator for the study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useigator for the study  and/or othe igator for the study
n, and audit of the study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen, and audit of the study
 results.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use results.
ng and pharmacovigilance relat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useng and pharmacovigilance relat ing to the study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useing to the study
n of regulatory
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen of regulatory  f
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use f n of regulatory  f n of regulatory
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen of regulatory  f n of regulatory ilings, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useilings,  filings,  f
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use filings,  f
ing to the study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useing to the study .
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.
n of regulatory
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen of regulatory
ing to other medications used in other clinical studies that m
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useing to other medications used in other clinical studies that m
pound present in the study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepound present in the study
ns and invest
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usens and invest igat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useigatio
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useio
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usens by [CONTACT_607351]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usens by [CONTACT_30962]
n and internal audit within [COMPANY_005], its affiliates, and licensing partners.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen and internal audit within [COMPANY_005], its affiliates, and licensing partners.
Archiving and a
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseArchiving and a udi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useudi Archiving and a udi Archiving and a
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseArchiving and a udi Archiving and a t of
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uset ofudit ofudi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useudit ofudi
ting investigator site contact [CONTACT_607352]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useting investigator site contact [CONTACT_607353], databases, and websites.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useclinical trial registries, databases, and websites.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInvest
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInvest
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useigator’s personal informat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useigator’s personal informat
protecti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useprotecti on laws that offer the same level of protection as data protection laws in invest
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon laws that offer the same level of protection as data protection laws in invest
country
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecountry
Invest
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInvest
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 69of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIALAppendix D Pregnancy and Contraception
Contraception and Pregnancy Avoidance Procedure
Male Participants
From  signing of informed consent, throughout the duration of the study, and for 90 days after 
dosing of stu dydrug, nonsterilized* male participants who are sexually act ive wit h a female 
partner of childbearing potential** must agree to use a condom with spermicide . In addi tion, they 
must be advised not to donate sperm during this period.Female Participants and Their Male Partners
From  signing of informed consent, throughout the duration of the study, and for 30 days after 
dosing of study drug, female participants of childbearing potential* who are sexually act ive with a 
nonsterilized male partner** must use a highly effective/effect ive method of contraception (fro m 
the list below). 
In addit ion they  must be advised not to donate ova during this period.
Definitions and Procedures for Contraception and Pregnancy AvoidanceThe follow ing definitions apply for contraception and pregnancy avoidance procedures.
* No restrictions are required for a vasectomized male provided his vasectomy has been performed 
4months or m ore pri or to dosing. A male who has been vasectomized less than [ADDRESS_804732] ions as a non-vasectomized male).
** A woman is considered a woman o f childbearing potential (WOCBP), ie, fertile, fo llowing 
menarche and unt il beco ming post -menopausal unless permanent ly sterile. Permanent sterilizat ion 
methods include hysterectomy, and bilateral oophorectomy . A postm enopausal  state i s defined as 
no menses for 12 months without an alternat ive medical cause. A high FSH level in the 
postm enopausal range (FSH >40 IU/L) may be used to confirm a post-menopausal state in 
younger wom en (eg, those <45 y ear ol d) or wom en who are not using hormonal contraception or 
horm onal replacement therapy . However, in the absence of [ADDRESS_804733] ive methods of contraception are defined as “those, alone or in combinat ion, that 
resul t in a l ow failure rate (i e, less than 1% failure rate per y ear when used consistent ly and 
corre ctly). In this study , where m edicat ions and devices containing hormones are included, 
acceptable methods of contraception are: 
Non-Hormonal Methods: 
–IUD
–Bilateral tubal occlusio n;
–bilateral  salpi[INVESTIGATOR_1656];Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, and for 90 days after 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, and for 90 days after 
h a female 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useh a female 
. In addi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. In addi ti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useti . In addi ti . In addi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. In addi ti . In addi on, they 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon, they 
, and for 30 days after 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, and for 30 days after 
, female participants of childbearing potential* who are sexually act
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, female participants of childbearing potential* who are sexually act
method of contraception (fro
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemethod of contraception (fro
ust be advised not to donate ova during this period.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useust be advised not to donate ova during this period.
Definitions and Procedures for Contraception and Pregnancy Avoidance
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDefinitions and Procedures for Contraception and Pregnancy Avoidance
definitions apply for contraception and pregnancy avoidance procedures.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedefinitions apply for contraception and pregnancy avoidance procedures.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usens are required for a vasectomized male provided his vasectomy has been performed 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usens are required for a vasectomized male provided his vasectomy has been performed 
or to dosing. A male who has been vasectomized less than 4
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useor to dosing. A male who has been vasectomized less than [ADDRESS_804734]
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use dosing must follow the same restrict io
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useions as a non
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usens as a non
** A woman is considered a woman o
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use** A woman is considered a woman o f 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usef childbearing potential (WOCBP), ie, fertile, fo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usechildbearing potential (WOCBP), ie, fertile, fo
ming post
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useming post -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-me
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemenopausal unless permanent
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenopausal unless permanent
methods include hysterectomy, and bilateral oophorectomy
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemethods include hysterectomy, and bilateral oophorectomy
no menses for 12 months without an alternat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useno menses for 12 months without an alternat
enopausal range (FSH >40 IU/L) may be used to confirm a
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useenopausal range (FSH >40 IU/L) may be used to confirm a
en (eg, those <45 y
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useen (eg, those <45 y
 replacement therapy
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use replacement therapy
easurement is insufficient.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useeasurement is insufficient.
ing 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useing procedures apply for contraception and pregnancy avoidance.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useprocedures apply for contraception and pregnancy avoidance.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useghly
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useghly effect
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use effectghly effectghly
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useghly effectghly
resul
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useresul
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uset in a l
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uset in a l resul t in a l resul
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useresul t in a l resul
corre
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecorre ctly
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usectly
acceptable methods of contraception are: 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useacceptable methods of contraception are: 
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 70of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIAL–hysterectomy;
–bilateral  oophorectomy;
– Vasectomised partner (provided that partner is the sole sexual partner of the study
participant and that the vasectomised partner has received medical assessment of the 
surgi cal success).
Horm onal Methods: 
Combined (estrogen and progestogen) hormonal contracepti on associated with inhibit ion of 
ovulation initiated at least [ADDRESS_804735] dose of study drug OR combined wit h a 
barrier m ethod (male condom , female condo m or diaphragm) if for shorter duration unt il she 
has been on contraceptive for 3 months;
oral.
Intravaginal (eg, ring).
transderm al.
Progestogen -only hormonal contracepti on associ ated wi th inhibit ion of ovulat ion initiated at least
6 mo nths pr ior to the dose of study drug OR combined with a barrier method (male condo m with or 
without spermicide) if shorter till she has been on contraceptive for 6 months;
oral.
Injectable.
Implantable.
2. Effect ive methods of contraception (there may be a higher than 1% failure rate). In this 
study , where m edicat ions and devices containing hormones are i ncluded, acceptable 
methods of contraception are:
–Double- barrier method (contraceptive sponge, diaphragm or cervical cap wit h spermicidal 
jellies or creams PLUS male condo m)
3. Unacceptable methods of contraception are:
Periodic abst inence (eg, calendar, o vulat ion, symptothermal, post- ovulation methods).
Spermicides only .
Withdrawal.
No m ethod at all.
Use of female and male condoms together.
Cap/di aphragm/sponge wi thout spermicide and wit hout condom .
Sexual abst inence is NOT an acceptable method of contraception.Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecipant and that the vasectomised partner has received medical assessment of the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecipant and that the vasectomised partner has received medical assessment of the 
on associated with inhibit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon associated with inhibit
iated at least [ADDRESS_804736] dose of study drug OR combined wit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useiated at least [ADDRESS_804737] dose of study drug OR combined wit
or diaphragm) if for shorter duration unt
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useor diaphragm) if for shorter duration unt
ated wi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useated wi th
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useth ated wi th ated wi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useated wi th ated wi  i
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use ith ith
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useth ith
e dose of study drug OR combined with a barrier method 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee dose of study drug OR combined with a barrier method 
t spermicide) if shorter till she has been on contraceptive for 6 months;
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uset spermicide) if shorter till she has been on contraceptive for 6 months;
methods of contraception (there may be a higher than 1% failure rate). In this 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemethods of contraception (there may be a higher than 1% failure rate). In this 
edicat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useedicat io
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useions and devices containing hormones are i
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usens and devices containing hormones are i
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemethods of contraception are:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemethods of contraception are:
barrier method (contraceptive sponge, diaphragm or cervical cap wit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebarrier method (contraceptive sponge, diaphragm or cervical cap wit
jellies or creams PLUS male condo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usejellies or creams PLUS male condo
Unacceptable methods of contraception are:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseUnacceptable methods of contraception are:

Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePeri
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePeri

Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804738] ive/effect ive methods of 
contraception as part of the participant informed consent process and will be asked to sign a 
consent form stating that they  understand the requirements fo r avoidance of pregnancy, 
donati on of  ova, and sperm donat ion during the course of the study .
5.During the course of the study , regular human chorio nic gonadotropin (hCG) pregnancy tests 
will be performed only  for all  females and all participants (male and female) will receive 
continued guidance with respect to the avoidance of pregnancy, ova donation, and sperm 
donati on as part of the study  procedures. Such guidance should include a reminder of the 
following:
a)contraceptive requirements of the study
b)reasons for use of barrier methods (ie, condom) in males with pregnant partners
c)assessment of participant compliance through questions such as
i.Have you used the contraception consistent ly and correctly since the last visit ?
ii.Have y ou forgotten to use contraception since the last visit ?
iii.Are y our menses l ate (even in wom en wi th irregular or infrequent menstrual cy cles a 
pregnancy test must be performed if the answer is “yes”)
iv.Is there a chance you could be pregnant?
6.In addit ion to a negative serum hCG pregnancy test at Screening, female participants of 
childbearing potential must also have confirmed menses in the mo nth before dosing (no 
delayed menses; with the except ion of female participants using a protocol acceptable 
contraception method that has a known side effect of delayed or irregular menses). In addit ion,
participants must also have a negative serum hCG pregnancy test prior to receiving the dose of 
investigat ional drug as close as possible and prior to the dose of invest igational drug, 
preferably on the same day.
General Guidance With Respect to the Avoidance of Pregnancy
Such guidance should include a reminder of the fo llowing:
contraceptive requirements of the study.
reasons for use of barrier methods (ie, condom) in males with pregnant partners.
assessment of parti cipant com pliance through questi ons such as:
– Have you used the contraception consistent ly and correctly since the last visit ?
–H ave y ou forgotten to use contraception since the last visit ? 
–Are y our menses l ate (even in wom en wi th irregular or infr equent m enstrual  cycles a 
pregnancy test must be performed if the answer is “yes”)
– Is there a chance you could be pregnant?Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenic gonadotropin (hCG) pregnancy tests 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenic gonadotropin (hCG) pregnancy tests 
male) will receive 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemale) will receive 
idance of pregnancy, ova donation, and sperm 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useidance of pregnancy, ova donation, and sperm 
 procedures. Such guidance should include a reminder of the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use procedures. Such guidance should include a reminder of the 
r use of barrier methods (ie, condom) in males with pregnant partners
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of User use of barrier methods (ie, condom) in males with pregnant partners
assessment of participant compliance through questions such as
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useassessment of participant compliance through questions such as
ly and correctly since the last visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usely and correctly since the last visit
since the last visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesince the last visit
th
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useth i
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use ith ith
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useth ithrregular or infrequent menstrual cy
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userregular or infrequent menstrual cy irregular or infrequent menstrual cy i
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use irregular or infrequent menstrual cy i
pregnancy test must be performed if the answer is “yes”)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepregnancy test must be performed if the answer is “yes”)
Is there a chance you could be pregnant
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIs there a chance you could be pregnant ?
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use?
n to a negative serum hCG pregnancy test
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen to a negative serum hCG pregnancy test
childbearing potential must also have confirmed menses in the mo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usechildbearing potential must also have confirmed menses in the mo
ayed menses; with the except
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useayed menses; with the except io
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useion of female part
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen of female part
contraception method that has a known side eff
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecontraception method that has a known side eff
cipants must also have a negative serum hCG pregnancy test prior to receiving the dose of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecipants must also have a negative serum hCG pregnancy test prior to receiving the dose of 
nal drug as close as possible and prior to the dose of invest
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenal drug as close as possible and prior to the dose of invest
preferably on the same
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepreferably on the same day
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useday
General Guidance With Respect to the Avoidance of Pregnancy
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseGeneral Guidance With Respect to the Avoidance of Pregnancy
Such guidance should include a reminder of the fo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSuch guidance should include a reminder of the fo
contraceptive requirements of the study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecontraceptive requirements of the study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usereasons for use of barrier methods (ie, condom) in males with pregnant partners.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usereasons for use of barrier methods (ie, condom) in males with pregnant partners.
assessment
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useassessment
–
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use–
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 72of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIALPregnancy
If any participant is found to be pregnant during the study  she shoul d be wi thdrawn and any 
sponsor- supplied drug should b e immediately  discontinued. In addi tion, any pregnancies in the 
partner of a male participant during the study  or for 90 day safter dosing, should also be recorded 
following authori zation from the participant’s partner. 
If the female participant and/or female partner of a male participant agrees to the primary care 
physician being informed, the investigator should notify the primary care physician that the female 
participant/female partner of the participant was participating in a clinical study  at the t ime she 
became pregnant and provide details of the study  drug the partici pant received (blinded or 
unblinded, as applicable).
All pregnancies, including female partners of male participants, in participants on active study
drug (including comparator, if ap plicable) will be followed up to final outcome, using the 
pregnancy form. Pregnancies will remain blinded to the study  team . The outcom e, including any
prem ature terminat ion, must be reported to the sponsor. An evaluat ion after the birth of the child 
will also be conducted.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon, any pregnancies in the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon, any pregnancies in the 
d also be recorded 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Used also be recorded 
male partner of a male participant agrees to the primary care 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemale partner of a male participant agrees to the primary care 
physician being informed, the investigator should notify the primary care physician that 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usephysician being informed, the investigator should notify the primary care physician that th
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe female 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee female 
cipant/female partner of the participant was participating in a clinical study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecipant/female partner of the participant was participating in a clinical study  at the t
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use at the t cipant/female partner of the participant was participating in a clinical study  at the t cipant/female partner of the participant was participating in a clinical study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecipant/female partner of the participant was participating in a clinical study  at the t cipant/female partner of the participant was participating in a clinical study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepant received (blinded or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepant received (blinded or 
All pregnancies, including female partners of male participants, in participants on active study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAll pregnancies, including female partners of male participants, in participants on active study
plicable) will be followed up to final outcome, using the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useplicable) will be followed up to final outcome, using the 
 team
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use team
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. The outcom
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. The outcom
n, must be reported to the sponsor. An evaluat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen, must be reported to the sponsor. An evaluat io
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useio
Soticlestat (TAK -935)
Study ID TAK -935-[ADDRESS_804739] of mild HI on the PK of soticlestat.
A summary of changes incorporated into Amendment 1 is provided in the table below. 
Summary of Changes(s) Since Last Version of Approved Protocol
Description of Change Section(s) Affected by [CONTACT_607354] 2 with
participants wi th mild HI. Title Page
Secti on 1.0 (Study  Summary )
Secti on 3.0 (Schedul e of Study  Procedures)
Secti on 4.2 (Rati onale for the Proposed Study )
Secti on 5.2.1 (Study  Primary  Objective)
Secti on 5.2.2 (Study  Secondary  Objective)
Secti on 5.2.3 (Study  Expl oratory  Object ive)
Secti on 6.1 (Study  Design)
Secti on 6.4.1 (Rati onal of Study  Desi gn)
Secti on 6.4.2 (Rati onale for Dose)
Secti on 6.5 (Study  Design/Dosing/Procedures 
Modificat ions Permitted Wit hin Protocol Parameters)
Secti on 7.1.1 (Incl usion for Parti cipants wi th Hepati c 
Impairment)
Secti on 7.2.1 (Excl usion for Participants with Hepatic 
Impairment)
Secti on 11.1.3 (PK Analysis)
Secti on 11.3 (Determinat ion of Sample Size)
Parti cipants wi th mild HI enrolled in 
Arm2 of the study  will receive a single 
300mg dose of soticlestat . The protocol is 
updated to the remove the allowance to 
modify the dose of soticlestat for Secti on 1.0 (Study  Summary )
Secti on 6.1 (Study  Design)
Secti on 6.5 (Study  Design/Dosing/Procedures 
Modificat ions Permitted Wit hin Protocol Parameters)Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use analysis in participants with moderate HI
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use analysis in participants with moderate HI
The interim analysis indicated higher 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe interim analysis indicated higher 
imulations.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useimulations. The 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe 
clestat will 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useclestat will 
ended to evaluate 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useended to evaluate 
 changes incorporated into Amendment 1 is provided in the table below. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use changes incorporated into Amendment 1 is provided in the table below. 
Summary of Changes(s) Since Last Version of Approved Protocol
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSummary of Changes(s) Since Last Version of Approved Protocol
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSection(s) Affected by [CONTACT_607355]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSection(s) Affected by [CONTACT_607355]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1.0 (Study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1.0 (Study  Summary
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use Summary 1.0 (Study  Summary 1.0 (Study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1.0 (Study  Summary 1.0 (Study
on 3.0 (Schedul
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon 3.0 (Schedul
on 4.2 (Rati
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon 4.2 (Rati
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSecti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSecti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon 5.2.1 (Study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon 5.2.1 (Study
Secti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSecti on 5.2.2 (Study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon 5.2.2 (Study
Secti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSecti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseParti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseParti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study ID TAK -935-1010 Page 74of 74
Protocol Incorporating Amendment No. 01 11April 2022
CONFIDENTIALparticipants in Arm 2 following interim 
PK analysis. Secti on 8.1 (Clinical Study  Drug)
Secti on 9.2.6 (Study  Drug Administrati on)
Secti on 11.2 (Interim Analysis and Criteria for Early
Terminat ion)
Rationale for the am endment and change 
in HI popul ation was added.Secti on 4.2 (Rati onale for the Proposed Study )
Secti on 6.4.1 (Rati onal of Study  Desi gn)
The protocol is updated to include data 
from the most current IB versi on: 
“TAK-935. Taked a Pharmaceut ical 
Com pany Ltd. Gl obal Invest igator’s 
Brochure. Addendum 1, 03 February
2022, for Edit ion 7, 31 January  2022”Secti on 4.1.1 (Soticlestat (TAK -035))
Secti on 16.0 (References)
The protocol is updated to correct units
used for creatinine clearance listed in the inclusio n criteria secti onasindicated in 
protocol  clarificat ion letter dated 
03 November 2021. Creatinine clearance 
units were incorrectly presented as 
mL/min/1.73m
2and are changed to 
mL/min since Cockcroft- Gaul tequation
will be used for creatinine clearance 
calculat ion.Secti on 1 (Study  Summary)
Secti on 7.1.1 (Incl usion for Parti cipants wi th Hepati c 
Impairment)
Secti on 7.1.2 (Incl usion for Healthy Parti cipants)
The protocol is updated to increase the 
numb er of planned clinical sites from up 
to 3 sites to up to 7 sites. Secti on 1 (Study  Summary)
The protocol is updated to include new 
details for future bi omedical research on
residual plasma PK samples.Secti on 6.4.4 (Future Biomedical Research)
The proto col is updated to clarify that 
HBV DNA will be measured in participants wi th HI wi th posi tive HBsAg 
resul ts. HCV RNA will be measured in 
participants wi th HI wi th posi tive HCV 
antibody  resul tsSecti on [IP_ADDRESS].1 (Other)
Typographi cal and grammat ical correc tions, as well as formatting changes, were made throughout 
the protocol.Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon 11.2 (Interim Analysis and Criteria for Early
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon 11.2 (Interim Analysis and Criteria for Early
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useonale for the Proposed Study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useonale for the Proposed Study )
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use) onale for the Proposed Study ) onale for the Proposed Study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useonale for the Proposed Study ) onale for the Proposed Study
gn)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usegn)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use035))
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use035))
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useequation
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useequationon 1 (Study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon 1 (Study  Summary)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use Summary) on 1 (Study  Summary) on 1 (Study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon 1 (Study  Summary) on 1 (Study
on 7.1.1 (Incl
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon 7.1.1 (Incl
ent)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useent)
Secti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSecti on 7.1.2 (Incl
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon 7.1.2 (Incl
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe protocol is updated to increase the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe protocol is updated to increase the 
anned clinical sites from up 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useanned clinical sites from up 
to 3 sites to up to 7 sites. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useto 3 sites to up to 7 sites. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe protocol is updated to include new 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe protocol is updated to include new 
ure bi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useure bi om
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useomedical research on
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useedical research on
dual plasma PK samples
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedual plasma PK samples
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useproto
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useproto co
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecol 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usel 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useis updated to clarify that 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useis updated to clarify that 
HBV DNA will be measured in 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHBV DNA will be measured in 
parti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useparticipants wi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecipants wi
resul
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useresul ts. HCV RNA will be measured in 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usets. HCV RNA will be measured in resul ts. HCV RNA will be measured in resul
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useresul ts. HCV RNA will be measured in resul
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useparti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useparticipants wi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecipants wi
ant
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useant
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
  ELECTRONIC SIGNATURES
Signed by [CONTACT_4232] 
(dd-MMM-yyyy HH:mm ‘UTC’) 
090101d6813057b6Phase 1 Pharmacokinetics and Safety Study of Oral Soticlestat in Participants with Moderate or Mild Hepatic
Impairment and Normal Hepatic Function
Clinical Pharmacology Approval 11-Apr-2022 20:35 UTC
Clinical Approval 11-Apr-2022 21:56 UTC
Biostatistics Approval 11-Apr-2022 23:36 UTC
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseServer Date 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseServer Date 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(dd-MMM-yyyy HH:mm ‘UTC’) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(dd-MMM-yyyy HH:mm ‘UTC’) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use11-Apr-2022 20:35 UTC
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use11-Apr-2022 20:35 UTC
11-Apr-2022 21:56 UTC
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use11-Apr-2022 21:56 UTC
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use11-Apr-2022 23:36 UTC
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use11-Apr-2022 23:36 UTC